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IκB kinase subunit alpha (IKK), a key component of the NFκB pathway, is 
implicated in prostate cancer progression and bone remodelling, but its role in the 
regulation of prostate cancer associated bone disease remains unknown. Here, we 
tested the effects of IKK manipulation on prostate cancer cell behaviour in vitro and 
on osteolysis in a xenograft model of human prostate cancer bone metastasis. The 
pharmacological inhibition of IKK using the novel and highly selective IKK 
inhibitor SU1349 and stable knockdown of IKK in PC3 cells significantly reduced 
cell viability, migration and invasion, whereas IKK overexpression was stimulatory. 
In prostate cancer cell - osteoclast co-cultures, IKK overexpression in PC3 enhanced 
RANKL-induced osteoclastogenesis, whereas SU1349 treatment and IKK 
knockdown reduced these effects. Exposure of osteoblasts to SU1349 enhanced 
alkaline phosphatase activity and bone nodule formation. Protein microarray analysis 
of tumour-derived factors in PC3 conditioned medium showed that these effects were 
associated with significant inhibition of various NFκB-mediated pro-inflammatory 
factors and reduction in PC3 conditioned medium induced NFκB activation in 
osteoclast and osteoblast precursors. In osteoclast and osteoblast precursors SU1349 
lead to inhibition of both canonical and non-canonical NFκB signalling. Interestingly, 
NFκB inhibition in osteoblasts was accompanied by an increase in GSK3β 
phosphorylation indicative of activation of the Wnt/β-catenin pathway, whereas the 
opposite occurred in osteoclast precursors. In vivo, administration of SU1349 
(20mg/kg/3times-weekly) in immuno-deficient BALB/c mice after intra-cardiac 
injection with human PC3 cells enhanced trabecular bone volume and this was 
associated with reduced osteoclast and increased osteoblast numbers. Paradoxically, 
SU1349 treatment reduced cortical bone volume, and this was associated with 
increased osteoclast and reduced osteoblast numbers. Thus, the novel IKK inhibitor 
SU1349 is of potential therapeutic value in protecting against prostate cancer-induced 
osteolysis. However, exacerbation of bone loss in the cortical compartment may limit 





Schematic representation of the effects of the IKK inhibitor SU1349 in trabecular and cortical bone in a mouse model of prostate cancer 
bone metastasis. 


































Bone is a highly dynamic and specialised connective tissue that together with cartilage 
forms the skeleton. Bone organic component is mainly composed of type I collagen 
fibres that represent approximately 90% of the proteins present in the bone matrix. The 
remaining 10% of the organic matrix consists mainly of non-collagenous proteins. 
Bone mineralised inorganic component is mainly comprised of crystals of 
hydroxyapatite [Ca10(PO4)6(OH)2] which are insoluble salts of calcium and 
phosphorus (Favus, 2006). 
1.1 Bone cells 
The main cellular components of bone are osteoclasts, osteoblasts, lining cells and 
osteocytes. They play a key role in the bone remodelling cycle, a process that maintains 
bone structural integrity through cycles of bone resorption and bone formation (Favus, 
2006).  
1.1.1 Osteoblasts 
Osteoblasts are cuboidal, mononuclear cells and are derived from mesenchymal stem 
cells (MSCs), which are pluripotent progenitor cells found in bone marrow (Favus, 
2006). MSCs also differentiate into myocytes, chondrocytes and adipocytes, the latter 
two cell types are implicated in pathological bone remodelling (Katagiri and 
Takahashi, 2002). A variety of growth factors, hormones and transcription factors act 
together to control mesenchymal progenitor differentiation toward osteoprogenitors, 
pre-osteoblasts, mature osteoblasts, and finally osteocytes or bone lining cells.  Runt-
related transcription factor 2 (Runx2) is the main transcription factor responsible for 
the commitment of MSCs towards cell of the osteoblastic lineage (Karsenty and 
Wagner, 2002).  Together with Osterix (Osx), Runx2 is also involved in osteoblast 
maturation (Lecka-Czernik et al., 1999).  
Mature osteoblasts express high levels of the enzyme alkaline phosphatase (ALP) and 
their main function is to synthesize and secrete osteoid, which are proteins that make 
up the unmineralised bone matrix (Katagiri and Takahashi, 2002). Osteoblasts also 
regulate osteoclast formation and bone resorption by producing osteolytic cytokines, 
macrophage colony-stimulating factor (M-CSF), receptor activator of nuclear factor 





κB ligand (RANKL), and the decoy receptor for RANKL: osteoprotegerin (OPG) 
(Troen, 2003). 
1.1.2 Osteoclasts 
Osteoclasts are terminally differentiated multinucleated cells of a hematopoietic 
origin. Osteoclasts are formed by the fusion of multiple mononuclear precursors in 
response to the action of M-CSF and RANKL (Vaananen and Laitala-Leinonen, 2008).   
M-CSF produced by osteoblasts binds to the c-Fms receptor, expressed by osteoclast 
precursors and mature osteoclasts (Weir et al., 1993).  This binding commits pre-
cursors cells towards osteoclastogensis and is important for osteoclast survival 
(Teitelbaum, 2000, Takayanagi, 2005). RANKL is produced by various cells including 
osteoblasts, osteocytes and immune cells namely T – lymphocytes and dendritic cells 
(Jones et al., 2002). RANKL binds to the receptor activator of nuclear factor B 
(RANK) to stimulate differentiation of precursors and fusion into mature 
multinucleated osteoclasts (Teitelbaum, 2000, Takayanagi, 2005). The main function 
of mature osteoclasts is bone resorption.   
1.2 Bone remodelling 
Normal bone remodelling is a highly dynamic and coordinated process that consists of 
two distinct phases: bone resorption and bone formation. Dysregulation of the bone 
remodelling cycle is the main cause of many diseases including osteoporosis, Paget’s 
disease, rheumatoid arthritis and cancer associated bone disease.  
1.2.1 Bone resorption 
After a period of quiescence and in response to micro damage, bone resorption is 
initiated by the recruitment of osteoclasts and their precursors to sites of bone to be 
remodelled. It is thought that osteocytes instruct osteoblasts and bone lining cells to 
secrete various proteolytic enzymes to dissolve the osteoid layer in order for 
osteoclasts to access the underlying mineralised layer (Troen, 2003, Hadjidakis and 
Androulakis, 2006). Furthermore, osteocytes together with osteoblasts and other bone 
marrow cells, release M-CSF and RANKL, which causes osteoclasts precursors to 
differentiate into mature osteoclasts (Proff and Romer, 2009).  





Mature osteoclasts adhere to the bone surface, polarise and release protons and 
chloride ions, which demineralise the bone matrix by converting hydroxyapatite into 
Ca2+, HPO42- and H2O (Bar-Shavit, 2007, Hill, 1998). This uncovers the underlying 
organic matrix that is in turn degraded by osteoclast-derived cathepsin K and MMP9 
(Teitelbaum, 2000). Both organic and inorganic degradation products are engulfed by 
osteoclasts and are secreted into the extracellular space (Vaananen and Laitala-
Leinonen, 2008). In healthy human adults, the bone resorption phase lasts for ten days 
after which osteoclasts undergo apoptosis (Hill, 1998). 
1.2.2 The reversal phase 
The reversal phase is characterised by: osteoclasts undergoing apoptosis; migration of 
osteoblast precursors to the newly resorbed bone; and appearance of mononuclear 
macrophage-like cells. The macrophage-like cells remove the residual organic matrix 
to form a ‘cement line’ that demarcates the boundary of bone resorption and joins old 
bone to new (Hill, 1998, Lerner, 2006).   
1.2.3 Bone formation 
The recruitment of osteoblasts and their precursors to the newly resorbed site is 
initiated by the release of systemic and bone-derived factors such as TGF, BMP2, 
IGFs, FGFs, and PDGFs (Mundy et al., 1982, Hill, 1998, Lerner, 2006). Mature 
osteoblasts initiate the production of new bone by producing type I collagen that 
together with various non-collagenous proteins form the osteoid (Katagiri and 
Takahashi, 2002). Osteoblasts initiate the transformation of osteoid into mineralised 
bone by producing ALP, which breaks down pyrophosphate an inhibitor of 
mineralization, and by releasing membrane bound bodies, known as matrix vehicles, 
throughout the collagen scaffold. These matrix vehicles contain calcium, phosphate, 
phospholipids and various proteins and that together induce the formation of 
hydroxyapatite giving rise to mature mineralised bone (Favus, 2006, Katagiri and 
Takahashi, 2002). The bone formation phase lasts for three months in a healthy adult 
human. At the end of which 65% of osteoblasts undergo apoptosis (Jilka, 1998). the 
remainder either differentiate into bone lining cells or transform into osteocytes 
(Favus, 2006).  






2. Prostate Cancer 
2.1 Epidemiology 
Prostate cancer (PCa) is the second most common cause of cancer and the sixth leading 
cause of cancer death among men worldwide (Center et al., 2012). The disease usually 
appears in men over the age of 60 and is more common in western countries than in 
developing countries (Marugame and Katanoda, 2006). In the US the incidence of PCa 
is highest amongst African Americans and lowest amongst Asian Americans (Zeigler-
Johnson et al., 2008).  
Early detection and treatment of locoregional PCa has a 5 year relative survival rate 
that is almost 100%, while in PCa with distant metastasis the survival rate drops to 
30% (Jemal et al., 2008). In a large-scale autopsy study of patients with PCa, 90% of 
metastases involved bone (Bubendorf et al., 2000). Although only a minority of men 
with PCa develop metastasis most of PCa related deaths are due to metastatic 
progression (Thobe et al., 2011).   
2.2 Genetics 
In addition to environmental and lifestyle related factors (Attard et al., 2015), 42% of 
the risk of developing PCa has been attributed to genetic factors (Eeles et al., 2014). 
Genome-wide association studies have associated 76 genetic loci of low penetrance 
with PCa (Eeles et al., 2014). In addition, a number of genes with rare but highly 
penetrant mutations have been implicated in PCa disposition, these include: BRAC1/2, 
HOXB13, CHEK2, PALB2, BRIP1 and NBS1(Kote-Jarai et al., 2011, Leongamornlert 
et al., 2012, Ewing et al., 2012, Cybulski et al., 2004, Erkko et al., 2007, Kote-Jarai et 
al., 2009, Hebbring et al., 2006).  
2.3 Pathophysiology 
2.3.1 Tumorigenesis 
The cell origin of prostate cancer cells has not been fully established, however, it is 
thought to be primarily derived from basal or luminal epithelial cells within the 





glandular pits of the prostate, although a rarer and more aggressive form of prostate 
cancer is derived from neuroendocrine cells (Attard et al., 2015, Berish et al., 2018).  
PCa is thought to progress from a pre-malignant condition of the prostatic gland, 
known as prostatic intraepithelial neoplasia (PIN) (De Marzo et al., 2007). PIN is 
characterised by multiple lesions that show a dysplasia of prostate epithelial cells and 
a reduction in basal layer cells (Schrecengost and Knudsen, 2013). PCa lesions can 
then develop into locally invasive adenocarcinoma and eventually into metastatic 
carcinoma.  
Serum prostate-specific antigen (PSA) is used in patients and population screening, as 
a predictive, diagnostic and prognostic marker (Attard et al., 2015). PSA is used to 
monitor progression, response to therapy and relapse. However, since PSA is prostate 
specific it can also indicate damage to the prostate due to inflammatory disease (De 
Marzo et al., 2007). Therefore, prostate cancer diagnosis and prognosis, also requires 
histological grading of primary prostate cancer biopsies using the Gleason score 
system, which assess the level of differentiation of glandular prostatic tissue and 
pattern of growth into the stroma to asses the pathological stage, predict aggressiveness 
of prostate cancer progression and the likelihood of developing metastasis (see Table 
1.1) (Sathianathen et al., 2018). 
The initiation and progression of PCa is associated with mutations in a number of key 
genes, notably: NKX3.1, FOXA1, Myc, TMPRSS2:ERG and the AR gene 
(Schrecengost and Knudsen, 2013, Gil et al., 2005, Gallucci et al., 2009, Jenkins et al., 
1997, Mosquera et al., 2008, Ganguly et al., 2014). Additionally, the expression of 
tumour suppressors such as PTEN, p53 and less frequently RB is commonly lost in 










Table 1.1: Gleason scoring and grading system. Traditional Gleason scoring system is made 
up of a total of two scores: one for the predominate histological appearance of biopsied tissue 
followed by a score for the second most common appearance of tissue (the two scores 
separated by the sum sign is shown in brackets). Gleason scores below 6 are uncommon as 






≤ 6 (3+3) 1 
Glands are well differentiated, small and 
closely packed. Tumour cells are likely to 
grow slowly. 
7 (3+4) 2 
Predominately well differentiated glands and 
tumour cells that are likely to grow slowly. 
Some poorly differentiated glands 
(hypertrophic) with more stroma in between 
glands and tumour cells that are likely to grow 
moderately 
7 (4+3) 3 
Predominately poorly differentiated glands 
with more stroma in between glands and 
tumour cells that are likely to grow 
moderately, also some infiltration of glands at 
margins. Some well differentiated glands with 
tumour cells that are likely to grow slowly. 
8 (3+5; 4+4; 5+3) 4 
Few glands left. Poorly differentiated tissue. 
Most Tumour cells are likely to grow 
moderately and/or quickly. 
9 (4+5; 5+4)-10 (5+5) 5 
Rare or no glands are present. Extremely 
poorly differentiated tissues. Tumour cells are 
likely to grow quickly.  
 
Androgen and androgen receptor (AR) signalling is important in prostate development 
and in cancer progression (Schrecengost and Knudsen, 2013). Synthesis of androgens 
is primarily regulated by the hypothalamic-pituitary-testicular axis with androgen 
synthesis by the adrenal glands being a secondary source (Watson et al., 2015). The 
hypothalamus produced gonadotropin-releasing hormone (GnRH) signals to the 
pituitary gland to produce luteinizing hormone, which in turn stimulates testosterone 
production in the testis. In the prostate, androgens such as testosterone and adrenal 
androgens are converted to dihydrotestosterone which binds to AR to activate AR 
signalling (Watson et al., 2015). Patients diagnosed with early stage PCa are 





responsive to androgen deprivation therapy (ADT) through chemical or surgical 
castration. Most commonly agonists or antagonists of GnRH are used to downregulate 
testosterone production by the testis,  however, as residual androgen are still produced 
by the adrenal glands, ADT is augmented by combing with Abiraterone which blocks 
androgen synthesis by the CYP17A1 (Cytochrome P450 family 17 subfamily A 
polypeptide 1) enzyme (Watson et al., 2015). Eventually some patients relapse and 
become unresponsive to ADT, and their tumours exhibit aberrant AR activation that 
is largely independent of circulating androgen, this is known as castration resistant 
PCa (CRPC) (Ganguly et al., 2014). Therefore, CRPC treatment also involves anti-
androgen drugs that inhibit androgen synthesis (Abiratrone) or block androgen 
receptor signalling (Enzalutamide) to address aberrant activation of androgen 
signalling, invariably, these patients still progress to metastatic disease, where they 
require additionally chemotherapy treatments using docetaxel (1st line chemotherapy)  
or later cabazitaxel (2nd line chemotherapy)  (Attard et al., 2015).  
2.3.2 Metastasis 
Most patients with advanced prostate cancer experience complications from lymph 
node and bone metastases. PCa metastasis, like other forms of metastases, follows 
recognised stages, these are: local invasion of surrounding tissue, intravasation into 
blood or lymphatic vasculature, transport through the blood or lymphatic systems to 
distant sites, extravasation from the vascular system and dissemination into site of 
metastasis, adaptation to the local environment and colonisation (Figure 1.1) (van der 
Pluijm, 2011, Chaffer and Weinberg, 2011).  
  








Figure 1.1 Mechanisms of metastasis. Note established (macrometastasis) can also detach and cause further metastases through the same mechanisms. 
See text for more details (source: ploscompbiol.org)






The PCa tumour microenvironment produces factors, such as TNFα, TGFβ and Wnt, 
promotes prostate epithelial cells to undergo an epithelial-mesenchymal transition 
(EMT) which increases their migratory and invasive capacity. PCa cells promote 
production of proteases (MMPs-1/2/9) that degrade the extra-cellular matrix (ECM) 
to facilitates the escape of PCa cells from the stromal compartment and intravasation 
into the blood and lymphatic vascular system (Ganguly et al., 2014).  
The homing of PCa cells to bone is mainly due to the action of various chemo-
attractant factors such as TGFβ, CXCL12 and VEGF (Ganguly et al., 2014). The 
sinusoids within the marrow of long provide a natural entry point for the circulating 
PCa cells (Thobe et al., 2011). The sinusoid epithelia express tethering proteins such 
as VCAM-1 which allow PCa cells to adhere to bone (Scott et al., 2001). 
2.3.2.1 Prostate cancer bone metastasis 
The development of PCa bone metastasis is a major cause of morbidity, including: 
bone pain, reduced mobility, pathologic fractures, spinal cord compression, 
hypercalcemia, anaemia and susceptibility to infection (Logothetis and Lin, 2005, 
Coleman, 2001). Unlike most types of cancers that metastasize to bone which typically 
cause osteolytic (bone-destroying) lesions, PCa in patients causes mixed lesions with 
more osteoblastic (bone-forming) lesions as well as the typical osteolytic lesions 
(Logothetis and Lin, 2005).  
In bone, PCa cells interact directly with osteoblasts through cadherin-11, and release 
factors (BMPs-2/4/6/7, ET1, Wnt and PDGF) that promote osteoblasts proliferation to 
form osteoblastic lesions (Table 1) (Ganguly et al., 2014). Osteoblasts then releases 
factors (FGF, IGF-1, IL-6 and TGFβ) that promote PCa cell growth and survival 
(Ganguly et al., 2014).  Moreover, PCa cells and osteoblasts elevate RANKL, M-CSF 
and PTHrP levels which increases osteoclasts and bone resorption (Keller and Brown, 
2004). Increased bone resorption further releases cytokines and factors (FGFs, IGFs 
and TGFβ) from the bone matrix which promotes the proliferation of cancer cells and 
osteoblasts (Ibrahim et al., 2010). The process of tumour cells promoting growth of 
osteoblasts and osteoclasts, followed by osteoblasts and osteoclasts promoting growth 
of tumour cells is known as the vicious cycle (see Figure 1.2).   





Patients with bone metastasis are often treated with drugs that inhibits osteolytic bone 
resorption such as Zoledronic acid (a next generation bisphosphonate that inhibits 
osteoclast survival and function) and Denosumab (anti-RANKL monoclonal antibody 
that inhibits osteoclast differentiation and function) (Sathianathen et al., 2018). 
However, while these treatments are effective in reducing some of the complications 
associated with bone metastasis –specifically increased bone resorption- they are 
unsuccessful in directly reducing prostate cancer skeletal tumour growth and 
metastasis (Clement-Demange and Clezardin, 2015, Todenhofer et al., 2015). More 
recently, Radium-223, was clinically approved for the treatment of CRPC and it was 
shown to both alleviate bone metastatic damage and improve survival (Sathianathen 
et al., 2018). Radium-223 is an α-particle emitting calcium mimetic that binds to areas 
of newly formed bone associated with prostate cancer osteoblastic lesions and due to 
its short radiation penetrance and half-life, it reduces off target cytotoxic effects and is 
therefore well tolerated in patients. 








Figure 1.2: The ‘vicious cycle’ of bone metastasis. Figure depicts some of the main factors involved in the interactions between tumour cells and 
osteoblasts and osteoclast in the bone microenvironment (Obl = osteoblasts). See text for detail (source: (Kingsley et al., 2007))






2.3.2.2 Molecular regulation of PCa bone metastases  
Many factors can regulate both PCa cell and the bone microenvironment during PCa 
bone metastasis. Of note is the RANK/RANKL/OPG axis, which regulates the NFκB 
pathway upstream of IKKα and plays a key role in the regulation of vicious cycle 
associated with prostate cancer bone metastasis, is discussed below.  
RANK/RANKL/OPG axis 
RANKL, RANK and OPG are members of the TNF and TNF receptor superfamily 
(Favus, 2006).  The RANK/RANKL/OPG axis regulates the NFκB pathway which is 
crucial for the regulation of osteoclastogenesis and has also been implicated in bone 
metastasis associated with prostate cancer (Jones et al., 2006, Schramek et al., 2011). 
Specifically an increased RANKL/OPG ratio, which is indicative of increased NFκB 
activation, has been linked to bone metastasis (Dougall and Chaisson, 2006). Invading 
PCa cells were shown to directly stimulate bone resorption by producing RANKL 
(Sabbota et al., 2010). In addition, PCa cells can release factors such as TGF and 
PTHrP that stimulate bone stromal cells to increase RANKL production (Leibbrandt 
and Penninger, 2008). Moreover, prostate cancer cells were shown to respond to the 
increase in RANKL expression by promoting the expression of genes involved in 
osteolysis and invasion (Armstrong et al., 2008). Whilst OPG is primarily produced 
by bone stromal cells to inhibit NFκB activation and therefore osteoclastogenesis, 
OPG has also been reported to be expressed by aggressive prostate cancer cells lines 
and was shown to be important for prostate cancer cell survival (Holen et al., 2002).  
Other factors that regulate both PCa cell and the bone microenvironment during PCa 
bone metastasis are summarised in Table 1.2.  
 
  





Table 1.2: A summary of some of the main factors that regulate PCa bone metastasis. 
 
Factor Source Effects References 
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(Anastas and Moon, 2013, 






(Sanchez-Fernandez et al., 
2008, Ustach et al., 2010). 
TGF PCa/BMx 
 
   (Janssens et al., 2003, 





   (Ganguly et al., 2014, Ryan 
et al., 2007). 




(Valta et al., 2008, Ganguly 





 (Ide et al., 2008) 
PTHrP PCa 
 




   (Ara and Declerck, 2010, 
Nguyen et al., 2014a). 
TNF PCa 
 
   (Abu-Amer et al., 2000, 




   (Schipani et al., 2009, Yang 






 (Ganguly et al., 2014, Krane 
and Inada, 2008) 
EGFs PCa/BMx 
 
   (Schneider et al., 2009, 
Chang et al., 2015). 
BMXs, bone matrix; OB, osteoblasts; OC, osteoclasts; Arrows indicate stimulation or 
inhibition of proliferation or activity.  






3. The NFκB signaling pathway  
IκB kinase (IKK), a key member of the NFB family, is implicated in the regulation 
of inflammation, cell death, immunity, bone remodelling and oncogenesis (Clement et 
al., 2008, Hayden and Ghosh, 2004, Gilmore, 2006, Basseres and Baldwin, 2006). IKK 
family members consist of IKK, IKK  IKK,  and TBK1. IKKs are important 
in regulating The classic IKK complex which consists of IKK, IKK and  IKK and 
are involved in the regulation of the canonical NFB pathway (Oeckinghaus et al., 
2011). An IKK dimer regulates the non-canonical NFB pathway (Clement et al., 
2008) (Figure 1.3).  
The canonical IKK/NFB pathway is activated by various inflammatory factors 
including RANKL, TNFα, IL-1, bacterial and viral antigens. Upon activation, the 
IKK/IKKIKK complex is formed and phosphorylates inhibitory IB proteins that 
bind to NFB proteins normally found in the cytoplasm. This leads to the dissociation 
of IBα protein and the translocation of NFB p65/p50 dimers to the nucleus and 
activation of target genes (Karin and Ben-Neriah, 2000). Several studies have shown 
that IKK does not play an essential role in the activation of the canonical pathway 
while IKK and IKK are essential (Hacker and Karin, 2006, Lee and Hung, 2008). 
The non-canonical IKK/NFB pathway is activated by a restricted number of stimuli 
that are members of the TNF superfamily, which include RANKL, lymphotoxin β, 
CD40L, BAFF and LPS. This leads to the stabilization of NIK kinase which 
phosphorylates IKK dimers that in turn phosphorylate the inhibitory p100 subunit 
bound to cytoplasmic RelB (Oeckinghaus et al., 2011). Phosphorylation of the p100 
subunit and allows for its partial degradation and processing to p52. The RelB-p52 
complex then translocates to the nucleus where it binds and activates the expression 
of target genes. Activated IKK translocates to the nucleus and activate the expression 
of NFB-dependent genes directly by phosphorylating histones H3 (Yamamoto et al., 
2003). 





Canonical NFκB signalling is understood to be primarily responsible for regulating 
innate immunity and inflammation whilst non-canonical NFκB signalling is more 
important for adaptive immunity and secondary lymphoid organogenesis (Baud and 
Karin, 2009, Polley et al., 2016). It is important to note that the NFB pathway is also 
activated by IKK kinases independent mechanisms, that phosphorylate IB and cause 
the nuclear translocation of NFB (Perkins, 2006, Perkins and Gilmore, 2006).  






Figure 1.3: The canonical and non-canonical NFB pathways. Activation of the respective pathways results in the phosphorylation (p) of inhibitory 
proteins followed by ubiquitylation (Ub) and subsequent proteasomal degradation. See text for more detail. (source: (Viennois et al., 2013)) 





IκB kinases (IKKs) 
IKKα shares a high degree of homology with IKKβ with around 50% sequence identity 
and 70% structure similarity, both kinases contain a N-terminal kinase domain, a 
leucine-zipper domain for protein dimerization and a C-terminal helix-loop-helix 
(Hacker and Karin, 2006). Unlike IKKβ that has primarily cytoplasmic functions, 
activated IKKα has additional important nuclear functions that can also be NFκB- and 
kinase-independent.  
IKKα nuclear and NFΚB independent roles 
IKKα has been shown to have a role in regulating NFκB independent gene expression 
in response to diverse signalling pathways and transcription factors including: 
PI3K/Akt, TGFβ/Smad, ATM, PKCδ, Notch, Fox2/Numb, STAT3, p53, p73, ERα, 
AP-1 and E2F (Ozes et al., 1999, Yoshida et al., 2008, Yamaguchi et al., 2007, 
Fernandez-Majada et al., 2007, Marinari et al., 2008, Liu et al., 2012, Ammirante et 
al., 2010, Furuya et al., 2007, Park et al., 2005, Tu et al., 2006, Huang et al., 2012). 
In the nucleus IKKα promotes gene expression by directly phosphorylating 
transcription factors such as p65 to enhance its DNA binding and transactivation (Jiang 
et al., 2003, Gloire et al., 2007), also by phosphorylating key epigenetic chromatin 
modifiers at the promotors of these genes to enhance expression, this includes: 
phosphorylation of histone H3 which opens-up chromatin structure (Yamamoto et al., 
2003), phosphorylation of transcriptional coactivators such as CBP (CREB-binding 
protein) to enhance their activity (Huang et al., 2007) and phosphorylation of 
transcriptional repressors like SMART/HDAC3 complexes to supress their activity 
(Gloire et al., 2007). It is important to note that activated nuclear IKKα has also been 
shown to have kinase independent functions in the regulation of epidermal 
keratinocyte differentiation and chondrocyte differentiation (Hu et al., 2001, Sil et al., 
2004, Olivotto et al., 2015). 
  





IKKα role in development 
Knockout of IKKα in mice results in perinatal lethality (i.e. Immediately before birth 
or soon after birth), with the foetuses displaying thickened skin, stunted limbs, as well 
as skeletal and craniofacial deformities (Hu et al., 1999, Takeda et al., 1999). These 
morphological defects were subsequently revealed to be due to a disruption of proper 
epidermal–mesodermal interaction and to be independent of IKKα kinase activity and 
NFκB activation (Sil et al., 2004). IKKα knockout mice were also described to show 
defective development of Peyer’s patch (lymphatic tissue in lowest part of small 
intestine) (Cildir et al., 2016). In comparison knockout of IKKβ in mice are more 
severe, resulting in embryonal lethality (around day 14) and severe liver degeneration 
and apoptosis (Tanaka et al., 1999). 
In humans, two cases of a lethal autosomal recessive syndrome charecterised by sever 
fetal encasement malformations- similar to those occuring in IKKα knockout mice- 
were described in a consangious finnish family (Lahtela et al., 2010). The fetal 
abnormalities included defective cranofacial development and seemingly absent limbs 
which were bound to the trunk and encased under the skin, as a results this syndrome 
is also known as “cocoon syndrome”. Genetic analysis revealed that it was caused by 
a homozygous missesne mutation, in CHUCK that encodes for IKKα, which resulted 
in reduced expression levels of a truncated IKKα with a missing kinase domain. More 
rcently a de novo- heterozygous- mutation in the CHUK gene, resulting in IKKα with 
an inactive kinase, was identified in patients with EEC/AEC like syndrome 
(Ectodermal dysplasia, Cleft lip/palate & Ankyloblepharon-Ectodermal defects-Cleft 
lip/palate) (Khandelwal et al., 2017). These patients display orofacial clefting, limb 
abnormalities, defects in the skin, hair and nails as well as immunodeficiency.  
IKKα dysregulation in disease 
A dysregulated role for IKKα has been reported in a variety of cancers including: 
prostate cancer, breast cancer, pancreatic cancer, colorectal cancer, gastric cancer, 
liver cancer and osteosarcoma (Fernandez-Majada et al., 2007, Park et al., 2005, Shiah 
et al., 2006, Hirata et al., 2006, Furuya et al., 2007, Huang et al., 2012). IKKα has also 
been identified to have a role osteoarthritis (Olivotto et al., 2015), diabetes (Starkey et 
al., 2006) and fear memory (Lubin and Sweatt, 2007). 





3.1 Role of IKK/NFκB activity in bone remodelling  
3.1.1 Role of IKK/NFκB in osteoclastic bone resorption 
The IKK/NFB pathway plays an important role in osteoclast differentiation, activity 
and survival (Soysa and Alles, 2009). Early studies in mice show that deletions of 
NFκB1 (encodes p105 precursor of p50) and NFκB2 (encodes p100 precursor of p52)  
had increased bone volume due to lack of osteoclasts (Iotsova et al., 1997). Later 
studies showed that mice with IKK deletion exhibited impaired osteoclast 
differentiation (Chaisson et al., 2004). Similarly, mice with deletion of RelB, a 
component of the NFB non-canonical pathway, also showed impaired osteoclast 
differentiation (Vaira et al., 2008). Deletion of IKK in mice, were more pronounced, 
with mice displaying reduced osteoclast formation, which resulted in increased bone 
volume (Otero et al., 2010).  
Pharmacological studies by our group have shown that combined inhibition of IKK 
and IKKβ reduces osteoclastic bone resorption and prevents bone loss in mouse 
models of postmenopausal osteoporosis (Idris et al., 2009, Idris et al., 2010). 
Conversely, constitutive activation of the canonical NF-κB pathway resulted in 
RANKL independent osteoclastogensis and severe bone loss in mice through a 
mechanism involving RelB and p52 (Otero et al., 2012, Otero et al., 2010) 
3.1.2 Role of IKK/NFκB in osteoblastic bone formation 
A number of studies have shown that the IKK/NFB pathway negatively regulates 
osteoblast bone formation. Inhibition of the NFB pathway using mutants deficient in 
IKK or with super IB repressor promoted osteoblast differentiation in vitro and 
promoted bone formation in mice (Chang et al., 2009). Selective inhibition of IKK 
increased osteoblast differentiation in vitro and bone formation in vivo (Alles et al., 
2010). 
  





3.1.3 Regulation of Wnt signalling by IKK/ NFκB in bone homeostasis 
Historically, the IKK/NFκB pathway was not thought to be very important for 
osteoblast biology, this is in contrast to the crucial role of the IKK/NFκB pathway in 
osteoclast differentiation and bone resorption function that was recognised early on 
(Novack, 2011). Indeed later work demonstrated that activation of IKK/NFκB 
pathway inhibits osteoblast differentiation and bone formation function (Chang et al., 
2009). The IKK/NFκB pathway was shown to negatively regulate the Wnt signalling 
pathway in osteoblasts, which is important for osteoblast differentiation and function, 
(Chang et al., 2013, Marino et al., 2018). Wnt signalling, particularly canonical Wnt 
signalling which is dependent on β-catenin, promotes osteoblast differentiation and 
bone formation function whilst inhibiting osteoclast differentiation and osteoclast 
bone resorption (Krishnan et al., 2006). NFκB pathway inhibition was established to 
enhance osteoblastic differentiation and function via its effects on enhancing Wnt/β-
catenin signalling (Chang et al., 2013, Marino et al., 2018). 
In canonical Wnt signalling, in the absence of activation or in the presence of Wnt 
signalling antagonists (such as Dkks, sFRPs or SOST), β-catenin is constitutively 
phosphorylated in the cytoplasm by GSK3β (glycogen synthase kinase 3 beta) which 
marks it for proteosomal degradation. Canonical Wnt activation occurs when 
activating Wnts (such as Wnt1, Wnt3a, Wnt10b) bind the frizzled receptor (a 7-
transmembrane domain) and the lipoprotein receptor–related protein 5 and 6 (LRP5/6) 
coreceptors. The signal is then transduced through proteins including Disheveled, 
Axin, and Frat-1 that inhibit GSK3β activity by its  phosphorylation, this leads to the 
accumulation of β-catenin in the cytoplasm and eventually β-catenin is shuttled to the 
nucleus where it associates with the TCF/LEF transcription factors to activate the 
expression of Wnt regulated genes (Krishnan et al., 2006). Non-canonical Wnt 
signalling is independent of β-catenin and is not as well characterised as canonical Wnt 
signalling, nonetheless, non-canonical Wnt signalling activation by Wnt5a has been 
shown to enhance canonical Wnt signalling to promote osteoblast differentiation 
(Okamoto et al., 2014).  





3.2 Role of IKK/NFκB in PCa cancer  
3.2.1 Role of IKK/NFκB in PCa tumorigenesis  
NFB is a major effector in PCa pathogenesis, involved in tumour growth, survival, 
invasion and metastasis (Nguyen et al., 2014b). NFB was shown to be constitutively 
activated in the advanced PCa cell line model, PC3, compared to the early stage PCa 
cell line model, LNCaP, and normal prostate epithelia (Gasparian et al., 2002). 
Increased nuclear localisation of NFB-p65/p50 and phosphorylated IκBα was 
observed during PCa progression in transgenic adenocarcinoma of the mouse prostate 
(TRAMP) mouse model (Shukla et al., 2005). Nuclear NFB localisation and IκBα 
phosphorylation was also associated with human PCa progression (Shukla et al., 
2004). Moreover, an elevated expression of NFB is observed in patients with CRPC 
(McCall et al., 2012). 
Inhibition of the NFB pathway, decreased PC3 invasiveness in vitro, this was 
associated with a reduction in pro-invasive factors such as VEGF and MMP-9 (Huang 
et al., 2001). Similarly, NFB inhibition was shown to supress epithelial to 
mesenchymal transition in PCa cells and supress snail-dependent migration and 
invasion (Baritaki et al., 2009). Overexpression of NFB enhanced the activation of 
CXCL12/CXCR4 pathway- known to be associated with PCa bone metastasis 
(Taichman et al., 2002)- and increased PCa cell adhesion and migration through 
endothelial cells which is one of the earliest steps in metastasis  (Kukreja et al., 2005).  
Blocking the NFB pathway in PC3 increased susceptibility to apoptosis in vitro 
(Shukla and Gupta, 2004).  Interestingly, the NFB pathway is activated in PCa cells 
by exposure to radiation and chemotherapy (Chendil et al., 2002, Huang et al., 2001), 
this could be a survival mechanism that contributes to PCa resistance to these therapies 
(Nguyen et al., 2014b). Moreover, inhibition of NFB has been demonstrated to 
sensitize PCa cells to radiotherapy and chemotherapy (Codony-Servat et al., 2013). 
Collectively, the NFB pathway is an attractive anti-cancer target that can be used in 
conjunction with conventional therapeutic strategies.   





3.2.2. Role of IKK/NFκB in PCa metastasis  
Microarray analysis showed the NFB pathway to be dysregulated in metastatic 
prostate cancer patients (Setlur et al., 2007). Activated nuclear NFB was found to be 
significantly upregulated in PCa lymph node metastasis (Ismail et al., 2004). 
Furthermore, nuclear NFB p65 subunit in primary tumours was found to be highly 
predictive of PCa lymph node metastasis (Lessard et al., 2006). NFB pathway 
upregulation, evident by increased phosphorylation of IκB, was associated with 
metastasis in CRPC patients (McCall et al., 2012). Moreover, NFB was shown to 
increase AR expression, and both positively correlated with metastatic CRPC (Zhang 
et al., 2009). 
Inhibition of NFB in PC3 delayed occurrence of lymph node metastasis in orthotopic 
mouse models (Huang et al., 2001). Activation of NFB through EZH2 silencing of 
the BAB2IP tumour suppressor was shown to be an important driver in PCa (lymphatic 
and bone) metastasis in mice (Min et al., 2010). 
The NFB pathway is significantly more active in the PCa cell lines known to cause 
bone metastasis, PC3 and C4-2B, than in the LNCaP cell line which does not normally 
cause bone metastasis. However, activating the NFB pathway in LNCaP did induce 
bone metastasis when injected in mice, while inactivating the NFB pathway in PC3 
and C4-2B inhibited their ability to cause bone metastasis (Jin et al., 2013). PC3 cells 
lacking NFB function could no longer promote osteolytic bone resorption when co-
cultured with rat marrow cells on bone (Andela et al., 2003); bone resorption is thought 
to be necessary for PCa induced bone metastasis (Kavitha et al., 2014). 
3.2.2.1 IKK  as a therapeutic target in PCa progression and bone metastasis 
IKK was shown to be more important in the development of PCa than IKK (Shukla 
et al., 2005, Nguyen et al., 2014b). A number of publications from Karin and 
colleagues investigated the role of IKK in PCa. They showed that using an inactive 
IKK mutant in TRAMP mice reduced PCa tumour growth, inhibited metastasis and 
increased expression of the tumour suppressor maspin (Luo et al., 2007). The ablation 
of maspin restored metastasis. IKK, activated by RANKL, translocates to the nucleus 





to directly interact with the maspin promoter and inhibit its expression. Furthermore, 
in mouse and human PCa samples activated nuclear IKK levels associated with 
metastatic progression, lower maspin expression and greater infiltration of 
inflammatory cells expressing RANKL. In another study, inactivating IKK in 
TRAMP mice prostate epithelia had no effect on PCa initiation and progression 
(Ammirante et al., 2010). A follow up study showed that IKK activation of the 
transcription factor E2F1 and its downstream target Bmil enhanced survival and 
proliferation of prostate progenitor stem cells thought to be important in the emergence 
of a castration resistant subpopulation and development of CRPC (Ammirante et al., 
2013). It is important to note that the mouse model used by Luo et al. does not generate 
bone metastasis, the metastases reported were in lymph nodes and internal organs. 
Bortezomib was the first clinically approved 26S proteasome inhibitor developed to 
block the NFB pathway as an anti-cancer agent (Richardson et al., 2005). In PCa, 
bortezomib had little or no reduction in the expression of most NFB regulated genes, 
however, there was an increased NFB p65 recruitment to the IL-8 promotor, 
increased IL-8 expression and increased IKK nuclear localization (Manna et al., 
2013). Increased IL-8 expression has been associated with PCa progression and 
metastasis (Singh and Lokeshwar, 2011). Inhibiting IKK significantly reduced p65 
recruitment to the IL-8 promotor and IL-8 expression (Manna et al., 2013). This 
indicates that inhibiting both IKK and the proteasome may increase efficacy of using 
bortezomib in treating PCa. 
Most of the drugs developed by the pharmaceutical industry to inhibit the NFB 
pathway have targeted IKK, however, these drugs have not proved successful in 
clinical trials (Verstrepen and Beyaert, 2014). Developing therapeutic inhibitors of the 
NFB pathway by targeting IKK is limited by the fact that it can have detrimental 
systemic effects on innate immunity (Baud and Karin, 2009).  Targeting IKK is 
thought to be a safer therapeutic option as it is not essential for the canonical NFB 
pathway and may therefore result in less serious side effects (Huang and Hung, 2013). 
However, IKK might be a more effective anti-cancer target than IKK exactly 
because it is involved in both the canonical and non-canonical NFB pathways, and it 





may in fact result in more adverse effects, which in a cancer setting may still be 
acceptable and warrants further investigation. 





Aims of this study 
The aim of this thesis is to establish if selective pharmacological inhibition of IKKα 
might be of value in the treatment of bone metastasis associated with prostate cancer.  
I hypothesise that inhibition of IKKα in highly metastatic prostate cancer cells 
suppresses bone metastasis, reduces skeletal tumour growth and inhibits osteolytic 
bone damage in preclinical mouse models of advanced prostate cancer. 
The specific aims of the work reported in this thesis are: 
 
• To establish whether selective inhibition of IKKα kinase activity affects: 
o prostate cancer cell growth, migration and invasion in vitro and in vivo 
o prostate cancer cell ability to influence  
▪ osteoclast signalling and differentiation in vitro and in vivo 
▪ osteoblast signalling, differentiation and activity in vitro in vivo 
o osteoclast differentiation in vitro 
o osteoblast differentiation and activity in vitro 
 
• To test the effects of a selective pharmacological inhibitor of IKKα kinase 
activity on cancer bone metastasis, skeletal tumour growth and osteolysis in 
vivo 
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Materials & Methods 
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2.1 Preparation of compounds tested 
The structurally related IKKα kinase inhibitors: SU1257 (non-active control), 
SU1261, SU1349, SU1361, SU1411, SU1266 and SU1087; were kindly gifted to us 
by Prof Simon MacKay (University of Strathclyde; patented by the university of 
Strathclyde and CRUK). The IKKα inhibitors were dissolved in dimethyl sulfoxide 
(DMSO) at a concentration of 30 mM for all drugs except drugs SU1349 and SU1361 
which were dissolved at 10mM. Serial dilutions of the IKKα inhibitors were made and 
stored at -20oC. Chemotherapy drugs: 5-fluorouracil, cyclophosphamide, doxorubicin, 
docetaxel, paclitaxel, tamoxifen and rapamycin were all purchased from Sigma-
Aldrich (Dorset, UK) and dissolved in DMSO at 10mM according to manufacturer’s 
instructions and stored at 4°C or -20°C, with the exception of cyclophosphamide 
which was prepared fresh by dissolving in DMEM at 100mM.  
2.2 Tissue culture 
2.2.1 Tissue culture medium 
Human PC3 and LNCaP prostate cancer cells, human Saos2 osteosarcoma cells, 
mouse RAW264.7 osteoclast precursors and mouse 3T3L1 preadipocytes were 
cultured in DMEM + GlutaMAX supplemented with 10% FCS, 100 U/ml penicillin 
and 100 µg/ml streptomycin (standard DMEM). Mouse calvarial osteoblasts, mouse 
osteoclasts, mouse bone-marrow cells, and mouse MC3T3 osteoblast precursors cells 
were cultured in αMEM + GlutaMAX supplemented with 10% fetal calf serum (FCS), 
100 U/ml penicillin and 100 µg/ml streptomycin (standard αMEM).  
2.2.2 Cell culture conditions 
Cell culture work was carried out in a laminar flow hood sprayed with 70% (v/v) 
ethanol before use. All solutions were pre-warmed to 37°C before use in cell culture 
work. Plastic ware was bought pre-sterilised or autoclaved prior to use. Standard 
conditions of 5% CO2: 95% air at 37°C in a humidified atmosphere was used to 
maintain cell cultures. Phase-contrast microscopy was used to examine confluence of 
cell cultures.   
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2.3 Cancer cell line cultures 
Human cancer cell lines  used include: LNCaP (androgen sensitive adenocarcinoma 
cell line derived from prostate cancer lymph node metastasis in a male patient; AR+ 
and PSA+); C4-2 (androgen insensitive cell line derived from LNCaP lymph node 
metastasis after injection in castrated nude mice; AR+ and PSA+); C4-2B4 (androgen 
insensitive cell line derived from LNCaP bone metastasis after injection in castrated 
nude mice; AR+ and PSA+); PC3 (androgen independent neuroendocrine cell line 
derived from prostate cancer bone metastasis in male patient; AR- and PSA-) and PC3 
clones (PC3-GFP, PC3-BT and PC3-NW1) that were kindly provided by Dr Ning 
Wang and Prof Colby Eaton (University of Sheffield) (Berish et al., 2018). The PC3 
cell clones were harvested after intracardiac injection in mice and metastasis to bone, 
specifically: PC3-GFP is GFP labelled and harvested after metastasis to bone, the 
related PC3-BT has the same origin as PC3-GFP, however, it was harvested after three 
cycles of injection in mice and metastasis to bone, and PC3-NW1 is Luciferase 
labelled and harvested after metastasis to bone. Cancer cells were cultured in 75 cm2 
flasks and passaged every 48-72 hours at a ratio of 1:3 – 1:6 for all PCa cells used, 
culture medium was removed, the cells washed in PBS and were detached by addition 
of trypsin. The trypsin was inactivated by adding twice the volume of standard medium 
to the cells, which were then transferred to a fresh sterile 15 ml tube that was then 
centrifuged at 1200 rpm for 3 minutes. The supernatant was discarded, and 1 ml 
standard medium was added to suspend cells, before a fraction of the suspension was 
placed into a new 75 cm2 flask containing 15 ml standard medium.  
2.3.1 Conditioned medium preparation 
PC3 cells were cultured in 6-well plates in standard medium and allowed to reach 80% 
confluence, before replacing medium with serum free medium. After 16 hours under 
standard culture conditions, the medium was then removed and filtered through a 0.2 
μm filter to obtain conditioned medium. Serum free medium was also added to empty 
wells with no cancer cells to obtain a conditioned medium control. 
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2.3.2 Cancer cell line drug treatments 
Human PC3 cells were seeded at density of 3000 cell/well of 96 well plates. After 24 
hours under standard culture conditions, the media was replaced with either fresh 
standard or serum free DMEM with drug or vehicle control at desired concentration 
and a final total volume of 100-150 µl. At the end of the experiment cell viability was 
assessed using the Alamar Blue assay. 
2.3.2.1 Combinational treatments with chemotherapeutic agents 
PC3 cells were seeded at density of 3000 cell/well of 96 well plates in 100 µl standard 
media. After 24 hours the media was replaced with serum free media and treated with 
1µM SU1349 and/or specific concentrations of chemotherapeutic agents in serum free 
media for 48-72hrs. At the end of the experiment cell viability was assessed using the 
Alamar Blue assay. 
For synergy and dose reduction analysis. PC3 cells were treated with different 
concentrations of docetaxel for 24 hours in serum free media before additional 
treatments 0.45 µM or 1.5 µM SU1349 or vehicle and left 48 hours. At the end of the 
experiment cell viability was assessed using the Alamar Blue assay. The Alamar Blue 
values were used to calculate the combination index (CI) and dose reduction index 
(DRI) using ComboSyn software (www.combosyn.com). 
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2.4 Bone cell cultures 
Osteoclast cultures 
2.4.1 Isolation of bone marrow cells 
Bone marrow cells (BM) were harvested from the tibia and femur of C57BL/6 female 
mice sacrificed aged 8-12 weeks. The hind limbs were dismembered using sterile 
scalpel and placed in tubes containing ice-cold PBS. In a hood, as much of the soft 
tissue was removed using a scalpel before the ends of the bone were cut off. The bone 
marrow cells were flushed out of the bone marrow cavity into a petri dish using a 5 ml 
syringe containing standard αMEM with a 25 gauge (G) needle attached.  The BM 
cells in αMEM were passed through syringes with needles of decreasing size (19G-
25G) to reach a single cell suspension. The suspension was centrifuged in a 15ml tube 
at 1200rpm for 3 minutes. The pellet was resuspended in 10mls of standard αMEM, it 
was then transferred to a fresh 100 mm petri-dish and cultured under standard 
conditions for 24 hours to allow attachment of stromal cells. The non-adherent cells 
were seeded in new plates for osteoclast formation experiments. 
2.4.2 Osteoclast formation cultures 
2.4.2.1 RANKL and M-CSF generated osteoclast cultures from mouse bone 
marrow cells 
For osteoclast PC3 co-cultures, non-adherent total bone marrow cells were seeded in 
96-well plate at 8 x 105 cells/well in 150 µl of standard αMEM. After 24 hours PC3 
cells at 200 cells/well were added. Cancer cells were allowed to settle for 6 hours 
before addition of 100 ng/ml RANKL, 10 ng/ml of M-CSF and drug treatments 
(SU1349 or vehicle) to avoid affecting cancer cell adherence. Cultures were 
maintained under standard conditions, while replacing 50% of the medium 
supplemented with fresh drug treatments, M-CSF and RANKL every 48 hours. The 
cultures were maintained for up to 7 days. 
For osteoclast – conditioned medium co-culture, non-adherent cells from total bone 
marrow culture were plated in 96-well plates at 12 x 103 cells/well in standard αMEM. 
After 24 hours conditioned medium from PC3 cells (10% v/v), 100 ng/ml RANKL, 10 
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ng/ml of M-CSF and drug treatments (SU1349 or vehicle) were added to the bone 
marrow osteoclast precursors and were cultured under standard conditions, while 
replacing 50% of the medium supplemented with fresh conditioned medium, drug 
treatments, M-CSF and RANKL every 48 hours. The cultures were maintained for up 
to 7 days.  
2.4.2.2 RANKL generated osteoclast cultures from RAW264.7 cells 
RAW264.7 cells were plated at 2000 cells/well of a 96-well plate in 100 µl of standard 
DMEM. After 24 hours the cultures were supplemented with RANKL (50ng/ml) and 
drug treatments (SU1349 or vehicle). Treatments were refreshed after 48hrs by 
replacing 50% of culture medium and the experiment was terminated 72hrs after the 
first addition of RANKL. Osteoclasts were fixed and identified using Tartrate-resistant 
Acid Phosphatase (TRAcP) staining.  
2.4.3 Characterisation and identification of osteoclasts 
2.4.3.1 Culture fixation 
Osteoclast culture media was removed, and the wells were washed twice with PBS to 
terminate cultures.  Cells were fixed by incubating with 150 µl of 4% (v/v) 
paraformaldehyde in PBS for 10 minutes at room temperature. The paraformaldehyde 
was removed, and the cells were washed twice with PBS and stored at 4°C in 200 µl 
of 70% ethanol (v/v). 
2.4.3.2 Tartrate-resistant Acid Phosphatase (TRAcP) staining 
Osteoclasts were identified using Tartrate-resistant Acid Phosphatase (TRAcP) 
staining as described in (van't Hof et al., 1995, Marino et al., 2014). In brief, the fixed 
cells were incubated with 100 μl of TRAcP staining solution at 37˚C for 45 minutes. 
The solution was then removed, and the cells were washed twice with PBS and stored 
at 4°C in 200 µl of 70% ethanol (v/v). A Leica DMIL light microscope using a 10x 
and 20x objective lens was used to count TRAcP positive cells (TRAcP+) with 3 or 
more nuclei as osteoclasts. 
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2.4.4 Osteoblast cultures 
2.4.4.1 Isolation of primary osteoblasts 
Primary osteoblasts were harvested from calvarial bones of 2-day-old mice by 
sequential collagenase digestion. The calvaria were first washed in Hank’s balanced 
salt solution (HBSS) before incubating in a tube containing 2 ml of collagenase type 
1 (1 mg/ml) in HBSS for 10 minutes at 37oC with frequent agitation. The supernatant 
was discarded and 4ml of fresh collagenase type 1 (1mg/ml in HBSS) was added to 
the calvariae and it was further incubated for 30 minutes. 6 ml of standard αMEM was 
mixed with the resultant cell suspension (fraction 1). The remaining calvarial tissue 
was washed in PBS and incubated with 4 ml of 4 mM ethylenediaminetetraacetic acid 
(EDTA) in PBS at 37oC for 10 min in a water bath with constant agitation. Another 6 
ml of standard αMEM was mixed with the resultant cell suspension (fraction 2). 
Fraction 3 was obtained by adding 4 ml of collagenase type 1 (1 mg/ml) in HBSS to 
the remaining calvarial tissue and incubated for 20 min at 37oC with constant agitation. 
The three fractions were combined together and centrifuged at 1200 rpm for 3 minutes. 
After discarding the supernatant, the pellet was resuspended in standard αMEM and 
cultured in a 75cm2 flask under standard conditions at a density of 3 calvariae per flask. 
After 24 hours the medium was changed to leave behind only adherent cells and the 
media was refreshed every 48 hours thereafter until confluence was reached. 
2.4.4.2 Passage of primary osteoblasts 
Primary osteoblasts were detached from 75cm2 culture flasks by incubating with 4 ml 
of trypsin for 3 minutes at 37oC and this was confirmed microscopically. The trypsin 
was then inactivated by adding 8 ml of standard αMEM to the flask. The cell 
suspension was then transferred to a 15 ml tube and centrifuged at 12000 rpm for 3 
minutes. The pellet was resuspended in standard αMEM before plating in 96-well plate 
at 8 x 103 cells/well in 150 μl or in 12-well plate 3x 105 cells/well in 1 ml of standard 
αMEM. 
2.4.5 Mouse calvarial osteoblast cultures 
For assessment of differentiation, mouse calvarial osteoblasts were seeded in 96-well 
plate at 8 x 103 cells/well in 150 μl of standard αMEM. After 24 hours the culture wells 
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were treated with SU1349 or vehicle and left for 48 hours before cell viability was 
assessed by the Alamar Blue assay and the wells were lysed in preparation for the 
alkaline phosphatase assay. 
For assessment of bone nodule formation, mouse calvarial osteoblasts were seeded in 
12-well plate at 3 x 105 cells/well in 1 ml of standard αMEM. Upon reaching 
confluence the media was changed to osteogenic αMEM media supplemented with 1% 
foetal bovine serum, 50 ng/ml ascorbic acid, 2mM β–glycerophosphate and drug 
treatment (SU1349 or vehicle). Cultures were maintained under standard conditions, 
while refreshing culture medium every 48-72 hours. The cultures were maintained for 
up to 21 days. 
2.4.6 Saos2 cultures  
Saos2 cells were seeded in 24-well plates at 1.5 x 105 cells/well in 1 ml of standard 
DMEM media. Upon reaching confluence the media was changed to osteogenic 
DMEM media containing 1% foetal bovine serum and where indicated media was 
supplemented with 50 ng/ml ascorbic acid and 2mM β–glycerophosphate. 
Additionally, the Saos2 cultures were treated with PC3 conditioned media 20% (v/v) 
or serum free control DMEM and/or drug treatments (SU1349 or DMSO vehicle). 
Treatments were refreshed every 48-72hr for 10-21 days. At the end of experiments 
cell viability of culture wells were assessed by the AlamarBlue assay before 
proceeding with lysis of wells for alkaline phosphatase assay or fixing of wells for 
Alizarin red staining. 
2.4.7 MC3T3 cultures  
MC3T3 cells were seeded in a 24-well plate at 1.5 x 105 cells/well in 1 ml of standard 
αMEM media. Upon reaching confluence the media was changed to osteogenic 
αMEM media supplemented with 1% foetal bovine serum, 50 ng/ml ascorbic acid and 
2mM β–glycerophosphate. Additionally, The MC3T3 cultures were treated with PC3 
conditioned media 20% (v/v) or serum free control αMEM and/or drug treatments 
(SU1349 or DMSO vehicle). Treatments were refreshed every 48-72hr for up to 21 
days. At the end of experiments cell viability of culture wells were assessed by the 
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AlamarBlue assay before proceeding with lysis of wells for alkaline phosphatase assay 
or fixing of wells for Alizarin red staining. 
2.4.8 Alkaline phosphatase assay  
Osteoblast differentiation was determined using the Alkaline phosphatase (ALP) 
assay. The assay measures the rate of conversion of colourless p-nitrophenol 
phosphate into yellow coloured p-nitrophenol by spectrophotometry. The measured 
absorbance values are proportional to alkaline phosphatase enzyme levels that are 
expressed at higher levels by osteoblast during differentiation. 
At the end of osteoblast differentiation experiments, cell culture wells were rinsed with 
PBS before being incubated with lysis buffer (Appendix table 2.2) at 150 µl for 96-
well plate cultures or 500 µl for 24-well plate cultures for 20 minutes. Serial dilutions 
of p-nitrophenol (0 – 30 nM) were used to create a standard curve. 50 µl of the standard 
solutions and lysates samples were plated in duplicates in a fresh 96-well plate and an 
equal amount of substrate solution was added. A Biotek Synergy HT plate reader was 
used to measure the absorbance and the readings were made at 414 nm at 37°C every 
5 minute for 30 minutes. The slope of the linear part of the kinetic curve generated was used 
to quantify ALP activity and this was expressed as fold change over control. Where 
appropriate, cell numbers as determined by Alamar Blue assay was used to normalise Alkaline 
Phosphatase activity (section 2.9). 
2.4.9 Bone nodule formation assay 
Osteoblastic bone nodule formation function was assessed by Alizarin Red S staining 
and quantification. Alizarin Red S binds to calcium deposits found in the mineralized 
extracellular matrix produced by osteogenic cells, which precipitates and forms brick-
red deposits (Chang et al., 2000, Coelho et al., 2000).  
At the end of experiments osteogenic cultures were fixed in 70% ethanol (v/v). 
Alizarin Red S staining solution was made fresh to a final concentration of 40mM in 
distilled water and the pH was adjusted to 4.1-4.3 using ammonium hydroxide.  Fixed 
osteogenic cultures were washed with PBS and incubated at room temperature with 1 
ml of Alizarin Red S staining solution for 20 minutes with gentle agitation on a rocker. 
The staining solution was removed, and culture wells were washed with distilled water 
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until water runs clear before removing water and allowing plates to dry overnight. The 
culture wells were scanned, and staining was quantified by ImageJ as described in 
Shah et al., (Shah et al., 2016).  
2.4.5 Adipocyte cultures 
2.4.5.1 3T3-L1 adipocyte cultures  
3T3-L1 preadipocytes cells were seeded at 2 x 105 cells/well of 24 well plate in 1ml 
of standard DMEM. 48hrs post confluence the media was changed to differentiation 
media containing standard DMEM supplemented with 0.5mM IBMX, 1µM 
dexamethasone and 1µg/ml insulin, plus/minus PC3 conditioned media 20% (v/v) or 
drug treatments (SU1349 or DMSO vehicle). After 48hrs the differentiation media was 
replaced with maintenance media containing standard DMEM, insulin (1µg/ml) and 
PC3 conditioned media or drug treatments. 50% of the media was replaced with fresh 
maintenance media plus experimental treatments every 48-72hrs for 14 days. The 
viability of cultures wells was assessed by the AlamarBlue assay before fixing wells 
in preparation of oil red staining. 
2.4.5.2 3T3-L1 adipocyte Oil red staining and quantification  
0.3 % Oil Red O stock solution was prepared in isopropanol in advance. Cell cultures 
were fixed in 10% formalin for at least 30 minutes. The cells were then washed twice 
in PBS and incubated in 60% isopropanol for 5 minutes. In the mean while Oil Red O 
staining solution was freshly prepared by diluting 3 parts Oil Red O stock solution to 
2 parts of distilled water. The 60% isopropanol solution was removed before 
incubating culture wells in Oil Red O staining solution for 30 minutes. The solution 
was removed, and the culture wells were washed in water several times until water 
runs clear. The culture wells were allowed to completely dry before destaining with 
250 µl with 100% isopropanol for at least 10 minutes. Absorbance of destained sample 
was measured at 490-520nm.  
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2.5 Molecular Biology techniques 
2.5.1 Preparation of Luria-Bertani (LB) broth  
20 g of LB broth was dissolved in 1 litre of distilled water, autoclaved and ampicillin 
(for IKKα overexpression construct) added to the cooled media at a final concentration 
of 100μg/ml. 
2.5.2 Preparation of LB/ampicillin agar plates  
40g of agar powder was dissolved in 1 litre of distilled water, which was then 
autoclaved and then cooled at room temperature to approximately 50°C before adding 
ampicillin at 100μg/ml, and then about 20 ml of LB agar media was poured into 
150mm petri dishes and left to set and was stored at 4°C.  
2.5.3 Bacterial transformation 
5µl of IKKα overexpression or GFP vector DNA was used to transform bacteria using 
the One Shot TOP10® Chemically competent E.coli system (Invitrogen) as per 
manufacturer’s instructions. The resultant bacterial cultures were grown overnight at 
37°C on selective agar plates, single colonies were picked the next day for expansion 
in LB broth culture.  
2.5.4 Preparation of broth culture  
LB bacterial growth medium was prepared using 10 µl of 100mg/ml of ampicillin (for 
IKKα overexpression construct) or carbenicillin (for IKKα ShRNA knockdown 
constructs) in 1 L of broth culture. A freshly picked bacterial colony from an agar plate 
or ~5 µl of bacterial glycerol stock was used to inoculate 100 ml of LB broth in a 500 
ml conical flask.  The flasks were covered with foil and left overnight at 37°C in a 
shaking incubator at 300rpm for the bacteria to grow. The next day, a High Speed 
QIAGEN Midi prep kit was used to recover DNA from the bacterial cultures according 
to manufacturer’s instructions. The recovered DNA was quantified using NanoDrop 
™ and stored at -20°C until further use. Also, some of the LB culture was set aside to 
prepare glycerol stocks by adding 150 µl of glycerol to 850 µl of bacterial suspension 
in a 2 ml cryogenic vial and stored at -80°C.   
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2.6 Retroviral gene delivery 
2.6.1 IKKα overexpression constructs 
The IKKα gene was overexpressed in human PC3 prostate cancer using a lentiviral 
delivery system.  The IKKα overexpression construct and a GFP control construct 
were kindly provided by Dr Yousef Abu-Amer (Washington University School of 
Medicine). The constructs used a pMXs vector with a puromycin selection cassette. 
Construct DNA was adsorbed onto paper and recovered by incubating with 100 µl of 
MillliQ water at 37°C for 30 min, it was then quantified using NanoDrop ™ and stored 
at -20°C. 
2.6.2 Short Hairpin RNA (shRNA) 
A vector-based short hairpin RNA (shRNA) method was used to generate knockdowns 
of IKKα expression in human parental PC3 prostate cancer cells. Three TRC human 
individual clones (TRCN-504, -505 and -506) and one empty vector control were 
supplied in glycerol (Thermo Scientific, Germany) ready for expansion in LB broth 
culture before use in transfection of PC3 cells. 
2.6.3 Kill curve and Puromycin selection  
Cells were plated 3000 cells per well in 96 well plate. Puromycin (ThermoFisher) was 
prepared in standard medium at 0, 0.25, 0.5, 0.75, 1, 1.5 and 2µg/ml. The growth media 
was replaced with media containing serial dilutions of puromycin and incubated at 
37°C for 48 hours. The viability of cells was measured using the AlamarBlue assay 
and the percentage of cell survival was calculated. The minimum antibiotic 
concentration that kills 100% of the cells was found to be 1 µg/ml and was 
subsequently used to select for successfully transfected cells.  
2.6.4 Retroviral transfection  
On day 1, HEK293ET cells were seeded (25 x 105 cells per T25 flask) in 5 ml of 
medium and allowed to grow overnight. By day 2 cells should have reached ~80% 
confluence and the media was changed at least 5 minutes before transfection reagents 
were added. Transfection mixture was prepared with 5µg of vector DNA, 5µg of gag 
and pol DNA, 5µg of pMD2.G vector, 40µl of polyethylenimine (PEI) transfection 
reagent and 450 µl of standard DMEM medium. After gently aspirating 5 ml of the 
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culture media, 5 ml of the transfection mixture was added to the flask and cultured 
under standard conditions. On Day 3, HEK293ET cells media was again changed and 
the recipient PC3 cells were seeded at a density of 7.5x105 PC3 cells per T75 flask.  
On day 4, the viral supernatant was collected and briefly centrifuged, before taking 1 
ml (containing the virus; back up 1 ml aliquots were also stored at -80°C) and adding 
it to 10 µl of 5 µg/ml polyberene (Sigma-Aldrich) and 9 ml of standard DMEM, the 
mixture was then filtered through a 0.45 µm low protein binding filter before adding 
it to the recipient PC3 cells.  On day 5, the medium for the recipient PC3 cells was 
replaced with selection medium of standard DMEM plus 1 µg/ml puromycin. The 
transfected PC3 cells were maintained in selection for at least two passages. The 
efficiency of the IKKα knockdown or overexpression was determined by western blot 
analysis. 
2.7 Alamar Blue assay 
Alamar Blue assay exploits a nontoxic dye containing resazurin which is blue in colour 
and non-fluorescent when in an oxidized state, that is taken up and reduced by 
metabolically active cells to resorufin which is red in colour and fluorescent. The 
degree of change in colour/fluorescence is proportional to the number of metabolically 
active viable cells. Cell viability is measured by adding the AlamarBlue reagent (10% 
v/v) in a hood at the end of the culture period to each well. Cell cultures were left for 
3 hours in standard culture conditions, after which fluorescence was measured 
(excitation, 530 nm, emission 590 nm) using a SpectraMax® M5 microplate reader. 
To correct for background fluorescence, AlamarBlue was also added to wells 
containing standard media and no cells or treatments. 
2.8 Migration assays  
The wound healing assay was used to measure 2D directional migration of PC3 cells 
transfected with mock or IKKα knockdown constructs. PC3 cells were plated at 200 x 
103 cells/well of 24-well plate in standard DMEM. After 24 hours, the confluent 
monolayer was scratched using a P10 pipette tip, the wells were washed at least 3 times 
to remove any cell debris and replaced with serum free DMEM. The IKKα inhibitor 
solubilised in serum free DMEM was added to some of the wells and the plate was 
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placed in humidified microscope maintained at 37°C and 5% CO2. Migration was 
monitored for up to 12 hours with a Leica AF6000 Time Lapse imaging system. 
Images were captured sequentially at 15-minute intervals. The T scratch software was 
used to calculate percentage wound closure. 
For random migration assay, PC3 cells were plated in 24 well plates (1x103 cells/well). 
Cells were pre-treated with vehicle or SU1349 (1μM) for 3 hours. Migration of 30-50 
individual cells per well was monitored for 8 hours with a Leica AF6000 Time Lapse 
microscope with images captured sequentially at 15-minute intervals. Cell velocity 
and accumulated distance travelled by cells (total track length) were measured using 
the Chemotaxis and Migration tool in ImageJ. 
2.9 Invasion assays  
Growth factor reduced matrigel was defrosted on ice and diluted to a concentration of 
1.5mg/ml using ice-cold serum free DMEM and pre-cooled (in -20oC freezer) pipette 
tips. 20 µl of diluted matrigel was used to coat Corning™ transwell inserts which was 
inserted over a 24-well tissue culture plate. The matrigel coated inserts were allowed 
to dry in the incubator at 37 oC for at least 3 hours. 500 µl of DMEM containing 10% 
foetal bovine serum was added to the bottom of the tissue culture wells, while PC3 
cells at 50 x 103 in 200 µl in serum free DMEM plus drug treatment was carefully 
added to the top of the insert. The culture plates containing the insert were placed in 
the tissue incubator under standard culture conditions for 72hrs. At the end of the 
experiments the matrigel on top of insert mesh containing non-invading cells was 
carefully removed using a cotton swab. The cells were quickly fixed in 100% ethanol 
for 5 minutes, followed by staining by incubating in eosin for 1 minute and 
haematoxylin for 5 minutes (briefly washed in water after each stain). The inserts mesh 
was removed using a scalpel and mounted using DPX on glass slides.  At least five 
non-overlapping colour images of each insert at 20x magnification were taken on a 
Leica AF4000 microscope and the average count was analysed using ImageJ. 
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2.10 WESTERN BLOT 
Western blot was used to measure protein expression in cells as previously described 
in (Idris, 2012). 
2.10.1 Preparation of cell lysates 
For prostate cancer cells, cells were plated in 6-well plate at 3-6 x 105 cells/well in 
standard medium until 80% confluence was reached. Before harvesting cells were 
incubated in medium with or without serum for 16 hours.  
For RAW264.7 and MC3T3 signalling experiments cells seeded at 1.5 x 105 cells/well 
in 12-well plates. After 48hrs, cells were pre-treated with vehicle or SU1349 for 1 hour 
in serum free media before stimulation with PC3 conditioned media 20% (v/v) for 10-
15 min or before stimulation with 150 ng RANKL for 5-10min. 
After cells were exposed to their conditions for the desired period of time the medium 
was then discarded, and ice-cold PBS was used to wash the cell monolayer before cells 
being gently scraped in 80-100 μl of RIPA lysis buffer (appendix table 2.3) with 2% 
(v/v) protease inhibitor cocktail and 0.4% (v/v) phosphatase inhibitor cocktail and left 
on ice for 5 minutes. The cell lysate was transferred to a new eppendorf tube and 
centrifuged at 14000g for 10 minutes at 4oC. The supernatant fraction of proteins was 
collected and stored at -20oC until further use. 
For studies involving cytoplasmic/nuclear fractionation, RAW264.7 and MC3T3 cells 
were seeded at 3 x 105 cells/well in 6-well plates. After 48hrs, cells were pre-treated 
with vehicle or SU1349 for 1 hour in serum free media before stimulation with PC3 
conditioned media 20% (v/v) for 45 minutes. The monolayer was washed in ice cold 
PBS before scrapping in 100 μl of Cytoplasmic lysis buffer (Appendix table 2.3) 
supplemented with protease and phosphatase inhibitor for up to 10 minutes until the 
cytoplasmic wall is lysed as observed on a microscope. The lysates were then 
centrifuged at 800 x g for 5 minutes at 4oC and the supernatant containing the 
cytoplasmic fraction was stored at -20oC for later use. The pellet was washed three 
time in ice-cold cytoplasmic lysis buffer and centrifuged at 800 x g for 5 minutes at 
4oC after every wash. The pellet was then resuspended in 50 μl of complete RIPA 
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buffer and centrifuged at 14000g for 10 minutes at 4oC. The supernatant corresponding 
to the nuclear fraction was collected and stored at -20oC for later use 
2.10.2 Measuring protein concentration 
Protein concentration was measured by the bicinchoninic acid (BCA) Pierce protein 
assay (Pierce, USA). Serial dilutions of bovine serum albumin (BSA) standads (0-
2000 µg/µl) were used to generate the standard curve. 10 µl of standard BCA dilution 
standards and protein samples (1:5 diluted in H2O) were plated in duplicates in a 96-
well plate, and to each well 200 µl of BCA solution (made of copper sulphate diluted 
in bicinchoninic acid at 1:50) was added. The plate was incubated for 15-30 minutes 
at 37oC. The absorbance was then measured at 562 nm on a DYNEX MRX II 
microplate reader and the BSA standard curve was used to calculate the protein 
concentration in each sample. 
2.10.3 Gel electrophoresis 
CriterionTM XT BioRad (12% Bis-Tris) pre-cast gels were positioned into a vertical 
electrophoresis tank filled with TGS running buffer. A 5X sample loading protein 
buffer was mixed with cell lysates (50-100 μg) then heated at 95°C for 5 minutes, 
before loading into the pre-cast gel wells. Magic Marker XP western standard and 
Kaleidoscope pre-stained standard were used to identify molecular weights. Gels were 
run at constant voltage of 150-180V for 45 minutes to 1 hr and 45 minutes. 
2.10.4 Electrophoretic transfer 
The proteins resolved on the polyacrylamide gel were transferred to a polyvinylidene 
difluoride (PVDF) membrane (Hybond TM-P membrane, Amersham). The PVDF 
membrane was first activated in 100% methanol and then allowed to equilibrate in 
transfer buffer for 5 minutes. The gel and PVDF membrane were sandwiched between 
two thick blotting paper pads pre-soaked in transfer buffer and placed in the transfer 
apparatus at a constant current of 90 mA for 2.5 hours. 
2.10.5 Immunostaining and antibody detection 
The PVDF membrane was incubated at room temperature on a rocker for 1 hour in 5% 
milk solution (w/v dried non-fat milk in TBST) to block non-specific antibody binding 
sites. The membrane was then washed in Tris buffer saline solution with 0.1% (v/v) 
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Tween 20 (TBST) for 10 minutes 3 times and incubated overnight at 4°C on a rocker 
with the primary antibody (at 1:1000 in 5% BSA in TBST). The following day, TBST 
was used to wash the membrane 3 times for 10 minutes and the membrance was then 
incubated with the HRP-conjugated secondary antibody (at 1:10000 in 5% milk in 
TBST) for 1 hour at room temperature. The membrane was washed again with TBST 
for 10 minutes and this was repeated 3 times, before visualising on a Chemidoc 
Imaging system (BioRAD) using ClarityTM western ECL substrate (Bio-Rad) 
chemiluminescent detection system. Native and phosphorylated proteins were 
detected using rabbit antibodies IKKα, phospho-p100, p100, p52, phospho-IκB, IκB, 
β-catenin, GSK3β and phospho-GSK3β, (1:1000 dilution, Cell Signalling Technology, 
USA). Bands were quantified using Image Lab Software (BioRAD) and levels of Actin 
or GAPDH (Sigma-Aldrich, UK) were used for normalization. 
2.11 Microarray of PC3 conditioned media 
PC3 cells were seeded at 3 x 105 cells/well in 6 well plate. After 24 hours the cells 
were incubated for 16 hours with vehicle or 1μM SU1349 in serum free medium. 
Conditioned medium was collected and protein expression in the conditioned medium 
was measured with the Proteome Profiler Human XL Cytokine Array Kit by R&D 
systems as per manufacturer’s instructions. The arrays were analyzed following 
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2.12 Animal work 
All procedures involving mice and their care were approved by and performed in 
compliance with the guidelines of Institutional Animal Care and Use Committee of 
Universities of Sheffield (England, UK) and L’Aquila (L’Aquila, Italy), and received 
institutional approval and conducted in conformity with laws and policies (UK Home 
Office and Italian authorities). In vivo experiments were performed by our 
collaborators: Marco Ponzetti and Prof Nadia Rucci in L’Aquila (Italy).  MicroCT and 
bone histomophometry was done in Sheffield.  
2.12.1 In vivo experiments 
BALB/c nu/nu mice were obtained from Charles River (Milan, Italy). 4-week-old male 
BALB/c nu/nu athymic mice were anesthetized with intraperitoneal injections of 
pentobarbital (60 mg/kg). 1 × 105 of luciferase expressing PC3 cells in 0.1 ml of PBS 
were intra-cardiacaly injected -into the left ventricle- using a tuberculin syringe with 
a 271/2G needle. Dosage and treatment regimen was based on previous data from Prof 
Simon MacKay (University of Strathclyde, UK; personnel communication). Animals 
were divided into two groups (8 animals per group) and received intraperitoneal 
injection of 150µl solution of SU1349 dissolved in mannitol at 20mg/kg 3x-weekly or 
vehicle control (see appendix 2.7). Animals were monitored daily for cachexia 
(evaluated by body weight waste), behaviour and survival. The development of 
metastasis was monitored by Bioluminescence imaging and X-ray analysis (36 KPV 
for 10 seconds) using a Cabinet X‐ray system (Faxitron model n.43855A; Faxitron X‐
Ray Corp., Buffalo Grove, IL, USA) and IVIS SpectrumCT In Vivo Imaging System 
(PerkinElmer, UK). Radiographs were scanned using the Bio‐Rad scanning 
densitometer (Hercules, CA, USA), model GS800, and quantification of the area of 
interest was done using the Bio‐Rad Quantity One image analysis software to quantify 
tumour size. Animals were sacrificed by carbon dioxide inhalation 40 days after intra-
cardiac injection, or earlier if they displayed signs of serious distress. At the end of the 
experiment animals were subjected to anatomical dissection to remove the hind legs 
and were fixed in 4% paraformaldehyde (v/v) in PBS. 
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2.12.2 Micro-computed tomography* 
Bone volume and architecture of mouse tibia was assessed by microcomputer 
tomography (μCT). The bone samples were wrapped in parafilm (to prevent 
desiccation) and placed in in a 2 ml syringe (with both ends cut). This was then placed 
ex vivo into the μCT scanner (SkyScan), then scanned after being fixed in an upright 
position on a platform within the scanner. The x-ray radiation source was set to 60kV 
and 150μA using the SkyScan. A 180˚ scan with a rotation step of 0.6 degrees was 
used using a 0.5 mm aluminium filter. The pixel size was set at 9μm for scanning 
mouse tibia. 3D image stacks were produced by reconstructing the data from the 
rotation image projections using the NRecon software (SkyScan). For trabecular bone 
measurements were taken near the proximal tibial metaphysis, 500 frames distal to the 
growth plate at baseline were chosen for reconstruction. For cortical bone, 
measurements of 100 frames situated 700 frames distal to the reference line, of the 
proximal diaphysis were selected for reconstruction. The parameters for reconstruction 
are shown in Table 2.1.  
Table 2.1: Reconstruction parameters used in NRecon software 
 
Parameter  Description  Setting 
Smoothing  Removes noise and smoothes images  




Corrects for the absorption of lower 




Corrects for the non-linear behaviour of 
pixels causing ring artifacts  
3 
 
Analysis of the reconstructed images were done using the CTAn software by SkyScan. 
A free-hand drawing tool was used to select the region of interest (ROI) at 3-7 different 
levels, and the software used auto-interpolation between these levels produced the total 
ROI. 
For trabecular bone, the point where the calcified cartilage ridges of growth plate fuse 
together was set as the reference line. At 200 frames distal to the reference point, 
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measurements were performed, 5µm apart, in trabecular bone specified by ROI. For 
cortical bone analysis, ROI was selected by an 8-figure drawing, which comprised 
only the cortex as a hollow tube. Measurements for 3D-reconstruction were performed 
on all 100 frames selected previously. A total bone analysis at the cortical level was 
also performed on these reconstructed frames. The analysis parameters for 3D-
reconstruction are shown in Table 2.2. 
Table 2.2: 3D reconstruction parameters used in CTAn software 
 
Parameter  Description  Setting 
Smoothing  
Smoothes images and 
removes noise  
Median filter; 2D space, radius 1 
Threshold  
Segments the foreground 
from background to binary 
images  
Global; low level 100, high level 
255 
Despeckle  
Removes speckles from 
binary images 




Creates a 3D surface from 
binary images  
Adaptive rendering; file saved 
as .p3g 
3D-Analysis  
Calculates 3D parameters of 
binary images 
Requested for basic values, 
trabecular thickness, number and 
separation 
 
Analysis was performed on trabecular bone volume, trabecular thickness, trabecular 
separation, trabecular number, trabecular porosity and trabecular pattern factor as 
shown in Table 2.3. Cortical bone analysis was performed on cortical bone volume, 
cortical thickness, cortical diameter, and cortical porosity. All calculations were saved 
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Table 2.3: 3D bone analysis parameters calculated by µCT 
 
Parameter  Abbreviation (unit) 
Trabecular bone volume fraction BV/TV (%) 
Trabecular bone volume  Tb. BV (mm3) 
Trabecular Thickness  Tb.Th (µm) 
Trabecular Separation  Tb.Sp (µm) 
Trabecular Number  Tb.N (1/mm) 
Trabecular Porosity Tb.Po (%) 
Trabecular Pattern factor  Tb.Pf (1/mm) 
Cortical bone volume fraction  BV/TV (%) 
Cortical bone volume  Ct.BV (mm3) 
Cortical Porosity  Ct.Po (%) 
 
 
* microCT methods sections were based on the theses of previous students in our 
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2.12.3 Bone histomorphometry 
Fixed mouse tibia were washed in PBS then decalcified with EDTA (pH 7.2) on a 
gentle rocker at 4oC for 1 month, the decalcification solution refreshed three time 
weekly. Bone samples underwent different stages of dehydration with ethanol 
dilutions and defatting with xylene as shown in Table 2.4. 
 
Table 2.4: Stages and reagents for Leica tissue processor programme 
 
Stage Reagent Time (hours) 
1 70% Ethanol 02.00 
2 95% Ethanol 02.00 
3 100% Ethanol 02.00 
4 100% Ethanol 02.00 
5 100% Ethanol 02.00 
6 Xylene 04.00 
7 Xylene 04.00 
8 Paraffin Wax 02.00 
9 Paraffin Wax 02.00 
 
Fixed mouse tibia were washed in PBS then decalcified with EDTA (pH 7.2) on a 
gentle rocker at 4oC for 1 month, the decalcification solution refreshed three time 
weekly. Bone samples underwent various stages of dehydration following the 
procedure summarize in Table 2.4, the samples were placed in freshly prepared 
paraffin-based infiltration solution for 4 hours at 60oC then embedded in moulds with 
paraffin wax. Sections of 4 μm were cut using a Leica microtome, at least 3 non-
consecutive sections were collected every interval of 20 μm and mounted on glass 
slides. Randomly selected cross sections from each sample were stained with tartrate-
resistant acid phosphatase (TRAcP) and counter staining with haematoxylin. TRAcP 
staining was performed using standard methods as follows: 
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1. De-wax the sections in xylene twice for 5 minutes each 
2. Rinse in 100% ethanol twice for 5 minutes each  
3. Rinse in 95% IMS (industrial methylated spirit) for 5minutes 
4. Rinse in 70% IMS for 5 minutes then deionized water for 1 minute 
5. Stain sections with TRAcP staining solution (see details in Appendix 2.5) for 20 minutes at 
37ºC 
6. Rinse sections in water stain in haematoxylin solution for 20 seconds 
7. Rinse in deionized water for 2 minutes 
8. Rinse in 70% IMS for 10 seconds 
9. Rinse in 95% IMS for 10 seconds 
10. Rinse in 100% ethanol twice for 30 seconds each 
11. Immerse in Xylene for 3 minutes  
12. Mount in DPX 
The Osteomeasure software was used for histomorphometry analysis of bone sections 
which was performed on trabecular and cortical bone 200µM distal from the growth 
plate at 20x magnification.   
2.12.4 Tissue microarray staining 
Prostate cancer tissue microarray (PR242b, US Biomaz Inc.) was stained using the 
following protocol (done by Anne Fowles): 
1. The pre-treatment module was pre-heated to 85oC and PBST was warmed to 35oC.  
2. Dewax sections and hydrated in 95% ethanol 
3. Block endogenous peroxidase with 3% H2O2 for 15 minutes. 
4. Quench sections in water then place in pre-warmed pre-treatment module in warm PBST. 
5. Retrieve antigen in citrate buffer (see appendix 2.6) for 10minutes at 80oC and collect in 
warm PBST.  
6. Block with 5% normal goat serum for 1 hour for rabbit antibodies or 2.5% horse serum for 
30 minutes for mouse antibodies.  
7. Incubate in primary antibody (mouse anti-IKKα monoclonal-antibody at 5mg/ml (Novus 
Biologicals)) overnight in the cold room.  Wash three times in PBST.  
8. Incubate with secondary SS Boost (Cell Signalling) kit for rabbit antibodies or IMPRESS 
reagent (Vector) for mouse antibodies for 30 minutes. Wash three times in PBST.  
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19. Apply DAB (from kit) 1 drop in 1 ml. wait for ~ 3 minutes. Wash in water and counterstain 
in Haematoxilin.  
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2.13 STATISTICAL & DATA ANALYSIS  
All statistical analysis was done using GraphPad Prism version 6.0. Student’s T test 
was performed to determine the significance level of differences between two sets of 
results. For multiple comparison between groups analysis of variance (ANOVA) 
followed by a post-hoc test. A p- value of 0.05 or below was considered statistically 
significant. The half maximal inhibitory concentration (IC50) was calculated by non-
linear regression analysis using the 4 parameter slope fit equation for dose-inhibition 
response in GraphPad.
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Selective IKKα inhibition reduced prostate cancer 
cell growth and motility in vitro 
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Previous work by Karen and colleagues demonstrated that IKK activation is 
correlated with prostate cancer progression in mouse models and in human patients. I 
hypothesized that IKK expression will correlate with prostate cancer progression and 
prostate cancer cell metastatic ability. Additionally, I hypothesized using a verified 
selective inhibitor of IKK will suppress the growth, migration and invasion of 
prostate cancer cells in vitro. I show that there is no association between total IKK 
expression and prostate cancer progression or the metastatic ability of various prostate 
cancer cell lines. This in broad agreement previous with work that showed activation 
of IKK and not its expression is correlated with prostate cancer progression. I also 
show for the first time that the verified selective IKK inhibitor, SU1349, significantly 
inhibited prostate cancer cell growth, migration and invasion in vitro. Consistently, 
IKK knockdown in PC3 cells reduced their viability, migration and invasion in vitro, 
whereas, IKK overexpression in PC3 was stimulatory. Overall, the results of this 
chapter show that selective IKK inhibition reduces both the growth and motility of 
prostate cancer cell tested, highlighting its therapeutic potential.  
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The NFB pathway plays an important role in primary prostate cancer tumour growth 
and progression to metastatic disease (Nguyen et al., 2014b). Microarray analysis 
showed the NFB pathway to be highly dysregulated in prostate cancer patients (Setlur 
et al., 2007). Increased activation of the NFB pathway, as evident by the increased 
nuclear localisation of NFB-p65/p50 and IκB-α phosphorylation, was observed 
during prostate cancer progression in humans and in the TRAMP mouse model of 
prostate cancer disease (Shukla et al., 2004, Shukla et al., 2005). Activated nuclear 
NFB-p65 was found to be both highly predictive of- and significantly upregulated 
in- prostate cancer lymph node metastases (Ismail et al., 2004, Lessard et al., 2006). 
Moreover, evidence of increased NFB pathway activation –indicated by elevated 
phospho-p65 and phospho-IκBα expression- was observed in patients with the 
advanced castration resistant prostate cancer (McCall et al., 2012). Whereas inhibition 
of NFB has been demonstrated to sensitize prostate cancer cells to chemotherapy and 
radiotherapy (Codony-Servat et al., 2013). 
In prostate cancer cells, the NFB pathway has been shown to regulate cell growth, 
survival, migration and invasion (Nguyen et al., 2014b, Huang et al., 2001, Baritaki et 
al., 2009, Taichman et al., 2002, Kukreja et al., 2005).  In cell line models of human 
prostate cancer, the NFB pathway was shown to be constitutively activated in the 
highly metastatic PC3 cell line model of advanced prostate cancer as compared to the 
weakly metastatic LNCaP cell line model of early stage prostate cancer or to normal 
prostate epithelia (Gasparian et al., 2002). Inhibition of the NFB pathway in PC3 
increased its susceptibility to apoptosis and reduced its invasiveness in vitro (Shukla 
and Gupta, 2004, Huang et al., 2001). Furthermore, while LNCaP cells are weakly 
metastatic and typically never metastasize to bone (Simmons et al., 2014), activation 
of the NFB pathway in LNCaP did induce bone metastasis when injected in mice, 
whereas inactivation of the NFB pathway in highly metastatic PC3 cells inhibited its 
ability to causes bone metastasis in mice (Jin et al., 2013).     
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The IκB kinases, IKK and IKK, are important in the regulation of the NFB 
pathway (Clement et al., 2008). Although some studies have shown that IKK plays a 
more essential role in the regulation of the canonical NFB pathway than IKK 
(Hacker and Karin, 2006, Lee and Hung, 2008, Ammirante et al., 2010),  IKK- which 
is involved in the regulation of both the canonical and non-canonical NFB pathway, 
was shown to play a more important role in the development of prostate cancer than 
the IKK (Shukla et al., 2005, Nguyen et al., 2014b).  
Work by Karin and colleagues show that genetic inactivation IKK in TRAMP mouse 
model of prostate cancer, reduced prostate tumour growth and metastasis (Luo et al., 
2007). Furthermore, they also show that phosphorylated and nuclear IKK in mouse 
and human sections correlated with tumour progression and metastasis. The TRAMP 
mice used in this study generated soft tissue metastasis and was not suitable for 
studying the characteristic bone metastasis associated with prostate cancer, therefore, 
the role of IKK in prostate cancer bone metastasis remains unknown. 
Currently, there are no commercially available selective IKK inhibitors. Most of the 
drugs developed by the pharmaceutical industry to inhibit the NFB pathway have 
either been non-specific IKKα/ inhibitors or have targeted IKK, however, these 
drugs have not proved successful in clinical trials (Verstrepen and Beyaert, 2014). It 
is thought that as IKK is essential in the regulation of the canonical NFB pathway 
and therefore innate immunity, targeting IKK could have detrimental effects in a 
clinical setting (Baud and Karin, 2009). IKK inhibitors that have been tested were 
shown to cause significant toxicity including liver and intestinal toxicity with side 
effects including the development of skin, liver and intestinal inflammatory disease  
(Pasparakis, 2009, Anthony et al., 2017). It is for this reason that some have argued 
that because IKK is understood not be essential for canonical NFB pathway 
signalling, selective targeting of IKK might be a better therapeutic option and is less 
likely to result in serious side effects (Huang and Hung, 2013). 
IKK inhibitors that have been described in literature either do not report enough 
details about their specificity and activity or they report pharmacodynamics readouts 
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that are not specific to IKK, for example, phosphorylation of IκB might be reported, 
which involves both IKKβ and IKK activity, rather than p100 phosphorylation and 
processing to p52 which is IKK specific (Llona-Minguez et al., 2013, Asamitsu et 
al., 2008, Liou et al., 2013, Doppler et al., 2013, Storz, 2013).  We were provided 
exclusive license by Prof Simon McKay (University of Strathclyde) to test a panel of 
novel and selective small molecular inhibitors of IKK in prostate cancer. Although 
these compounds are patented and details about them have not been published, 
McKay’s group have recently published details on an earlier generation of inhibitors 
(Anthony et al., 2017). Anthony et al. utilised recent high-resolution crystal structures 
of IKK and IKKβ to identify key differences around the ATP binding site within the 
IKK kinase domain -where IKK appeared more flexible than IKKβ- to design 
structure-based compounds. These compounds are 4-substituted 2-amino-5-
cyanopyrrolo[2,3-d]pyrimidines that selectively bind IKK and inhibit IKK-specific 
pharmacodynamics markers (p100 phosphorylation) without affecting markers that are 
also common to IKKβ (IκB degradation and p65 phosphorylation). 
In the light of above, the study of selective IKK inhibition in prostate cancer and 
prostate cancer bone metastasis, using these novel IKK inhibitors, may shed more 
light on its therapeutic potential -alone or in combination with existing therapies- for 
a more effective treatment of patients with advanced prostate cancer. 
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The aim of this chapter is to investigate if IKK expression is correlated with prostate 
cancer progression and prostate cancer cell metastatic ability in human prostate tissue 
sections and in commonly used prostate cancer cell lines. Additionally, to investigate 
the efficacy of a verified -‘first in class’- selective IKK inhibitor on the growth, 
migration and invasion of prostate cancer cells in vitro. Furthermore, to validate the 
effects of pharmacological inhibition of IKK in prostate cancer cells through the 
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3.4.1 IKKα is expressed in human prostate tissue samples and cell lines 
To explore if total IKKα expression is correlated with prostate cancer cell metastatic 
ability and prostate cancer progression, IKKα expression in various prostate cancer 
tissues and cell line models was examined by immunohistochemistry and western 
blots. First, with help from Anne Fowles (University of Sheffield), we examined IKKα 
expression, in a commercially available microarray panel (PR242b, US Biomaz Inc.) 
which contains human paraffin embedded prostate adenocarcinoma tissue from cases 
of various stages of prostate cancer progression and adjacent normal tissue. Prostate 
cancer progression is based on the Gleason score which is a grading system of how 
likely the prostate cancer will grow and spread based on the microscopic appearance 
of prostate tissue. The tissue microarray was probed with a monoclonal anti-IKKα 
antibody or a control anti-IgG antibody followed by assessment of DAB 
immunohistochemical staining intensity. As shown in Figure 3.1, There were no 
significant differences in overall IKKα expression with prostate cancer progression, as 
evident by the progressive loss of tissue differentiation, from normal prostatic tissue 
to cancerous prostatic tissue with increasing Gleason scores. Overall IKKα expression 
was similar in all stages of prostate cancer progression. IKKα was also expressed in 
the aggressive human prostate cancer cell line model PC3 and in PC3 cells that have 
successfully metastasized to mouse bone after intra-cardiac injection in BALB/c mice 
(section provided by Anne Fowles) (Figure 3.1). 
Furthermore, I examined total IKKα expression in human cell line models of prostate 
cancer with variable metastatic abilities, including: weakly metastatic LNCaP cells; 
moderately metastatic but non bone-tropic LNCaP derived C4-2 cells; moderately 
metastatic and bone-tropic LNCaP derived C4-2B4 cells; and the highly metastatic 
and bone tropic PC3 cells. As shown in Figure 3.2, there was also no significant 
difference in overall IKKα expression between total lysates of these cells as assessed 
by western blot analysis (Figure 3.2). 
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Figure 3.1: IKKα is expressed at all stages of prostate cancer progression and in cell models of prostate cancer. Immunohistochemistry (DAB) 
staining of monoclonal anti-IKKα and control anti-IgG antibodies: human prostate tissue microarray representing a range from normal to primary 
prostate cancer tissue with increasing Gleason scores (higher Gleason scores indicate increased likelihood of cancer growth and metastasis); human 
PC3 cell metastasis in mouse bone after intra-cardiac injection in BALB/c mice (section courtesy of Anne Fowles from Dr Colby Eaton’s group); and 
PC3 cells suspended in agar. Immunohistochemistry work was done by Anne Fowles. 
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Figure 3.2: IKKα expression in prostate cancer cell lines of various metastatic potentials. 
A: Western blot analysis of total IKKα expression relative to actin in: LNCaP (cell line model 
of early PCa), C4-2 (androgen insensitive cell line of LNCaP lineage), C4-2B4 (bone 
metastatic cell line of LNCaP lineage) and PC3 (aggressive cell line model of advanced PCa). 
Cells were grown in standard media before being serum starved overnight and lysed. Total 
cellular protein (70 μg/lane) were probed using rabbit anti-IKKα and anti-actin antibodies. All 
values in the graphs are mean ± s.d. and are obtained from 3 independent experiments. B: 
Shows representative western blot images.   
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3.4.2 Pharmacological inhibition of IKKα reduced prostate cancer cell 
growth 
To investigate the role of IKKα kinase activity on human prostate cancer cell viability, 
I blind tested a panel of seven drugs that included six novel structurally-related IKKα 
kinase inhibitors and a non-specific control on the viability of human prostate cancer 
cell lines of various metastatic abilities, these include: LNCaP, C4-2, C4-2B4, PC3 
and PC3-BT (PC3 clones harvested from bone marrow of mice after 3 cycles of PC3 
intra-cardiac injection and metastasis to bone; personnel communication: Anne 
Fowles). We were given exclusive license to test these novel IKKα inhibitors in 
prostate cancer by Prof Simon MacKay (University of Strathclyde). The Alamar Blue 
assay was used to assess prostate cancer cell viability in complete media after 48hrs 
and calculate the IC50 values.  All drugs tested, except for SU1257 (the control; 
personnel communication: MacKay), showed efficacy in reducing prostate cancer cell 
viability, however, SU1349 showed the most potent reduction in cell viability across 
the different cell lines tested as shown by the IC50 values (Table 3.1).  Subsequently 
provided Ki data (MacKay, unpublished data), which compares the selectivity of each 
drug for the related IKKα vs. IKKβ kinases, revealed SU1349 to also be the most 
selective drug against IKKα kinase activity (Table 3.1). 
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Table 3.1: Table compares calculated IC50 values for several novel IKKα inhibitors in different prostate cancer cell lines after 48hrs of treatment in 
complete media. Cell lines tested include: LNCaP, C4-2, C4-2B4, PC3 and PC3-BT (PC3 clones harvested from bone marrow of mice after 3 cycles 
of PC3 intra-cardiac injection and metastasis to bone); * Ki values for IKKα and IKKβ for each drug courtesy of Prof Simon MacKay, University of 
Strathclyde (NT = not tested). Alamar blue assay was used to calculate mean IC50 ± s.d. from 3 independent experiments. Lower IC50 values indicate 
potency, while lower Ki values indicate selectivity. Highlighted in bold are the IC50 and Ki values for SU1349 which was selected for use in all follow 
up experiments. (See figures S3.1.1-5 for original dose response graphs in appendix 1).
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Also, SU1349, showed a time and concentration dependent reduction on prostate 
cancer cell viability, as shown by the dose response in PC3 over 24hr and 48hr period 
(figure 3.3).  
 
Figure 3.3. The selective IKKα inhibitor, SU1349, reduced PC3 cell viability in a time 
and concentration dependent manner. A: Shows Alamar blue cell viability results for PC3 
after treatment with SU1349 after 24 and 48hrs in complete media, as a percentage of the 
vehicle control (0.3% DMSO). Values in the graphs are mean ± s.d. and are obtained from 3 
independent experiments. B: Representative microscopy images of PC3 after 48hrs treatment 
with IKKα kinase inhibitor, SU1349, or vehicle control (0.3% DMSO). 
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3.4.3 Stable IKKα knockdown reduced PC3 viability 
To validate the effects of pharmacological inhibition of IKKα and to investigate the 
role of cancer specific expression of IKKα expression levels in human PC3 viability, 
I generated PC3 clones with stable IKKα overexpression and knockdown vectors using 
a lentviral transfection system and puromycin selection.  I used an IKKα 
overexpressing pMXs vector and a GFP expressing control vector - kindly gifted to us 
by Prof Yousef Abu-Amer (Washington university, USA)- to successfully generate 
PC3 clone that overexpress IKKα (IKKαOE) by ~20 fold (p<0.001) compared to its 
mock GFP-transfected control (see Figure 3.4: A and B).  I used shRNA vectors from 
two human TRC clones (-504 and -505; Thermo Fisher), to successfully generate two 
PC3 clones with stable IKKα knockdown (IKKαKD1 and IKKαKD2) corresponding to 
reductions in IKKα expression by 77% (p<0.01) and 59% (p<0.01) respectively, 
compared to PC3 cells transfected with a pLKO.1 empty (mock) control vector (see 
Figure 3.4: A and B).  
Next, I examined the effects of genetic manipulation of IKKα on PC3 cell viability. 
PC3 cells were seeded at 3000/well of a 96-well plate and allowed to grow in complete 
media for 24 hours before using the Almar Blue assay to measure cell viability. I show 
that in PC3-IKKαOE cells viability was enhanced by 42% (p<0.05), while in PC3-
IKKαKD1 and PC3-IKKαKD2, viability was reduced by 33% (p<0.001) and 23% 




Chapter 3       






Figure 3.4. Overexpression and knockdown of IKKα in PC3 cells affected their viability. 
A: Western blot analysis of relative IKKα expression in PC3 cells transfected with an IKKα 
overexpression vector (OE) or one of two shRNA IKKα knockdown vectors (KD1 and KD2) 
compared to mock vector controls. Total cellular protein (50 μg/lane) were probed using rabbit 
anti-IKKα and anti-actin antibodies. Expression results are expressed as percentage of actin 
loading control. B: Representative western blot images shown below. C: Alamar Blue assay 
comparing viability of PC3 cells overexpressing or downregulating IKKα to their mock 
controls after 24hrs in standard media. All values in the graphs are mean ± s.d. and are obtained 
from 3 independent experiments. (Statistics: t-test; * = P≤0.05; ** = P≤0.01; *** = P≤0.001). 
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3.4.4 IKKα knockdown and pharmacological inhibition reduced PC3 
directional cell migration  
To investigate the role of IKKα in PC3 cell migration, I tested the effects of IKKα 
overexpression, knockdown and pharmacological inhibition on PC3 migration using 
the wound healing assay (as detailed in section 2.8). Briefly, for each experimental 
condition the PC3 cell monolayer was scratched and the media was replaced with 
serum free media containing 1µM SU1349 or a vehicle control before assessing 
percentage wound closure after 12 hours using a Leica time lapse imaging system. As 
shown in Figure 3.5 (panel A and B): PC3-IKKαOE showed significantly increased 
migration by 61% (p<0.01) compared to its mock transfected control; PC3-IKKαKD1 
and PC3-IKKαKD2 showed reduced migration by 27% (p<0.01) and 23% (p<0.05) 
respectively compared to their mock transfected controls; while PC3 treated with 1µM 
SU1349 showed reduced migration by 26% (p<0.01) compared to the vehicle treated 
control. These effects were not associated with significant changes in PC3 cell viability 
as measured by the Alamar Blue assay in these wells at the end of the experiment, see 
Figure 3.5: C. As these migration experiments were carried out in serum free media 
and over a period of 12hrs, which is less than the PC3 doubling times of 36 hours, the 
confounding effects of proliferation can be considered negligible. Nonetheless, as a 
proof of principle, I repeated the experiment for SU1349 only using a pre-treatment 
with Mitomycin C -to block cell proliferation- and saw an almost identical reduction 
in PC3 migration (see appendix Figure S3.2). 
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Figure 3.5. IKKα regulates PC3 cell directed migration. A: compares the migration of PC3 
cells with IKKα overexpression (OE), IKKα knockdowns (KD1 and KD2) or PC3 cells treated 
with 1µM SU1349 after 12 hours compared to their respective mock transfected and/or vehicle 
treated (0.1% DMSO) controls. B: Representative microscopy images of PC3 migration edge 
at start of experiment (yellow line) and after 12 hours (white line). C: Viability of PC3 cells 
at the end of the migration experiment assessed using the Alamar blue assay. Values in the 
graphs are mean ± s.d. and are obtained from 3 independent experiments (* = P≤0.05; ** = 
P≤0.01). 
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3.4.5 IKKα knockdown and pharmacological inhibition reduced random 
PC3 migration  
Next, I studied the effects of IKKα knockdown, overexpression and pharmacological 
inhibition on PC3 random migration (detailed in section 2.8). The migration of single 
PC3 cells was monitored in serum free media over a 6-hour period using a Leica time 
lapse imaging system. The path, directionality, distance and velocity of individual PC3 
cells were tracked and analysed using a manual tracker utility on ImageJ. Results in 
Figure 3.6 (panel A and B) show that compared to their respective controls: PC3-
IKKαOE showed significantly increased cell velocity by 53% and distance travelled by 
55% (p<0.05), PC3-IKKαKD1 and PC3-IKKαKD2 showed reduced cell velocity and 
distance travelled by 48% (p<0.05), while treatment of PC3 with 1uM SU1349 
reduced both cell velocity and distance travelled by 50% (p<0.001). Figure 3.6 (panel 
C), show representative summary windrose plots of the directionality and distance of 
PC3 cell paths as they are tracked relative to their starting points.  
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Figure 3.6. IKKα regulates PC3 cell random migration. The movements of PC3 cells with 
IKKα overexpression (OE), IKKα knockdowns (KD1 and KD2) or PC3 cells treated with 1µM 
SU1349 were tracked over 6 hours using a time lapse microscope and compared to their 
respective mock transfected and/or vehicle treated (0.1% DMSO) controls. Cells were treated 
with SU1349 or vehicle (0.1% DMSO) before the start of the experiment, At least 50 cells per 
experimental well were tracked. A: compares the velocity (μm/min) of tracked cells. B: 
compares the accumulated distance travelled (μm) of tracked cells. C: Summary plots of 
tracked PC3 cell random migration directionality and distance in a representative experimental 
well (red or black line represents up or down end points for tracked cells). Values in the graphs 
are mean ± s.d. and are obtained from 3 independent experiments (* = P≤0.05). 
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3.4.6 IKKα knockdown and pharmacological inhibition reduced PC3 
invasion  
To investigate the role of IKKα in PC3 invasion, I looked at the effects of IKKα 
overexpression, knockdown and pharmacological inhibition on PC3 cell invasion 
using the matrigel invasion assay (as detailed in section 2.9). In brief, PC3 cells in 
serum free media were added to a matrigel coated transwell mesh that sits on top of a 
well containing with media with 10% serum. Due to the chemoattractant effects of 
serum, the number of cells that have successfully invaded the matrigel and which are 
trapped by the transwell mesh are stained and quantified. Figure 3.6 shows that 
compared to their respective controls PC3 c3ll invasion was: increased in PC3-IKKαOE 
by 51% (p<0.01), reduced in PC3-IKKαKD1 and PC3-IKKαKD2 by 43% (p<0.01) and 
44% (p<0.01) respectively, while PC3 cell treatment with 0.3uM SU1349 reduced PC3 
cell invasion by 38% (p<0.01). Of note, 0.3uM SU1349 had no significant effects on 
PC3 viability over 72hrs (see appendix figure S3.3). 
 
  
Chapter 3       







Figure 3.7. IKKα regulates PC3 cell invasion. A: Transwell matrigel invasion assay 
comparing the invasion of PC3 cells overexpressing IKKα (OE), downregulating IKKα (KD1 
and KD2) or PC3 cells treated with 0.3 µM SU1349 after 72hrs compared to their respective 
controls. 5x104 of PC3 cells in 200µl of serum free media plus 0.3 µM SU1349 or vehicle 
(0.03% DMSO) were added to a transwell coated with a matrigel (20µl at 1.5mg/ml). 500µl 
of media containing 10% serum were added to well of a 24-well plate below the transwell 
insert to act as a chemoattractant. After 72hrs the number of invading cells, trapped by the 
transwell mesh, were stained and quantified from 5 representative microscopy fields at 20x. 
B: Representative microscopy images of invading PC3 cells (eosin and hematoxylin stained). 
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The aim of this chapter is, first, to characterize if total IKK expression is correlated 
with prostate cancer progression and prostate cancer cell line metastatic ability; and 
second, to establish for the first time the effects of selective IKK pharmacological 
inhibition on prostate cancer growth, migration and invasion in vitro and to validate 
these effects through the use of IKK overexpression and knockdowns in prostate 
cancer cells. 
Increased expression of IKKα in tissues has been associated with certain cancers 
including hepatocellular carcinoma, skin squamous cell carcinoma, head and neck 
squamous cell carcinomas (Jiang et al., 2010, Alameda et al., 2011, Nottingham et al., 
2014); in prostate cancer evidence of increased IKKα activation and not increased total 
IKKα expression has been associated with prostate cancer. Previous work by Luo et 
al., show that activated IKK- i.e. nuclear and phosphorylated IKK- is correlated 
with prostate cancer stage and progression in mouse and human tissue sections (Luo 
et al., 2007). Our analysis of a prostate cancer tissue samples indicates that total IKK 
is not correlated with prostate cancer progression. Furthermore, my analysis of total 
IKK expression in various human prostate cancer cell lines, did not find a significant 
correlation between metastatic ability and total IKK expression. Based on these 
results, combined with previous studies, one can speculate that physiologically and in 
the context of prostate cancer, IKK dysregulation occurs mainly at the level of its 
activity and not its expression level. IKK is ubiquitously expressed and IKK 
knockout in mice is perinatally lethal, and results in severe skin and skeletal 
abnormalities (Takeda et al., 1999, Hu et al., 1999). Subsequent work showed that 
introduction of a catalytically inactive form of IKK rescued IKK knockout mice 
from these morphological abnormalities, highlighting the importance of  IKK kinase 
independent function in normal development (Sil et al., 2004). A kinase independent 
role for nuclear IKK have been demonstrated to be important for the regulation of 
differentiation of epidermal keratinocytes and chondrocytes (Hu et al., 2001, Sil et al., 
2004, Olivotto et al., 2015). Therefore, targeting IKK kinase activity without 
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affecting its expression and its important kinase independent functions may lower 
unwanted side effects.  
With this in mind, I went on to test a first in class family of verified- selective- IKK 
inhibitors on the viability of human prostate cancer lines of varying metastatic abilities 
(courtesy of Prof Simon McKay, University of Strathclyde, UK). The lead compound, 
SU1349, was selected as it had the highest selectivity for IKK over the related IKKβ, 
in addition, to showing the most potent effects on cell viability across the different 
prostate cancer cell line I tested. Previously, the plant derived compound, apigenin- 
which was described as an IKK kinase inhibitor that binds with greater affinity to 
IKKα than IKKβ in qualitative ex vivo pulldown assays- was shown to sensitises PC3 
cells to apoptosis and reduce PC3 proliferation (Shukla and Gupta, 2004, Shukla et al., 
2015). These findings highlight the importance of IKKα activity in prostate cancer cell 
proliferation. 
To investigate this further and to validate the effects of SU1349 on prostate cancer 
cells in subsequent experiments I successfully generated clones of the prostate cancer 
cell lines, PC3, with IKK overexpression and IKK knockdowns. Genetic 
manipulation of IKK expression in PC3 also affected its viability: whereas, IKK 
overexpression significantly increased PC3 viability, IKK knockdowns significantly 
reduced PC3 viability. These results are in agreement with previous work by Shukla 
et al. that reported shRNA knockdown of IKKα in PC3 decreased their proliferation 
due to cell cycle arrest (Shukla et al., 2015).  
Next I examined the effects of the selective IKK inhibitor, SU1349, as well as IKK 
overexpression and knockdown on PC3 migration. The directed migration was 
significantly enhanced in PC3 cell with IKK overexpression, whereas IKK 
knockdown and SU1349 treatment significantly reduced PC3 directed migration. 
Similarly, in random migration experiments, both the total distanced travelled and the 
velocity of tracked PC3 was significantly enhanced with IKK overexpression, where 
IKK knockdown and SU1349 treatment significantly inhibited the distance travelled 
and velocity of PC3 cells. Previously, Shukla et al. show that apigenin reduced PC3 
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migration in wound healing assays (Shukla and Gupta, 2004, Shukla et al., 2015). 
While overexpression of the NFB p65 subunit and downstream target of IKKα was 
shown to increase prostate cancer cell migration (Kukreja et al., 2005). 
Encouraged by these results, I examined the effects of IKK modulation on PC3 
matrigel invasion. I show that whereas overexpression of IKK in PC3 significantly 
enhanced invasion, both IKK knockdown and pharmacological inhibition reduced 
PC3 invasion.  Previously, siRNA inhibition of  IKK  in PC3 was shown to reduce 
invasion (Mahato et al., 2011). Also, the inhibition of the NFB pathway in PC3 was 
associated with a reduction in pro-invasive factors such as VEGF and MMP-9 (Huang 
et al., 2001). I found similar effects by SU1349 in supressing PC3 derived factors 
important for its growth, migration and invasion in chapter 6. 
In this chapter, I show that in the context of prostate cancer, overall IKK expression 
is not associated with prostate cancer progression in human sections or the metastatic 
ability of commonly used human prostate cancer cell lines. This is in broad agreement 
with previous work that correlated IKK activity and not expression with prostate 
cancer.  I also show for the first time, that targeting the kinase activity of IKK, using 
the verified selective IKK kinase inhibitor SU1349, significantly reduced prostate 
cancer cell growth, migration and invasion in vitro. Moreover, I was able to validate 
the effects of SU1349 on prostate cancer cells through the successful generation of 
PC3 clones with IKK overexpression and knockdowns. Altogether, my results 
confirm the importance of IKK in the regulation of prostate cancer growth and 
metastatic behaviour, it indicates that targeting IKK  kinase activity might be a 
valuable therapeutic option in the treatment of prostate cancer.
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Selective IKKα inhibition reduced 
osteoclast formation in vitro  
Chapter 4      





The NFB pathway is known to play an important role in osteoclast differentiation, 
activity and survival. Previously, cells derived from mice with IKKα deletion were 
shown to exhibit impaired osteoclast formation in vitro. I hypothesize that selective 
pharmacological inhibition of IKKα will suppress osteoclast formation in vitro. In this 
chapter, I show that pharmacological IKKα inhibition- using the verified IKK 
inhibitor SU1349- significantly supressed osteoclast formation in RAW264.7 pre-
osteoclast cultures and in mouse total bone marrow cultures in vitro. To validate this, 
I also show that prostate cancer specific IKK manipulation regulated the ability of 
PC3 cells to influence osteoclast formation in prostate cancer-bone marrow cell co-
cultures, with IKK overexpression enhancing osteoclast formation and IKK 
knockdown inhibiting osteoclast formation in vitro. This indicates that 
pharmacological IKKα inhibition maybe useful in the treatment of osteolytic bone 
damage associated with prostate cancer bone metastasis.    
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The IKK/NFB pathway is known to play an important role in osteoclast 
differentiation, activity and survival (Soysa and Alles, 2009). Mice with deletions of 
NFκB1 (encodes p105 precursor of p50) and NFκB2 (encodes p100 precursor of p52) 
had increased bone volume due to lack of osteoclasts (Iotsova et al., 1997). Also, mice 
with IKK deletions showed increased bone growth as a result of reduced osteoclast 
formation (Otero et al., 2010). Hematopoietic cells derived from mice with IKK 
deletions also exhibited impaired osteoclast differentiation in vitro (Chaisson et al., 
2004), in vivo these mice had a reduced number of multinucleated osteoclasts when 
compared to wild type littermates. Similarly, mice with deletions of RelB, a 
component of the non-canonical NFB pathway, also showed impaired osteoclast 
differentiation (Vaira et al., 2008). 
The NFκB pathway was also shown to regulate the ability of prostate cancer cells to 
promote osteoclastogenesis. Genetic constitutive activation of the NFκB pathway in 
LNCaP was shown to induce osteoclatogenesis in bone marrow cultures in vitro, 
whereas parental control cells failed to induce osteoclatogenesis (Jin et al., 2013). 
Also, the NFκB pathway was shown to regulate PC3 induced osteoclast formation in 
RAW264.7 cultures (Akech et al., 2010, Kavitha et al., 2014).. 
Previous pharmacological studies by our group have shown that combined inhibition 
of IKK and IKKβ reduces osteoclasts numbers and associated osteolytic damage in 
a breast cancer bone metastasis model in rats and in a mouse model of postmenopausal 
osteoporosis (Idris et al., 2009, Idris et al., 2010). Conversely, constitutive activation 
of the canonical NF-κB pathway in mice was shown to result in RANKL independent 
osteoclastogensis and severe bone loss in mice (Otero et al., 2012, Otero et al., 2010). 
Collectively, these studies suggest that inhibition of IKK will disrupt prostate cancer 
cell ability to enhance osteoclastogenesis and may be useful in the treatment prostate 
cancer associated osteolysis. 
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In this chapter I aim to investigate the effects of pharmacological IKKα inhibition on 
RANKL induced osteoclastogenesis in vitro, in the presence and absence of prostate 
cancer cells or their derived factors. Also investigate the prostate cancer specific 
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4.4.1 IKKα pharmacological inhibition reduced RANKL induced 
osteoclast formation in vitro 
A previously study reports that cells derived from mice with IKKα deletion exhibited 
impaired osteoclast formation in vitro (Chaisson et al., 2004). Here, I investigated the 
effects of selective pharmacological inhibition of IKKα, using the verified IKKα 
inhibitor SU1349, on osteoclast formation in cultures with the macrophage-like 
osteoclast precursor cells, RAW264.7. RAW264.7 cells were co-treated with RANKL 
(50ng/ml) and different concentrations of SU1349 (0.1-1 µM) or a vehicle control for 
72hrs. As shown in Figure 4.1, SU1349 reduced RANKL induced osteoclast formation 
in a concentration dependent manner (by 43% at 0.3µM to 86% at 1 µM, p<0.0001). 
Similarly, in the absence of RANKL over the same period, RAW264.7 cell viability 
also showed a concentration dependent reduction (IC50 = 0.32 ± 0.06 µM).  
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Figure 4.1: IKKα inhibitor, SU1349, reduced RAW264.7 osteoclast formation in vitro. A: Shows the number of RANKL (50 ng/ml) generated 
osteoclasts in RAW264.7 cultures after treatment for 72hrs with different concentrations of the IKKα inhibitor SU1349. RANKL and SU1349 or 
vehicle treatments were refreshed after 48hrs. Osteoclast numbers was assessed by counting multinucleated TRAcP positive cells. B: representative 
microscopy images of TRAcP stained osteoclast cultures (at 10x magnification); arrows indicate osteoclasts. C: viability of RAW264.7 cells, measured 
by alamar Blue, after 72hrs treatment with different concentrations of SU1349. Values in the graphs are mean ± s.d. and are obtained from 3 
independent experiments (**** = P≤0.0001).   
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4.4.2 Cancer specific IKKα regulates PC3 induced osteoclast formation in 
vitro 
Next, I used a co-culture system with human prostate cancer cells and mouse bone 
marrow cells in the presence of M-CSF and RANKL, in order to study the effects of 
both prostate cancer-specific and systemic IKKα inhibition on osteoclastogenesis in 
vitro. As shown in figure 4.2, co-cultures with PC3-IKKαOE enhanced 
osteoclastogenesis by 55% (p<0.05), whereas PC3-IKKαKD1 and PC3-IKKαKD2 
supressed osteoclastogenesis by 91% (p<0.0001) and 93% (p<0.0001) respectively. 
Finally, treatment of co-cultures with 0.1µM SU1349 supressed osteoclastogenesis by 
93% (p<0.0001). 
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Figure 4.2: Overexpressing of IKKα in PC3 significantly enhanced osteoclast formation, whereas IKKα knockdown and pharmacological 
inhibition in PC3 supressed osteoclast formation in vitro. A: Shows the number of M-CSF (10 ng/ml) and RANKL (100 ng/ml) generated osteoclasts 
in mouse bone marrow cultures co-plated with PC3 cells (200 cells/well). Wells were seeded with PC3 cells: with IKKα overexpression (IKKαOE), 
IKKα knockdowns (IKKαKD1 and IKKαKD2), PC3 mock controls plus 0.1µM SU1349 or vehicle control. Media was refreshed every 48hrs plus/minus 
drug treatments and cultures were maintained for up to 7 days. Osteoclasts number was assessed by counting multinucleated TRAcP positive cells. 
Values in the graphs are mean ± s.d. and are obtained from 3 independent experiments (**** = P≤0.0001).  B: representative microscopy images of 
TRAcP stained osteoclast cultures. 
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4.4.3 Cancer specific manipulation of IKKα regulates ability of PC3 
derived factors to affect osteoclast formation in vitro  
Next, I studied the effects of IKKα overexpression and IKKα knockdowns in PC3 cells 
on the ability of their tumour derived factors -using conditioned media-  to affect 
osteoclast formation in mouse bone marrow cultures in vitro. Additionally, I studied 
the effects of IKKα pharmacological inhibition on osteoclast formation in the presence 
and absence of PC3 derived factors. As shown in figure 4.3, conditioned media from 
PC3 cells overexpressing IKKα, significantly enhanced osteoclast formation in M-
CSF and RANKL stimulated mouse bone marrow cultures by 144% (p<0.01) 
compared to its mock control, whereas conditioned media from PC3 with IKKα 
knockdowns had no significant effects on osteoclast formation- in the M-CSF and 
RANKL treated cultures- compared to their mock controls. 0.1µM SU1349 
significantly suppressed osteoclast formation in the presence and absence of PC3 
conditioned media by 66% (p<0.01) and by 84% (p<0.001) respectively (figure 4.3).  
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Figure 4.3: conditioned media from PC3 cells over-expressing IKKα significantly enhanced osteoclast formation in vitro, whereas 
pharmacological inhibition of IKKα supressed osteoclast formation in vitro. A: Shows the number of M-CSF (10 ng/ml) and RANKL (100 ng/ml) 
generated osteoclasts from mouse bone marrow cultures treated with 10% (v/v) conditioned media from PC3 cells with IKKα overexpression (IKKαOE) 
or IKKα knockdowns (IKKαKD1 and IKKαKD2), or treated with 0.1µM SU1349 in the presence and absence of PC3 conditioned media (PC3CM). 
Treatments were refreshed every 48hrs and cultures were maintained for up to 7 days. Osteoclasts number was assessed by counting multinucleated 
TRAcP positive cells and expressed as percentage of its mock and/or vehicle treated control. Values in the graphs are mean ± s.d. and are obtained 
from 3 independent experiments (** = P≤0.01).  B: representative microscopy images of TRAcP stained osteoclast cultures.
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The NFB pathway plays an important role in osteoclast differentiation, activity and 
survival (Soysa and Alles, 2009). Previous findings in our group show that osteoclast 
formation is inhibited by parthenolide- a non-selective IKKα/β inhibitor-(Idris et al., 
2010), and by selective IKKβ inhibition (Idris et al., 2010, Marino et al., 2018). Also, 
previous work has revealed that genetic inactivation of IKKα in mouse hematopoietic 
cells impaired osteoclastogenesis in vitro and reduced the number of multinucleated 
osteoclasts in mouse bones (Chaisson et al., 2004). My results show that in cultures 
with the macrophage-like osteoclast precursor RAW264.7 cells, selective IKKα 
inhibition -using SU1349- reduced RANKL induced osteoclastogenesis and the 
viability of RAW264.7 cells in a concentration dependent manner. Moreover, in 
cultures with total mouse bone marrow cells, 0.1 µM of SU1349, significantly 
supressed M-CSF and RANKL induced osteoclastogenesis in the presence and 
absence of prostate cancer cell derived factors.  Furthermore, the same concentration 
of 0.1 µM of SU1349, did not affect the viability of the osteoclast precursor cells as 
indicated by the number of TRAPc positive cells present at the end of the experiment. 
My results are in agreement with previous findings and confirm that targeting IKKα 
in osteoclast precursors reduces RANKL osteoclast formation in vitro. It is possible 
that SU1349 may also be affecting osteoclast survival and this should be explored in 
future experiments.   
Previously, Jin et al. showed that conditioned media from LNCaP cells with genetic 
NFκB activation (constitutively active IKKβ) promotes osteclastogensis in mouse 
bone marrow cultures and increased the expression of the osteoclastic RANKL and 
PTHrP genes in prostate cancer cells (Jin et al., 2013). In agreement with this, my 
results show that IKKα regulates the ability of prostate cancer cells to influence 
osteoclastogenesis in vitro. IKKα overexpression in PC3 significantly enhanced 
osteoclastogenesis in mouse bone marrow cultures whether in direct co-culture 
experiments or in experiments with conditioned media treatments.  
However, IKKα knockdown in PC3 significantly supressed osteoclast formation in 
mouse bone marrow cultures in direct co-culture experiments but not in experiments 
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with conditioned media treatments. Conditioned media from PC3 with IKKα 
knockdown did not have a significant effect on osteoclastogenesis, this might be due 
to the concentration of RANKL in these cultures masking the subtle effects of IKKα 
knockdown in PC3. Additionally, in conditioned media experiments mouse bone 
marrow cells were treated with conditioned media once every 48hrs, whereas, in a co-
culture system the PC3 cells are constantly releasing factors that can influence bone 
marrow culture for the duration of the experiment. Moreover, the RANKL in these 
cultures can itself directly promote the production of NFκB regulated osteoclastic 
factors by PC3 cells. It is also possible that IKKα knockdown in PC3 may result in the 
production of factors that inhibit osteoclastogenesis and this might be more 
pronounced in a co-culture experiments as opposed to experiments with conditioned 
media for the reason explained above. Results from chapter 6, show that IKKα 
inhibition in PC3 cells using SU1349 was associated with an overall downregulation 
of pro-osteoclastic PC3 derived factors.  This would suggest that IKKα knockdown in 
PC3 would similarly result in a downregulation of PC3 derived pro-osteoclastic factors 
and thus reduced ability to support osteoclast formation.  
Interestingly I noted that conditioned media from parental PC3 cells supressed 
RANKL induced osteoclastogenesis in mouse bone marrow cultures (figure S4.1). In 
contrast to my findings, previous studies in mouse primary bone marrow cells reported 
no significant effects for PC3 conditioned media on osteoclastogenesis (Fradet et al., 
2013), while another study reported a significant stimulation of osteoclast 
differentiation even in the absence of RANKL (Alsulaiman et al., 2016). However, a 
study on human peripheral blood mononuclear precursors report a significant 
inhibition of osteoclastogenesis by PC3 conditioned media  (Borghese et al., 2013). 
This indicates that at least in the PC3 cells I used, there are factors present in PC3 
conditioned media that can inhibit osteoclastogenesis, nonetheless, experiments with 
IKKα overexpression and knockdown in PC3, indicate that IKKα does regulate pro-
osteoclastic PC3 derived factors.    
In conclusion, my results in this chapter show that verified IKKα inhibitor, SU1349, 
directly supress osteoclastogenesis in vitro as well as supressing the ability of prostate 
cancer cells to promote osteoclastogenesis in vitro. Future experiments should also 
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explore the effects of SU1349 on mature osteoclast survival and activity such as in 
bone resorption assays. Overall, my results shows promise for the use of the selective 
IKKα inhibitor SU1349 in alleviating osteolytic bone damage associated with prostate 
cancer bone metastasis in preclinical mouse models.
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Selective IKKα inhibition enhanced osteoblast 
differentiation and bone nodule formation in vitro 
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5.1 Summary  
The NFB pathway is known to negatively regulate osteoblast differentiation and 
function. Previous studies have shown that both genetic and pharmacological 
inhibition of the NFκB pathway enhances osteoblast differentiation and function in 
vitro and in vivo. I hypothesize that pharmacological inhibition of IKKα, using the 
verified selective IKKα inhibitor SU1349, will enhance osteoblast differentiation and 
bone nodule formation in vitro. I show that pharmacological IKKα inhibition 
significantly enhanced osteoblastic differentiation and bone nodule formation in vitro. 
Moreover, prostate cancer specific inhibition of IKKα enhanced the ability of prostate 
cancer cells and their derived factors to stimulate osteoblast differentiation and bone 
nodule formation in vitro. Furthermore, since the differentiation of osteoblasts and 
adipocytes from common mesenchymal progenitors is largely mutually exclusive: I 
hypothesized and successfully demonstrate that pharmacological IKKα inhibition and 
prostate cancer-specific inhibition of IKKα suppresses adipocytes differentiation in 
pre-adipocyte 3T3L1 cultures in vitro. My results reveal an inhibitory role for IKKα 
in the regulation of osteoblastic differentiation and function in vitro. 
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Historically, the NFκB pathway was not thought to be important for osteoblast 
differentiation in contrast to the crucial role of the NFκB pathway in osteoclast 
differentiation that was recognised much earlier (Novack, 2011). Early studies in mice 
with NFκB1 (p105/p50) and NFκB2 (p100/p52) double knockout showed increased 
bone volume due to osteoclast inhibition, however, osteoblast function and bone 
formation in these mice was shown not to be impaired  (Iotsova et al., 1997, Boyce et 
al., 2010).  
Later studies demonstrated that the NFκB pathway negatively regulates osteoblast 
differentiation and function. The inflammatory cytokine TNFα and activator of the 
NFκB pathway reduced bone formation in vitro and in vivo (Gilbert et al., 2005, Li et 
al., 2007b).  Gilbert and colleagues, demonstrated that TNFα downregulates the 
expression of Runx2 and osterix transcription factor that are essential for osteoblast 
differentiation (Lu et al., 2006a, Gilbert et al., 2005). Furthermore, TNFα inhibited the 
production of type I collagen and osteocalcin- important for bone formation- by 
osteoblasts (Ding et al., 2009a). High levels of TNFα was shown to induce apoptosis 
in the MC3T3 osteoblastic cell line via activation of the NFκB pathway (Kitajima et 
al., 1996) .  
Initially, studies highlighted the inhibitory role of the canonical NFκB pathway in 
osteoblasts. Inhibition of the NFB p65 in mice deficient in IKK or with super IB 
repressor promoted osteoblast differentiation in vitro and promoted osteoblast bone 
formation in vivo (Chang et al., 2009). Similarly, selective inhibition of IKK 
increased osteoblast differentiation and function in vitro, as well as and bone formation 
in vivo (Alles et al., 2010, Marino et al., 2018). 
Later work demonstrated the importance of the non-canonical NFκB pathway for 
osteoblasts differentiation and function.  RelB, a member of the non-canonical NFκB 
pathway, was shown to negatively regulate osteoblast differentiation and bone 
formation. Osteoblastic precursor cells from RelB knockout mice, showed increased 
proliferation and differentiation in vitro, moreover, they displayed increased bone 
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volume due to increased osteoblast bone formation in vivo (Soysa et al., 2010, Yao et 
al., 2014). Whereas, overexpression of non-canonical NFκB p52 and RelB proteins 
were linked to the inhibition of osteoblast differentiation from mesenchymal stem cells 
(Zhang et al., 2014).  
The general inhibitor of IKKα/β, parthenolide, was shown to promote osteoblast 
differentiation and bone nodule formation function in vitro through a mechanism that 
involves the activation of the Wnt/β-catenin pathway (Zhang et al., 2017b). However, 
the specific role of IKKα inhibition in the regulation of osteoblast differentiation and 
function in vitro remains unknown. Since prostate cancer bone metastatic lesions in 
patients are known to produced mixed osteoblastic as well as osteolytic lesions, it is 
important to characterise the effects of selective IKKα inhibition on osteoblast 
differentiation and function in vitro and in vivo.    
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5.3 Aims  
In this chapter I aim to investigate the effects of pharmacological IKKα inhibition 
using the verified selective IKKα inhibitor, SU1349, on osteoblast differentiation and 
bone nodule formation in vitro as well as investigating the prostate cancer specific 
effects of IKKα inhibition on their ability to influence osteoblast differentiation and 
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5.4.1 IKKα pharmacological inhibition stimulated osteoblastic 
differentiation and bone nodule formation in vitro  
Previous work has shown that pharmacological NFκB inhibition, using parthenolide a 
general inhibitor of IKKα/β, stimulates osteoblast differentiation and function in vitro 
(Zhang et al., 2017b). Here, I investigated the effects of selective pharmacological 
inhibition of IKKα, using the verified IKKα inhibitor SU1349, on osteoblastic 
differentiation as quantified by alkaline phosphatase (ALP) activity and osteoblastic 
bone nodule formation function as assessed by Alizarin red staining, in different 
osteoblastic cell models. In the human osteoblast-like Saos2 cell line, SU1349 had a 
biphasic effect on Saos2 differentiation and bone nodule formation after 3 weeks of 
treatments depending on concentration tested. As shown in figure 5.1, 0.01µM 
SU1349 increased ALP activity in Saos2 cells and bone nodule formation in Saos2 
cells, by 34% (p<0.05) and 61% (p<0.01) respectively, without affecting their cell 
viability. However, 0.1µM SU1349 reduced ALP activity in Saos2 cells and bone 
nodule formation in Saos2 cells by 42% (p<0.01) and 59% (p<0.05) respectively, in 
the same cultures 0.1µM SU1349 reduced Saos2 cell viability by 38% (p<0.01). In 
mouse calvarial osteoblasts, 0.1µM SU1349 increased their ALP activity after 48hrs 
by 35% (p<0.05) (figure 5.1: E). In longer experiments in mouse calvarial osteoblasts, 
0.01µM SU1349 increased bone nodule formation by 38% (n=1) after 3 weeks of 
treatment without affecting their cell viability, whereas, 0.1µM SU1349 had no 
significant effects on bone nodule formation or cell viability (figure 5.1: F-H). 
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Figure 5.1: The IKKα inhibitor, SU1349, stimulated osteoblastic differentiation and activity in vitro. Saos2 cells (in 1% FBS media) and mouse 
calvarial osteoblast (in 1% FBS media plus ascorbic acid and β- glycerophosphate) were treated with different concentrations of SU1349 or vehicle 
control for up to 3 weeks. Treatments were refreshed every 48hrs. At the end of the experiments culture wells were assessed for: osteoblastic 
differentiation by measuring alkaline phosphatase activity; osteoblastic bone nodule formation by quantifying Alizarin red staining intensity; and cell 
culture viability using the Alamar Blue assay.  A-D: Shows differentiation, bone nodule formation, viability and representative images for Saos2 
cultures treated with 0.01µM or 0.1µM SU1349 for 3 weeks. E: Shows differentiation for mouse calvarial osteoblasts after 48hrs in treatment with 
0.1µM SU1349. F-H: Shows bone nodule formation and cell viability for mouse calvarial osteoblast cultures (n=1) treated with 0.01µM or 0.1µM 
SU1349 for 3 weeks; including representative images. Values in the graphs are mean (expressed as % of vehicle control) ± s.d. and are obtained from 
3 independent experiments.  
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5.4.2 IKKα inhibition stimulated osteoblastic differentiation and bone 
nodule formation in the presence of prostate cancer derived factors in 
vitro  
Next, I investigated the effects of IKKα pharmacological inhibition on osteoblastic 
differentiation and bone nodule formation function in the presence of PC3 conditioned 
media. In the human osteoblast-like Saos2 cultures in the presence of PC3 conditioned 
media, SU1349 had a biphasic effect after 10 days of treatments depending on the 
concentration of SU1349. As shown in figure 5.2, 0.01µM SU1349 increased Saos2 
bone nodule formation, by 23% (p<0.05) without significantly affecting their ALP 
activity or viability. However, 0.1µM SU1349 reduced bone nodule formation in 
Saos2 by 56% (p<0.0001) and ALP activity in Saos2 by 40% (p<0.001), whilst Saos2 
cell viability was increased by 12% (p<0.001). In contrast, after 3 weeks of treatment, 
in cultures with mouse MC3T3 osteoblastic cell line (used instead of mouse calvarial 
osteoblasts, due to lack of access to mouse calvarial osteoblasts) in the presence of 
PC3 conditioned media, only 0.1µM SU1349 increased the ALP activity of MC3T3 
cells by 40% (p<0.05) without significantly affecting their viability, and this was 
associated with a non-significant trend of increased Alizarin staining (figure 5.2: E-
H). 0.01µM SU1349 had no significant effects on MC3T3 differentiation, Alizarin 
staining or viability after 3 weeks of treatment. It is important to state here that 
although MC3T3 did stain with Alizarin red, microscopic examination revealed that 
this was not associated with obvious bone nodule formation unlike in Saos2 and mouse 
calvarial osteoblasts cultures.   
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Figure 5.2: The IKKα inhibitor, SU1349, stimulated osteoblastic differentiation and activity in the presence prostate cancer derived factors 
in vitro. Saos2 and MC3T3 cells (in 1% FBS media plus ascorbic acid and β- glycerophosphate) were treated with 0.01µM or 0.1µM SU1349 in the 
presence of PC3 conditioned media (20% v/v) for up to 3 weeks. Treatments were refreshed every 48hrs. At the end of the experiments culture well 
were assessed for: osteoblastic differentiation by measuring alkaline phosphatase activity; osteoblastic bone nodule formation by quantifying Alizarin 
red staining intensity; and cell culture viability using the Alamar Blue assay. A-D: Shows results for experiments in Saos2 after 10 days. E-H: Shows 
results for experiments in MC3T3 after 3 weeks. Values in the graphs are mean (expressed as % of vehicle control) ± s.d. and are obtained from 3 
independent experiments.  
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5.4.3 IKKα knockdown in PC3 stimulated osteoblastic differentiation and 
bone nodule formation in vitro  
Next, I investigated the prostate cancer specific effects of IKKα inhibition on 
osteoblastic differentiation and osteoblastic bone nodule formation activity in the 
human osteoblast-like Saos2 cells. As shown in figure 5.3 (A-D): conditioned media 
from PC3 with IKKα knockdown IKKαKD1 but not IKKαKD2 increased Saos2 bone 
nodule formation by 25% (p<0.001) and showed a non-significant increase in ALP 
activity by 29%±13 (p>0.05) without significantly affecting cell viability. Also shown 
in figure 5.3 (E-H), PC3 cells with IKKα knockdown, IKKαKD1 but not IKKαKD2, in 
direct co-culture experiments increased ALP activity in Saos2 cultures by 33% 
(p<0.05) and bone nodule formation in Saos2 cultures by 15% (p<0.05) and this was 
associated with a modest reduction in Saos2 cell viability by 9% (p<0.001). 
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Figure 5.3: IKKα knockdown in PC3 stimulated osteoblastic differentiation and activity in vitro. Saos2 cells were treated with conditioned media 
(20% v/v) from PC3 cells with IKKα knockdown or mock transfected PC3 control. In separate experiments, Saos2 cells were directly co-cultured with 
PC3 cells (1000 cells/well) with IKKα knockdown or mock transfected PC3 controls. At the end of the experiments (after ~3 weeks) culture wells 
were assessed for: osteoblastic differentiation by measuring alkaline phosphatase activity; osteoblastic bone nodule formation by quantifying Alizarin 
red staining intensity; and cell culture viability using the Alamar Blue assay. A-D: Shows results for differentiation, bone nodule formation and viability 
in Saos2 cultures treated with conditioned media (20% v/v) from PC3 cells with IKKα knockdown or mock transfected PC3 control. E-H: Shows 
results for differentiation, bone nodule formation and viability in Saos2 cultures directly co-cultured with PC3 cells with IKKα knockdown or mock 
transfected control Values in the graphs are mean (expressed as % of mock control) ± s.d. and are obtained from 3 independent experiments. 
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5.4.4 Pharmacological IKKα inhibition and IKKα knockdown in PC3 
cells supressed 3T3L1 adipocyte differentiation in vitro.  
Bone marrow adiposity has been linked to prostate cancer bone metastasis (Laurent et 
al., 2016, Morris and Edwards, 2016). The differentiation of osteoblasts and 
adipocytes from mesenchymal stem cells in the bone marrow microenvironment is 
understood to be largely mutually exclusive (Muruganandan and Sinal, 2014). Because 
I found that both pharmacological IKKα inhibition and IKKα knockdown in PC3 
stimulated osteoblastic differentiation in vitro, I investigated the effects of both 
pharmacological IKKα inhibition and PC3 specific IKKα knockdown on the 
differentiation in 3T3L1 pre-adipocyte cells. Adipocyte differentiation was assessed 
by quantifying oil red staining. As shown in figure 5.4 (A-C), 1µM SU1349 
significantly supressed adipocyte differentiation by 78% (p<0.0001) without 
significantly affecting cell viability in these cultures. Also shown in figure 5.4 (D-F), 
treatment of 3T3L1 cells with conditioned media from PC3 cells with IKKα 
knockdown, IKKαKD1 and IKKαKD2, supressed adipocyte differentiation by 16% 
(p<0.05) and 19% (p<0.01) respectively (figure 5.4 (D-F)).  
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Figure 5.4: Pharmacological IKKα inhibition and IKKα knockdown in PC3 cells supressed 3T3L1 adipocyte differentiation in vitro. 3T3L1 
cells were differentiated (as described in section 2.4.5) in the presence and absence of 1µM SU1349 or conditioned media (20% v/v) from PC3 cells -
PC3 with IKKα knockdown or mock transfected PC3 controls- for 15 days. At the end of the experiments the differentiation of 3T3L1 cultures was 
assessed by quantifying eluted oil red staining measured by spectrophotometry and the viability was measured using the Alamar Blue assay. A-C: 
Shows the differentiation and viability of 3T3L1 cells after treatment with 1µM SU1349 or vehicle control; representative images are shown (5x 
magnification). D-F: Shows the differentiation and viability of 3T3L1 cells after treatment with conditioned media from PC3 with IKKα knockdown 
or mock transfected PC3 controls; representative images are shown (5x magnification). Values in the graphs show means (expressed as % of control) 
± s.d. obtained from 3 independent experiments.  
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Most types of cancers that metastasize to bone typically cause osteolytic lesions, 
however, prostate cancer patients characteristically display mixed lesions with more 
osteoblastic lesions as well as the typical osteolytic lesions (Logothetis and Lin, 2005). 
In view of this I investigated the effects of pharmacological IKKα inhibition on 
osteoblast differentiation and function in vitro, as well the prostate cancer specific 
effects of IKKα knockdown on its ability to influence osteoblast differentiation and 
function in vitro.  I used different complementary models of osteoblast cells. Primarily, 
I used human Saos2 ostosarcoma cell line which is a model of mature osteoblasts that 
highly expresses ALP and has an enhanced ability to form bone nodules in vitro. Also, 
where possible this was complemented with using non-cancer derived osteoblast cell 
models such as primary mouse calvarial osteoblasts (which I had limited access to) or 
mouse MC3T3 cells. MC3T3 cells are a pre-osteoblast model and although certain 
sub-clones of this cell line are able to form bone nodules in vitro, the MC3T3 cells I 
used did not appear to produce obvious bone nodules unlike Saos2 and mouse calvarial 
osteoblasts cultures.  
Previous studies report that the NFκB pathway negatively regulates osteoblast 
differentiation and function (Iotsova et al., 1997, Boyce et al., 2010). Pharmacological 
inhibition of NFκB, using a peptide inhibitor of NEMO, was shown to stimulate 
osteoblastic differentiation and bone nodule formation in mouse bone marrow cells 
and in osteoblastic MC3T3 cells (Li et al., 2007b). While, genetic inactivation of 
NFκB, using a constitutively activated IκBα, was also shown to inhibit differentiation 
in the osteoblastic Saos2 cell line in vitro by inhibiting BMP/Smad signalling (Eliseev 
et al., 2006). In agreement with these findings I show that selective IKKα inhibition, 
using SU1349, promoted osteoblastic differentiation and bone nodule formation in 
mouse calvarial osteoblasts and in the osteoblastic Saos2 cell line. However, SU1349 
also appeared to have a biphasic effect on osteoblast differentiation and function, 
where higher concentration of SU1349 supressed Saos2 differentiation, bone nodule 
formation and cell viability. In support of this, NFκB was previously reported to have 
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a pro-survival role in osteoblasts and NFκB inhibition was shown to induce apoptosis 
in a human foetal osteoblast cell lines (Xiao et al., 2009). 
The IKKα inhibitor, SU1349, stimulated osteoblastic differentiation and bone nodule 
formation in the presence of PC3 conditioned media: it increased bone nodule 
formation in experiments with Saos2 without affecting Saos2 differentiation in these 
experiments, however, SU1349 did increase MC3T3 differentiation. It is possible that 
stimulatory effects of SU1349 on Saos2 differentiation in the presence of PC3 
conditioned media were masked: first, because I had established that PC3 conditioned 
media in itself stimulated osteoblastic differentiation (as well as osteoblastic function 
and viability; see figure S5.1); second, unlike my previous experiment (that were 
performed in the absence of PC3 conditioned media) these cultures were co-treated 
with ascorbic acid and β-glycerophosphate both of which are known to promote 
osteoblast differentiation (Langenbach and Handschel, 2013); third, the addition of 
ascorbic acid and β-glycerophosphate, accelerated bone nodule formation and 
therefore resulted in an earlier termination of experiments by day 10 compared to day 
21 in previous experiments in the absence of ascorbic acid and β-glycerophosphate, it 
is possible that longer treatments are needed to detect the effects on ALP-activity. 
Nonetheless, in agreement with experiment in the absence of PC3 conditioned media, 
higher concentrations of SU1349, significantly inhibited Saos2 differentiation and 
bone nodule formation, while surprisingly, it also resulted in a modest but significant 
increase in Saos2 viability. Cellular differentiation is generally understood occur at the 
expense of proliferation and vice versa (Ruijtenberg and van den Heuvel, 2016) 
My results also show that knockdown of IKKα in PC3 stimulated Saos2 differentiation 
and bone nodule formation in vitro.  These results suggest that knockdown of IKKα in 
PC3 cells promotes the production of pro-osteoblastic factors or supresses the 
production of osteoblastic inhibitors. PC3 cells are known to release factors such as 
Wnts and BMPs that promote osteoblast differentiation and function, as well as 
expressing the DKK-1 or SOST which strongly inhibits Wnt signalling (Ganguly et 
al., 2014, Hall et al., 2005, Heiland et al., 2010). The NFκB pathway was demonstrated 
to have a direct inhibitory role on Wnt and BMP protein expression (Tarapore et al., 
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2016).  Furthermore, NFκB activation through TNFα was shown to activate the 
expression of the Wnt inhibitors, DKK1 and SOST (Heiland et al., 2010). While, 
genetic inhibition of DKK1 in PC3 was shown to promote osteoblast differentiation 
and bone nodule formation in mouse bone marrow cultures (Hall et al., 2005). 
Interestingly, in chapter 6, I show that SU1349 supressed the expression of PC3 cell 
derived factors that are known to negatively regulate osteoblast differentiation and 
function, which supports the possibility that knockdown of IKKα in PC3 might be 
stimulating osteoblastic differentiation and bone nodule formation through a similar 
mechanism. 
Bone marrow adiposity has been linked to prostate cancer bone metastasis (Laurent et 
al., 2016, Morris and Edwards, 2016). Conditioned media from adipocytes has been 
demonstrated to promote PC3 proliferation and migration (Onuma et al., 2003, Laurent 
et al., 2016), Interestingly, I have observed a previously unreported role for PC3 
conditioned media in the promotion of adipocyte differentiation (figure S5.2). Since, 
the differentiation of osteoblasts and adipocytes from mesenchymal stem cells in the 
bone marrow microenvironment is understood to be largely mutually exclusive 
(Muruganandan and Sinal, 2014) and because I observed that both pharmacological 
IKKα inhibition and knockdown of IKKα in PC3 promoted osteoblast differentiation 
and function: I hypothesized that the opposite effects would be observed in adipocyte 
differentiation experiments using the mouse pre-adipocyte 3T3L1 cell line. My results 
clearly confirm my hypothesis, showing a significant inhibition on adipocyte 
differentiation with SU1349 treatment and a more modest but significant inhibition in 
adipocyte differentiation with conditioned media treatments from PC3 with IKKα 
knockdowns. Interestingly, in support of my findings, a previous study reports that 
inhibiting the IKKα related IKKβ, using an antisense oligonucleotide inhibitor, also 
resulted in the inhibition of 3T3L1 adipocyte differentiation and this was associated 
with increasing Wnt/β-catenin in these cells (Helsley et al., 2016). My present results 
suggest a previously unknown role for IKKα in prostate cancer-adipocyte interactions. 
However, further studies on bone marrow derived osteoblasts and adipocytes 
precursors in vitro and in vivo are needed to confirm these results 
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In conclusion, my results show that both pharmacological IKKα inhibition and IKKα 
knockdown in PC3 promotes osteoblast differentiation and function in vitro while 
inhibiting adipocyte differentiation in vitro. Indicating that a shared mechanism, 
involving IKKα, that promotes the differentiation of osteoblasts over adipocytes from 
early precursor cells. Further experiments are needed to elucidate whether IKKα 
inhibition might mediate some of its effects on osteoblast differentiation and function 
through the Wnt/β-catenin pathway.
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Effects of SU1349 on NFκB signalling  
in cancer and bone cells 
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In previous chapters I show that verified IKKα inhibitor, SU1349, reduced prostate 
cancer cell growth and motility, suppressed osteoclast formation, and stimulated 
osteoblast differentiation and function, in vitro. These results are consistent with 
inhibition of the NFκB pathway. In this chapter, I investigate if SU1349 inhibits NFκB 
signalling in osteoclasts, osteoblasts and prostate cancer cells. I show that SU1349 
supressed PC3-induced activation of both canonical and non-canonical NFκB pathway 
in osteoblast and osteoclast precursors’. Therefore, I also investigated the effects of 
SU1349 on the Wnt/β-catenin pathway. Significant cross-regulation is known to exist 
between the NFκB and Wnt/β-catenin pathways, with Wnt/β-catenin activation being 
important for enhancing osteoblast differentiation and function whereas it has an 
inhibitory role in osteoclasts. I show that SU1349 had differential effects on Wnt/β-
catenin signalling, where it activated Wnt/β-catenin signalling in osteoblast 
precursors, as shown by the increased phosphorylation of GSK3β and increased levels 
of cytoplasmic β-catenin, whereas the opposite effect was observed in osteoclast 
precursors. Collectively, these results confirm that the differential effects of SU1349 
on osteoclast and osteoblast differentiation can be explained both by its effects on the 
NFκB pathway and by its differential effects on Wnt signalling in these cell types. The 
NFκB pathway regulates expression of pro-inflammatory factors that are important in 
prostate cancer growth and metastasis to bone. Investigate if treatment of PC3 cells 
with SU1349 will downregulate PC3 production of pro-inflammatory factors. I show 
that SU1349, downregulates the production of various pro-inflammatory factors by 
PC3 prostate cancer cells. The downregulation of these pro-inflammatory factors 
explains- at least in part- the observed inhibitory effects of SU1349 on PC3 cell growth 
and motility, also the ability of PC3 cells to promote osteoclastogenesis in vitro 
described in previous chapters. Moreover, a majority of the downregulated factors are 
also involved in the negative regulation of osteoblast differentiation and thus may 
explain why PC3 cell specific IKKα inhibition enhanced osteoblast differentiation and 
function in co-cultures and conditioned media experiments. 
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Activation of NFκB pathway signalling occurs through the canonical NFκB pathway, 
which is characterised by a rapid and reversible activation, and the non-canonical 
NFκB pathway which is characterised by a delayed and persistent activation (Shih et 
al., 2011).  The canonical NFκB pathway is activated by a wide range of ligands 
binding to receptors, including: tumour necrosis factor receptor 1 (TNFR1), Toll-like 
receptors (TLRs), interleukin-1 receptor (IL1R), and T-cell receptors (TCR). While a 
more restricted set of ligands acting through specific receptors that include RANK, 
CD40, lymphotoxin β receptor (LTβR) and B-cell activating factor receptor (BAFFR) 
activate the non-canonical NFκB pathway in addition to activating the canonical 
pathway (Verstrepen and Beyaert, 2014, Sun, 2017). Canonical NFκB pathway 
activation is characterised by phosphorylation of cytoplasmic IκBα by IKKα in a 
complex with IKKβ and IKKγ, this allows for the rapid degradation of IκBα and the 
release and translocation of p65-p50 heterodimer into the nucleus. Whereas, in non-
canonical NFκB activation: activated IKKα homodimers phosphorylate p100 which 
allow for its partial processing to p52, followed by the translocation of the p52-RelB 
heterodimer into the nucleus. (Oeckinghaus et al., 2011). Although, the canonical and 
non-canonical NFκB pathway have distinct characteristics, significant cross-
regulation exists between the two pathways (Shih et al., 2011).  
Activation of the NFκB pathway plays a central role in inducing the expression of pro-
inflammatory factors (Tak and Firestein, 2001). Prostate tumour derived inflammatory 
factors (such as IL-6 and IL-1β) have been shown to promote prostate cancer cell 
growth and survival, while other prostate tumour derived inflammatory factors (such 
as IL-8, CXCL12, MMP-9 and VEGF) have been shown to promote prostate cancer 
cell metastasis and invasion (Nguyen et al., 2014b, Pu et al., 2009, Stark et al., 2015). 
In the bone metastatic niche, prostate tumour derived inflammatory cytokines play an 
important role in regulating the differentiation and function of osteoclasts and 
osteoblasts; in turn osteoclasts and osteoblasts release inflammatory factors that 
promote the growth and establishment of prostate tumour metastasis in bone (Roca 
and McCauley, 2015).  
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Prostate cancer cells promote osteoclast differentiation and function, by producing 
pro-inflammatory factors such as: RANKL, PTHrP, M-CSF, IL-6, and TNFα; most of 
these factors promote NFκB activation and are themselves regulated by the NFκB 
pathway (Gupta et al., 2012, Jin et al., 2013, Kavitha et al., 2014, Nguyen et al., 2014a). 
Jin et al., have previously reported that activation of NFκB in prostate cancer cells 
leads to increased expression of PTHrP and RANKL which are known to promote 
osteoclastogenesis  (Jin et al., 2013). PC3 conditioned media was shown to increase 
the expression of osteoclastic genes in RAW264.7 osteoclast precursor cells and to 
regulate RAW264.7 osteoclastogenesis through the production of a variety of pro-
inflammatory cytokines including IGF-1, TGFβ, TNFα, and M-CSF (Akech et al., 
2010, Kavitha et al., 2014). A study by Armstrong et al., highlighted the importance 
of the NFκB in the cross-talk between prostate cancer cells and osteoclasts in vivo, 
where they showed that injection of PC3 cells into mice induced stromal and 
systematic RANKL expression, moreover, injected PC3 cells were shown to respond 
to the increase in RANKL expression by promoting the expression of genes involved 
in osteolysis and invasion (Armstrong et al., 2008). Recently, work by Marino and 
colleagues, from our group, demonstrate that disrupting NFκB activation is effective 
in reducing breast cancer induced osteolysis in vivo (Marino et al., 2018).  Marino et 
al., used a selective pharmacological inhibitor of IKKβ to suppress breast cancer- and 
RANKL- induced NFκB activation in osteoclasts, as shown by reduced 
phosphorylation of IκBα (Marino et al., 2018). 
Prostate cancer cells also produce a variety factors that regulate osteoblast 
differentiation and function, including pro-inflammatory: TGFβ, TNFα and IL-1β 
(Barrack, 1997, Tang and Alliston, 2013, Ganguly et al., 2014, Graham et al., 2010, 
Ritchie et al., 1997, Ide et al., 1997, Thomas and Hamdy, 2000, Schulze et al., 2012). 
Prostate tumour derived cytokines such as IL-1, IL-6 and TNFα where shown to 
promote RANKL expression by osteoblasts in bone and thereby promote 
osteoclastogenesis (Gupta et al., 2012, Kavitha et al., 2014, Roca and McCauley, 
2015). Additionally, PC3 conditioned media was shown to induce the expression of 
NFκB-regulated chemokines in osteoblasts, these include: IL-8, CXCL5 (ENA-78), 
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CCL5 and CXCL1 (Schulze et al., 2012). These effects were mediated by IL-1β 
present in PC3 conditioned media activating the NFκB pathway in osteoblasts. IL-1β 
increased p65 phosphorylation, which in turn increased IL-1β expression in 
osteoblasts and in PC3 cells.  The study by Schulze et al., higlights the importance of 
NFκB in the cross-talk between prostate cancers cells and osteoblasts (Schulze et al., 
2012). Increased NFκB activation is known to inhibit osteoblastic differentiation and 
function, by promoting β-catenin degradation and thereby supressing Wnt signalling, 
whereas, blocking NFκB activation was shown to enhance osteoblastic differentiation 
and function (Le Henaff et al., 2015, Chang et al., 2009, Chang et al., 2013, Ma and 
Hottiger, 2016). Prostate cancer cell produced TNFα (an activator of NFκB signalling) 
has been shown to inhibit osteoblast differentiation by disrupting Wnt signalling 
(Heiland et al., 2010, Tse et al., 2012). Chang et al., showed that a small molecular 
inhibitor of IKKβ was effective in blocking TNFα induced NFκB activation in mouse 
MSCs, as shown by the suppression of IκBα-phosphorylation/degradation and p65- 
phosphorylation, and that this reversed the inhibitory effects of TNFα on the 
osteoblastic differentiation of MSCs (Chang et al., 2013). Marino et al., showed that 
inhibition of the NFκB pathway, using the general inhibitor of IKKα/β parthenolide, 
enhanced osteoblast differentiation and this was associated with increased β-catenin 
activation (Marino et al., 2017).  
The evidence presented above highlights the importance of the NFκB pathway in 
regulating the behaviour and interaction of prostate cancer cells, osteoclasts and 
osteoblasts. Therefore, it is important to establish the effects of the verified IKKα 
inhibitor, SU1349, on NFκB signalling in prostate cancer cells, osteoclasts and 
osteoblasts, in order to better understand the effects of SU1349 on these cells and their 
ability interact in vitro and in vivo.   
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In this chapter I aim to investigate the role of IKKα/NFκB signalling pathway in the 
interactions between prostate cancer cells and bone cells, in particular osteoclasts and 
osteoblasts. Additionally, to investigate the effects of pharmacological inhibition by 
verified IKKα inhibitor, SU1349, on both canonical and non-canonical NFκB 
signalling in osteoclasts and osteoblasts. Also, in this chapter I aim to investigate the 
effects of IKKα pharmacological inhibition, by SU1349, on PC3 prostate cancer cell 
derived pro-inflammatory soluble factors that are involved in the regulation of prostate 
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6.4.1 Pharmacological inhibition of IKKα supressed PC3 induced NFκB 
activation in osteoclast precursors 
Previous work has shown that PC3 conditioned media induced the expression of 
osteoclastic genes in RAW264.7 osteoclast precursor cells (Akech et al., 2010). Here, 
I first investigate if PC3 conditioned media activated the NFκB pathway in the 
osteoclast precursor cells RAW264.7 using western blots. RAW264.7 cells cultured in 
serum free media were treated with PC3 conditioned media (20% v/v) for 10-15mins 
or left untreated. As shown in figure 6.1, there was a significant increase in phospho-
IκB by 430% (p<0.05) and this was associated with a significant degradation of total 
IκB by 94% (n=2; p<0.0001), indicating activation of canonical NFκB signalling. 
There was also a non-significant increase in phospho-p100 by 61% (±24%, p=0.069) 
and this was associated with a non-significant increase in total p52 levels by 51% 
(±21%, p=0.051), indicating activation of non-canonical NFκB signalling. The effects 
on total p100 were not significant (p=0.19).  
In chapter 4, I show that SU1349 supressed osteoclastogenesis in the presence of PC3 
derived factors. Next, I investigated the effects of the IKKα inhibitor, SU1349, on PC3 
induced NFκB activation in RAW264.7 cells. RAWA264.7 cells were pre-treated with 
10µM SU1349 for 1 hour before stimulation with PC3 conditioned media (20% v/v). 
As shown in figure 6.1, there was a significant suppression of both canonical and non-
canonical NFκB activation. SU1349 supressed phospho-p100 by 34% (p<0.0001), 
which was associated with total p100 increase by 253% (±92%; p=0.052) and total 
p52 reduction by 48% (p<0.05), indicating an inhibition of p100 processing to p52. 
Also, phospho-IκB was reduced by 60% (p<0.01), which was associated with an 
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Figure 6.1: SU1349 supressed NFκB Activation by PC3 conditioned media in osteoclast precursor cells. RAW264.7 cells were pre-treated with 
10µM SU1349 or vehicle control (1% DMSO) for 1hour in serum free media before stimulation with PC3 conditioned media (20% v/v) for 10-15mins. 
Total cellular lysates (50µg/lane) were subjected to western blot analysis. A-C: western blot analysis of phospho-proteins: phospho-p100 (p-p100) and 
phospho-IκB (pIκB); representative blot image shown.  D-G: western blot analysis of total proteins: NFκB p100; p52; and IκB; representative blot 
image shown.  Values in the graphs are mean (expressed as % of control) ± s.d. and are obtained from 3 independent experiments. 
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6.4.2 Pharmacological inhibition of IKKα supressed RANKL induced 
NFκB activation in osteoclast precursors 
In chapter 4, I show that SU1349 supressed RANKL-induced osteoclastogenesis 
including in RAW264.7 cells. Here, I first show that RANKL activated the canonical-
NFκB pathway in the osteoclast precursor cells RAW264.7 using western blots. 
RAW264.7 cells in serum free media were treated with RANKL (150ng/ml) for 5mins 
or were left untreated. As shown in figure 6.2, there was an increase in phospho-IκB 
by 371% (±275%; p=0.12), however, although phospho-IκB levels were increased 
consistently in 3 independent experiments, it did not reach statistical significant due to 
considerable variability in the magnitude of this increase between experiments.  
Nonetheless, there was a significant reduction in total IκB by 63% (p<0.001), further 
indicating canonical-NFκB activation by RANKL that is promoting IκB degradation. 
RANKL effects on the non-canonical NFκB, at this time point (5min), did not appear 
to be significant on the whole, as shown by the non-significant effects on phospho-IκB 
and total p52 by RANKL, however, there was an associated increase in total p100 by 
27% (p<0.001).  
Next, I show that the IKKα inhibitor, SU1349, suppressed RANKL induced canonical-
NFκB activation in RAW264.7 cells. RAWA264.7 cells were pre-treated with 10µM 
SU1349 for 1 hour before stimulation with RANKL (150ng/ml). As shown figure 6.2, 
SU1349 supressed phospho-IκB by 71% (p<0.05), however, this was associated with 
an unanticipated reduction in total IκB by 45% (p<0.05). The effects of SU1349 had 
non-significant effects on the non-canonical NFκB pathway after 5min of RANKL 
stimulation.  
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Figure 6.2: SU1349 supressed NFκB Activation by RANKL in osteoclast precursor cells. RAW264.7 cells were pre-treated with 10µM SU1349 
or vehicle control (1% DMSO) for 1hour in serum free media before stimulation with RANKL(150ng/ml) for 5mins. Total cellular lysates (50µg/lane) 
were subjected to western blot analysis. A-C: western blot analysis of phospho-proteins: phospho-p100 (p-p100) and phospho-IκB (pIκB); 
representative blot image shown.  D-G: western blot analysis of total proteins: NFκB p100; p52; and IκB; representative blot image shown.  Values in 
the graphs are mean (expressed as % of control) ± s.d. and are obtained from 3 independent experiments.  
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6.4.3 Pharmacological inhibition of IKKα supressed PC3 induced NFκB 
activation in osteoblast precursors 
Schulze et. al., previously report that PC3 conditioned media induced the expression 
of NFκB-regulated chemokines in osteoblasts (Schulze et al., 2012). However, they 
did not directly explore the effects of PC3 conditioned media on the NFκB in 
osteoblasts. Here, I established that PC3 conditioned media activated the NFκB 
pathway in the osteoblast precursor cells MC3T3s using western blots. MC3T3s cells 
in serum free media were treated with PC3 conditioned media (20% v/v) for 10-15mins 
or left untreated. Figure 6.3 shows, that there was a significant activation of the 
canonical NFκB pathway by PC3 conditioned media, as shown by the increase in 
phospho-IκB by 85% (p<0.05) and this was associated an increase in degradation as 
shown by the decrease of total IκB by 23% (p<0.001). Although PC3 conditioned did 
not have a significant effect on phospho-p100, there was an associated a decrease in 
total p100 by 50% (p<0.01) and an increase in total p52 levels 221% (p<0.05), 
indicating an activation of non-canonical NFκB signalling.   
Previous work has shown that inhibition of NFκB activation enhances osteoblastic 
differentiation and function (Chang et al., 2013). Consistently, I show in chapter 5, 
that SU1349 - in the presence of PC3 derived factors - stimulated osteoblastic 
differentiation and bone nodule formation in vitro. Therefore, here I first established 
the effects of the IKKα inhibitor, SU1349, on PC3 mediated NFκB activation in 
MC3T3 cells. MC3T3s cells were pre-treated with 10µM SU1349 for 1 hour before 
stimulation with PC3 conditioned media (20% v/v). As in shown figure 6.3, there was 
a significant suppression of both canonical and non-canonical NFκB activation. 
SU1349 supressed phospho-p100 by 52% (p<0.01), this was associated with an 
increase in total p100 by 175% (n=2; p<0.0001) and total p52 reduction by 44% 
(p<0.01), indicating an inhibition of p100 processing to p52. Also, phospho-IκB was 
reduced by 56% (p<0.05) and this was associated with a non-significant increase in 
total IκB by 24% (±19%; p=0.29).  
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Figure 6.3: SU1349 supressed NFκB Activation by PC3 conditioned media in osteoblast precursor cells. MC3T3 cells were pre-treated with 
10µM SU1349 or vehicle control (1% DMSO) for 1 hour in serum free media before stimulation with PC3 conditioned media (20% v/v) for 10-15mins. 
Total cellular lysates (50µg/lane) were subjected to western blot analysis. A-C: western blot analysis of phospho-proteins: phospho-p100 (p-p100) and 
phospho-IκB (pIκB); representative blot image shown.  D-G: western blot analysis of total proteins: NFκB p100; p52; and IκB; representative blot 
image shown.  Values in the graphs are mean (expressed as % of control) ± s.d. and are obtained from 3 independent experiments.
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6.4.4 Pharmacological inhibition of IKKα supressed Wnt signalling in 
osteoclast precursors  
Activation of Wnt signalling is known to inhibit osteoclast differentiation (Albers et 
al., 2013). In the same western blots where I show SU1349 supressed PC3 induced 
NFκB activation, I found that SU1349 also supressed activation of Wnt signalling in 
RAW264.7 cells. As shown in figure 6.4, PC3 conditioned appeared to activate the 
Wnt pathway, as shown by the non-significant increase in phospho-GSK3β by 146% 
(±61%; p=0.054). However, SU1349 supressed Wnt activation, as shown by the 
significant reduction in phospho-GSK3β by 40% (p<0.01).  
Wnt activation is characterized by increased GSK3β phosphorylating, which protects 
cytoplasmic β-catenin from degradation, and thus allows for increased nuclear 
translocation of β-catenin (Carayol and Wang, 2006). Therefore, in order to further 
validate the effects of SU1349 on Wnt signalling, I next investigated the effects of 
SU1349 on β-catenin subcellular levels. First, I established the effects of PC3 
conditioned media on p65 (nuclear p65 is indicator of NFκB activation) and β-catenin 
subcellular shuttling in the osteoclast precursor cells RAW264.7. RAW264.7 cultures 
in serum free media were treated with PC3 conditioned media (20% v/v) for 45mins 
or left untreated. As shown in figure 6.5, PC3 conditioned media significantly reduced 
levels of the canonical NFκB transcription factor p65 in the nucleus by 32% (p<0.05) 
and this was associated with a non-significant increase in cytoplasmic p65 levels. PC3 
conditioned media did not appear to significantly affect levels of cytoplasmic β-
catenin. Pre-treatment of RAW264.7 cells with 10µM SU1349 for 1 hour before 
additional treatment with PC3 conditioned media, appeared to increase nuclear p65 
levels by 167% (±72%; p=0.082) and cause a modest but non-significant reduction in 
cytoplasmic β-catenin by 16% (±10%; p=0.2). Nuclear β-catenin in RAW264.7 cells 
was not detected. 
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Figure 6.4: SU1349 supressed GSK3β phosphorylation in osteoclast precursor cells. RAW264.7 cells were pre-treated with 10µM SU1349 or 
vehicle control (1% DMSO) for 1 hour in serum free media before stimulation with PC3 conditioned media (20% v/v) for 10-15mins. Total cellular 
lysates (50µg/lane) were subjected to western blot analysis. Western blot analysis of PC3 conditioned media effect on phospho-GSK3β (pGSK) levels 
and SU1349 effect on phospho-GSK3β (pGSK) levels in the presence of PC3 conditioned media; representative blot image shown.  Values in the 
graphs are mean (expressed as % of control) ± s.d. and are obtained from 3 independent experiments.
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Figure 6.5: SU1349 caused a non-significant reduction in cytoplasmic β-catenin in osteoclast precursor cells. RAW264.7 cells were pre-treated 
with 10µM SU1349 or vehicle control (1% DMSO) for 1 hour in serum free media before stimulation with PC3 conditioned media (20% v/v) for 
45mins. Cytoplasmic fraction (80µg/lane) and all of the nuclear fraction were subjected to western blot analysis. A-C: western blot analysis of PC3 
conditioned media effect on nuclear and cytoplasmic p65 and β-catenin levels; representative blot image shown.  D-F: western blot analysis of SU1349 
effect on nuclear and cytoplasmic p65 and β-catenin levels in the presence of PC3 conditioned media; representative blot image shown. Values in the 
graphs are mean (expressed as % of control) ± s.d. and are obtained from 3 independent experiments 
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6.4.5 Pharmacological inhibition of IKKα enhanced Wnt signalling in 
osteoblast precursors  
Previous work has shown that NFκB inhibition enhances osteoblastic differentiation 
and function and this is associated with increased Wnt/β-catenin signalling (Chang et 
al., 2013, Marino et al., 2018). In the same western blots where I show SU1349 
supressed PC3 induced NFκB activation, I found that SU1349 also increased 
activation of Wnt signalling in MC3T3 cells. In figure 6.6, I show that PC3 conditioned 
media appeared to activate the Wnt pathway, as shown by the non-significant increase 
in phospho-GSK3β levels. However, SU1349 treatment increased Wnt activation, as 
shown by the increase in phospho-GSK3β by 46% (p<0.05). Wnt activation is 
characterized by increased GSK3β phosphorylation, which protects cytoplasmic β-
catenin from degradation, and thus it allows for increased nuclear translocation of β-
catenin (Carayol and Wang, 2006). Therefore, in order to further validate the effects 
of SU1349 on Wnt signalling, I next investigated the effects of SU1349 on β-catenin 
subcellular levels. 
First, I established that PC3 conditioned media on p65 (nuclear p65 is indicator of 
NFκB activation) and β-catenin subcellular shuttling in the osteoclast precursor cells 
MC3T3. MC3T3 cells in serum free media were treated with PC3 conditioned media 
(20% v/v) for 45mins or left untreated. As shown in figure 6.7, PC3 conditioned media 
appeared to promote p65 shuttling from the cytoplasm to the nucleus, as shown by the 
significant reduction in cytoplasmic p65 by 38% (p<0.05) and appeared to cause a 
non-significant increase in nuclear p65 by 124% (±80%; p=0.2). MC3T3 showed high 
expression of β-catenin that was predominately localised to the nucleus. PC3 
conditioned media did not have any significant effects on nuclear or cytoplasmic levels 
of β-catenin.  
Pre-treatment of MC3T3 cells with 10µM SU1349 for 1 hour before additional 
treatment with PC3 conditioned media, appeared to reduce p65 shuttling to the nucleus 
and protect cytoplasmic β-catenin from GSK3β mediated proteasomal degradation. As 
shown in figure 6.7, SU1349 increased cytoplasmic p65 levels by 40% (p<0.01) and 
reduced nuclear p65 by 24% (p<0.0001), indicating an inhibition of NFκB mediated 
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shuttling of p65 to the nucleus.   SU1349 treatment was associated with a significant 
increase in cytoplasmic β-catenin levels by 16% (p<0.01), indicating protection from 
proteasomal degradation. However, SU1349 did not have significant effects on nuclear 
β-catenin levels which showed a non-significant reduction by 10% (±11%; p=0.44). 
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Figure 6.6: SU1349 increased GSK3β phosphorylation in osteoblast precursor cells. MC3T3 cells were pre-treated with 10µM SU1349 or vehicle 
control (1% DMSO) for 1 hour in serum free media before stimulation with PC3 conditioned media (20% v/v) for 10-15mins. Total cellular lysates 
(50µg/lane) were subjected to western blot analysis. Western blot analysis of PC3 conditioned media effect on phospho-GSK3β (pGSK) levels and 
SU1349 effect on phospho-GSK3β (pGSK) levels in the presence of PC3 conditioned media; representative blot image shown.  Values in the graphs 
are mean (expressed as % of control) ± s.d. and are obtained from 3 independent experiments.
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Figure 6.7: SU1349 caused a significant increase in cytoplasmic β-catenin in osteoblast precursor cells. MC3T3 cells were pre-treated with 10µM 
SU1349 or vehicle control (1% DMSO) for 1 hour in serum free media before stimulation with PC3 conditioned media (20% v/v) for 45mins. 
Cytoplasmic fraction (80µg/lane) and all of the nuclear fraction were subjected to western blot analysis. A-C: western blot analysis of PC3 conditioned 
media effect on nuclear and cytoplasmic p65 and β-catenin levels; representative blot image shown.  D-F: western blot analysis of SU1349 effect on 
nuclear and cytoplasmic p65 and β-catenin levels in the presence of PC3 conditioned media; representative blot image shown. Values in the graphs 
are mean (expressed as % of control) ± s.d. and are obtained from 3 independent experiments. 
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6.4.6 Pharmacological inhibition of IKKα reduced PC3 derived pro-
inflammatory factors 
Activation of the NFκB pathway plays a central role in inducing the expression of pro-
inflammatory factors (Tak and Firestein, 2001). In this chapter I showed that PC3 
conditioned media activated NFκB signalling in osteoclast and osteoblast precursors. 
Moreover, in chapter 3, I show SU1349 supressed PC3 growth and motility.  Here I 
investigated the effects of the verified IKKα inhibitor, SU1349, on the levels of PC3 
derived pro-inflammatory factors, which could inhibit PC3 cells ability to influence 
osteoclasts and osteoblast, also inhibit the ability of PC3 cells to promote their own 
growth and motility. Two membrane-based microarrays, with capture antibodies for 
102 human cytokines that are spotted in duplicate on the membrane, were incubated 
with conditioned media from PC3 cells treated with 1µM SU1349 or vehicle control 
for 24 hrs in serum free media, before undergoing chemiluminescence detection and 
analysis. The effect of SU1349 treatment on the production of soluble factors by PC3 
was expressed as percentage of vehicle treatment. As shown in figure 6.8 (panel A), 
22 soluble factors were considered to be significantly differentially regulated with 
SU1349 treatment (this was based on whether the standard deviation in means from 
spotted duplicates for each factor were small enough within the array and were 
adequately different between the arrays- i.e. that percent changes were going in the 
same directions; furthermore, differences were confirmed by visual inspection of 
probes on each array blot to limit false positives). Also shown in figure 6.8 (panel B), 
a Venn diagram of the overlapping role for these pro-inflammatory factors in the 
regulation of prostate cancer cell growth and metastasis, as well as the regulation of 
cells found within the bone metastatic niche notably osteoclasts, osteoblasts and 
adipocytes. Table 6.1, shows a summary of effects based on the literature for each of 
the 22 factors in prostate cancer cells, osteoclasts, osteoblasts and adipocytes.  
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Figure 6.8: Pharmacological inhibition of IKKα reduced PC3 derived pro-inflammatory factors. A: Microarray analysis of soluble factors in 
PC3 conditioned media treated with 1μM SU1349 or vehicle control (0.1% DMSO) for 24hrs, using Proteome ProfilerTM Human XL Cytokine Array 
Kit (R&D systems). B: Venn diagram of microarray results shows differentially expressed factors have overlapping roles in the regulation of prostate 
cancer cells & cells found in the bone microenvironment.  
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Table 6.1: Summary table for effects of SU1349 differentially regulated factors on prostate 
cancer cells, osteoclasts, osteoblasts and adipocytes. Effects on cells (reported in the literature) 
are indicated by: ↑ = positive; ↓ = negative; ↑↓ = positive and/or negative; ↔ = an ambiguous 




Osteoclast Osteoblast Adipocytes Refs 
MCP-1 ↑ ↑ ↔ ↓ 
(Lu et al., 2009, Li et al., 
2007a, Lu et al., 2007, 
Kanda et al., 2006) 
IL-1β ↑ ↑ ↓ ↓ 
(Voronov et al., 2003, Lee 
et al., 2010, Taichman and 
Hauschka, 1992, Bing, 
2015, Trebec-Reynolds et 
al., 2010) 
ENA-78 ↑ ↑ ↔ ↓ 
(Begley et al., 2008, 
Sundaram et al., 2013, Roca 
et al., 2018, Hsu et al., 
2013, Chavey and Fajas, 
2009, Kabir et al., 2014) 
IL-2 ↑ ↑ _ ↑ 
(Belldegrun et al., 2001, 
Ries et al., 1989, Vielma et 
al., 2013, Huh et al., 2014) 
IL-1α ↑ ↑ ↓ ↓ 
(Ricote et al., 2004, Tani-
Ishii et al., 1999, Tanabe et 
al., 2004, Um et al., 2011, 
Sauane et al., 2008) 
IL-24 ↓ _ ↑↓ ↔ 
(Sauane et al., 2008, Lee et 
al., 2012, Kragstrup et al., 
2017, Kragstrup et al., 
2016, Strong et al., 2017) 
OPN ↔ ↑ ↓ ↓ 
(Thoms et al., 2012, 
Yamate et al., 1997, Huang 
et al., 2004, Tardelli et al., 
2016, Zeyda et al., 2011) 
RBP-4 ↑ ↔ ↑↓ ↓ 
(Uehara et al., 2013) 
(Ghanem et al., 2017, 
Hogstrom et al., 2008, 
Norseen et al., 2012, Leitch 
et al., 2013) 
IL-8 ↑ ↑ ↔ ↓ 
(Neveu et al., 2014, Bendre 
et al., 2003, Bussard et al., 
2010, Kobashi et al., 2009) 
IL-17A ↑ ↓ ↑↓ ↓ 
(Zhang et al., 2017a, Kitami 
et al., 2010, Croes et al., 
2016, Qu et al., 2016, Wang 
et al., 2017, Ahmed and 
Gaffen, 2013) 
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MIP-3β ↑* ↑ ↑ ↔ 
(Peng et al., 2015, Lee et 
al., 2017, Qin et al., 2014, 
Tourniaire et al., 2013) 
*retracted 
IL-11 ↑ ↑ ↑↓ ↓ 
(Furuya et al., 2005, Kudo 
et al., 2003, Matsumoto et 
al., 2012, Keller et al., 
1993) 
LCN2 ↑ ↓ ↓ ↑ 
(Tung et al., 2013, Kim et 
al., 2015, Rucci et al., 2015, 
Zhang et al., 2008) 
TGF-α ↑ ↑ ↑ 
↑↓ 
 
(Liu et al., 1993, Takahashi 
et al., 1986, Panagakos, 
1994, Butterwith et al., 
1992) 
uPAR ↑ ↑ ↓ ↑ 
(Margheri et al., 2005, 
Furlan et al., 2007, Kanno 
et al., 2010) 
Adipsin ↔ _ _ ↔ (Ribeiro et al., 2012) 
C5/C5a ↑ ↑ ↔ ↓ 
(Nitta et al., 2013, Ignatius 
et al., 2011, Phieler et al., 
2013) 
IL-33 ↓ ↓ ↑ ↑ 
(Saranchova et al., 2016, 
Saleh et al., 2011, Han et 
al., 2015) 
GDF-15 ↑↓ ↑ ↓ ↓ 
(Husaini et al., 2015, 
Westhrin et al., 2015, 
Yanagitai et al., 2012, Ding 
et al., 2009b) 
TSP-1 ↑ ↑ ↓ ↑↓ 
(Firlej et al., 2011, Amend 
et al., 2015, DuBose et al., 
2012, Varma et al., 2008) 
Angiogenin ↑ ↓ _ _ 
(Li et al., 2011, Morita et 
al., 2008) 
Emmprin ↑ ↑ ↑ _ 
(Hao et al., 2010b, Rucci et 
al., 2010, Lu et al., 2013, 
Hao et al., 2010a) 
 
Abbreviations: MCP-1 (Monocyte chemotactic protein-1 aka. CCL2); ENA-78 (Epithelial-
neutrophil activating peptide; aka. CXCL5); OPN (Osteopontin); RBP-4 (Retinol binding 
protein 4); MIP-3β (Macrophage inflammatory protein 3 beta aka. CCL19); LCN2 
(Lipocalin-2); TGF-α (Transforming growth factor- α); uPAR (Urokinase plasminogen 
activator receptor); C5/C5a (Complement component C5/C5a); GDF-15 (Growth 
Differentiation Factor 15); TSP-1 (Thrombospondin-1); Emmprin (Extracellular matrix 
metalloproteinase inducer aka. CD147). 
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The NFκB pathway is known to be important in the regulation of prostate cancer cells, 
osteoclasts and osteoblasts and their interactions in vitro and in vivo (Tak and Firestein, 
2001, Nguyen et al., 2014b, Pu et al., 2009, Stark et al., 2015, Roca and McCauley, 
2015). In previous chapters I presented effects for the novel IKKα inhibitor, SU1349, 
in prostate cancer cells, osteoclasts and osteoblasts that are consistent with inhibition 
of the NFκB pathway. In this chapter I verify that the IKKα inhibitor, SU1349, exerts 
its effects on prostate cancer cells, osteoclasts and osteoblasts–at least in part- through 
the inhibition of the NFκB signalling and shed light on SU1349 mechanism of action. 
Effects of SU1349 on NFκB signalling in osteoclasts and osteoblasts 
I show, in RAW264.7 osteoclast precursor cells, that PC3 conditioned media 
significantly activated the canonical NFκB pathway, as shown by the increase in 
phospho-IκBα and IκBα degradation, in addition, PC3 conditioned media activated the 
non-canonical NFκB pathway as shown by the increase in phospho-p100 and the 
increased processing of p100 to p52. This is in agreement with previous studies that 
show PC3 conditioned media activates RAW264.7 osteoclastogenesis (Kavitha et al., 
2014) and that PC3 cells produce a variety of factors that can activate both the 
canonical and/or the non-canonical NFκB pathways including classic NFκB activators 
such as RANKL and TNFα (Gupta et al., 2012, Kavitha et al., 2014). I show that the 
selective IKKα inhibitor, SU1349, significantly supressed PC3 induced canonical and 
non-canonical NFκB activation. This is evidenced by reduced IκBα phosphorylation 
and total IκBα protection from degradation, in addition to reduced p100 
phosphorylation and inhibition of p100 to p52 processing.  
Furthermore, I show that SU1349 supressed RANKL induced activation of canonical 
NFκB signalling, as shown by the significant suppression of IκBα phosphorylation, 
however, unexpectedly this was not associated with IκBα protection from degradation, 
rather total IκBα levels were further reduced. This can be explained by a study which 
reports that certain forms of IκBα can exist free of association with p65 and this free 
IκBα can  be degraded independently of phosphorylation by IKKs (Mathes et al., 
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2008), therefore, it is possible that reduced IκBα that I observed in this experiment 
might be due to IKK independent degradation. Moreover, no significant effects were 
observed in non-canonical NFκB signalling after RAW264.7 treatment with RANKL, 
this can be explained by the fact that these experiments were stopped after 5min of 
RANKL stimulation in contrast to experiments with PC3 conditioned media which 
were stopped 10-15min after stimulation, this agrees with the literature which reports 
that canonical NFκB activation is known to be more rapid in comparison to non-
canonical NFκB activation that is known to be slower (Shih et al., 2011).   
In MC3T3 osteoblast precursor cells, PC3 conditioned significantly activated the 
canonical NFκB pathway as shown by the increase in phospho-IκBα and IκBα 
degradation, in addition, PC3 conditioned media activated the non-canonical NFκB 
pathway as evident by the increase in p100 processing to p52. Previous studies report 
that conditioned media from PC3 cells regulate osteoblast differentiation through 
factors that include TGFβ, TNFα and IL-1β which also are known to activate the NFκB 
pathway in osteoblasts (Graham et al., 2010, Ganguly et al., 2014). Schulze et al., 
demonstrated that PC3 derived IL-1β caused a rapid expression of NFκB-regulated 
chemokines in osteoblasts (Schulze et al., 2012). I demonstrate that pre-treatment of 
MC3T3 cells with the selective IKKα inhibitor, SU1349, significantly supressed PC3 
induced NFκB activation of canonical and non-canonical signalling. This is evident by 
the reduction in IκBα and p100 phosphorylation as well as the inhibition of p100 
processing to p52. These results are further supported by subsequent sub-cellular 
fraction analysis which show PC3 conditioned media increased p65 nuclear shuttling 
and this was supressed by SU1349 pre-treatment.  
Effects of SU1349 on Wnt/β-catenin signalling in osteoclasts and osteoblasts 
Activation of Wnt signalling has also been demonstrated to inhibit osteoclast 
differentiation (Albers et al., 2013) and promote osteoblast differentiation (Gaur et al., 
2005). In the absence of Wnt activation GSK3β constitutively phosphorylates 
cytosolic β-catenin which targets it for proteasomal degradation, however, activation 
of Wnt signalling blocks GSK3β inhibitory role by phosphorylating GSK3β, this 
protects cytoplasmic β-catenin from degradation, as a results it increases cytoplasmic 
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levels of β-catenin which ultimately allows for the nuclear translocation of β-catenin 
and the activation of Wnt-regulated gene expression (Carayol and Wang, 2006). 
Significant crosstalk exists between the NFκB and Wnt/β-catenin pathways, 
previously, NFκB activation has been shown to inhibit osteoblast differentiation by 
promoting β-catenin degradation and thereby inhibiting Wnt signalling (Le Henaff et 
al., 2015, Chang et al., 2009, Chang et al., 2013, Ma and Hottiger, 2016). Since I had 
previously observed that the IKKα inhibitor, SU1349, supressed osteoclast 
differentiation and stimulated osteoblast differentiation, I hypothesised that SU1349 
might inhibit Wnt signalling in osteoclast precursors and activate Wnt signalling in 
osteoblast precursor cells, this might further explain- at least in part- the differential 
effects of SU1349 on osteoclast and osteoblast differentiation. Although not 
statistically significant, PC3 conditioned media appeared to activate Wnt signalling in 
osteoblast precursors (MC3T3 cells) and more so in osteoclast precursors (RAW264.7 
cells), as evident by the increase in phosphorylation of GSK3β. PC3 conditioned media 
contain factors that activate both the NFκB pathway (such as RANKL and TNFα) and 
Wnt pathway (such as ET-1 and Wnts) simultaneously (Armstrong et al., 2008, Chang 
et al., 2013, Ganguly et al., 2014). Pre-treatment of cells with SU1349 prior to 
exposure to PC3 conditioned media stimulation significantly supressed 
phosphorylation of GSK3β in RAW264.7 cells, in contrast, SU1349 significantly 
increased phosphorylation of GSK3β in MC3T3 cells. The differential effects of 
SU1349 on phosphorylation of GSK3β, were further supported in subsequent sub-
cellular fractionation analysis, as shown by the significant increase in cytoplasmic β-
catenin in MC3T3 cells and an apparent decrease in cytoplasmic β-catenin in 
RAW264.7 cells (statistically non-significant). Collectively my results indicate that 
IKKα inhibitor, SU1349, inhibits Wnt activation in osteoclast precursors whilst 
stimulating Wnt activation in osteoblast precursors. Interestingly, SU1349 also 
reduced total β-catenin levels in PC3 (figure S6.1); reduced β-catenin expression was 
previously associated with supressing prostate cancer progression in mice (Shukla et 
al., 2007).  
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Differential effects of SU1349 on canonical vs non- canonical NFκB pathway? 
In subcellular fractionation experiments, the response of p65 in MC3T3 cells 
confirmed NFκB activation by PC3 conditioned media and inhibition of NFκB by 
SU1349 in total cellular extracts. Surprisingly, results from sub-cellular fractionation 
experiments showed that PC3 conditioned media significantly reduced nuclear p65 in 
RAW264.7 cells, whereas SU1349 significant increased nuclear p65. This seemingly, 
contradicts the RAW264.7 cells results in total cellular extracts. I would have expected 
an increase in nuclear p65 as PC3 conditioned media contains a variety of factors - 
described previously- that activate the NFκB pathway. However, previous studies 
report that PC3 cells when compared to less aggressive prostate cancer cells such as 
LNCaP, produce relatively high amount of the potent NFκB inhibitor, Osteoprotegerin 
(OPG), which was reported to be important for prostate cancer cell survival (Holen et 
al., 2002). Factors such as OPG present in PC3 conditioned media might explain the 
inhibitory effect of PC3 conditioned media on nuclear p65 seen in RAW264.7 cells. 
Similarly, it might in part explain my observation that PC3 conditioned media 
supressed RANKL induced osteoclast formation in mouse total bone marrow cultures 
(figure S3.1), in addition to completely preventing RANKL induced 
osteoclastogenesis in RAW264.7 cells (results not shown). Furthermore, I would have 
anticipated a reduction in nuclear p65 due to NFκB inhibition by SU1349 in osteoclast 
precursors similar to my results in osteoblast precursors. However, the unexpected 
increase in nuclear p65 in RAW264.7 seen with SU1349 treatment is supported by a 
previous study which report that genetic inactivation of IKKα in mouse macrophages 
leads to an increase in p65 nuclear accumulation, due to delayed p65 turnover, in 
response to activation of the NFκB pathway (Lawrence et al., 2005). Lawrence et al., 
demonstrae that normal IKKα function attenuates NFκB activation in macrophages by 
directly phosphorylating p65 which acclerates p65 promoter clearence and therefore 
leads to the resolution of inflammation. Since RAW264.7 cells are considered 
macrophage-like cells, this might partially explain the increase in nuclear p65 I 
observed with SU1349 treatment. Moreover, the increase in nuclear p65 in RAW264.7 
with SU1349 treatment might partially explain why I had observed that osteoclasts 
generated from RAW264.7 cultures in the prescence of 0.1µM SU1349  appeared to 
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be considerably larger in size (however not in number) when compared to control 
cultures (figure 4.1 (B)), this indicates SU1349 at this concentration might have 
prolonged the NFκB activation signal in these RAW264.7 cells.  
It is possible to speculate that the differential effects of SU1349 on nuclear p65 and 
Wnt activation in RAW264.7 and MC3T3 cells might be explained by different effects 
on canonical and non-canonical NFκB signalling that are cell type specific. First, 
considering the fact that although the accumulation of nuclear p65 in osteoclast 
precursors has been demonstrated to be dependent on IKKα inhibition, classically, 
nuclear p65 is an indicator of canonical NFκB activation for which the activity of 
IKKβ is important. Second, previous studies report that IKKβ decreases β-catenin 
dependent transcriptional activation, whereas IKKα increases β-catenin dependent 
transcriptional activity, and this was shown to be due to IKKβ promoting β-catenin 
degradation while IKKα was shown to stabilize cytoplasmic β-catenin (Lamberti et 
al., 2001, Carayol and Wang, 2006). Taken altogether, this indicates that observed 
effects of SU1349 on signalling in RAW264.7 cells might be primarily due to 
inhibition of non-canonical NFκB activation which is dependent on IKKα activity, 
whereas the effects of SU1349 in MC3T3 cells might be primarily due to inhibition of 
canonical NFκB activation which is more dependent on IKKβ activity. To understand 
the relative contribution of canonical and non-canonical NFκB pathway future 
signalling experiments should explore a more comprehensive analysis of other 
members of the NFκB pathway such as p50 and RelB, in addition to exploring nuclear 
and cytoplasmic localisation over an extended range of time points. The signalling 
time points I investigated are relatively short and are more optimised for detecting 
effects on canonical NFκB signalling, which is more rapid transit in nature occurring 
within minutes’ after stimulation, compared to non-canonical signalling which is 
slower and may need hours to fully affect the levels of its target proteins (Shih et al., 
2011, Yilmaz et al., 2014). 
Simon McKay’s group - that designed SU1349- recently published their results on an 
earlier generation of SU1349 related inhibitors (Anthony et al., 2017).  They show, 
using the U2OS osteosarcoma cell model, that their two lead IKKα-selective inhibitors 
successfully inhibited p100 phosphorylation, a marker of the non-canonical NFκB 
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pathway, without affecting markers of canonical NFκB signalling, namely, IκBα 
degradation and p65 phosphorylation (only at relatively high concentrations (100 µM) 
of one of their lead inhibitors that there was detectable inhibition of IκBα degradation). 
Although the Ki values for SU1349 indicate a far greater selectivity for IKKα over 
IKKβ compared to the Ki values reported for the first-generation IKKα inhibitors 
published by Anthony et al., my results clearly show that SU1349 significantly 
supressed canonical NFκB signalling in both osteoclast and osteoblast precursors. 
Other than accepting the possibility that SU1349 at the concentrations used in my 
experiments is affecting IKKβ activity (at 10µM which is nearly threefold higher than 
the IKKβ Ki value of 3.4 µM), my results could also indicate that IKKα is more 
important in canonical NFκB signalling than previously understood.  
A number of early influential studies on mouse embryonic fibroblasts (MEFs) have 
reported that IKKα- unlike IKKβ- is dispensable for canonical NFκB signalling (Li et 
al., 1999b, Li et al., 1999c, Tanaka et al., 1999), specifically, early studies show that 
lack of IKKα did not to prevent cytokine induced IκBα degradation (Li et al., 1999a, 
Hu et al., 1999, Takeda et al., 1999). However, more recent studies in mice and humans 
highlight a far more important role for IKKα in canonical NFκB signalling than 
previously appreciated (Adli et al., 2010, Khandelwal et al., 2017). Adli et al., show 
in MEFs that IKKα is important in canonical NFκB signalling in reporter assays, and 
even though it did not induce IκBα degradation, it was still able to release p65 from 
IκBα and induce p65 phosphorylation and NFκB DNA binding. Furthermore, Adli et 
al., demonstrated that IKKα was essential in inducing IκBα degradation in HeLa cells 
where it was not essential for IκBα degradation in MEFs, indicating that the relative 
importance of IKKα vs. IKKβ in IκBα degradation maybe cell type or species specific 
(Adli et al., 2010). Therefore, the results reported by Anthony et al., that their lead 
IKKα inhibitors did not affect canonical NFκB pharmacodynamics markers, might be 
specific to the osteosarcoma U2OS cell line. Furthermore, IKKα was shown to be 
constitutively active in the U2OS cells which might exaggerate the reported effects on 
non-canonical vs canonical NFκB signalling (Leopizzi et al., 2017, Anthony et al., 
2017).  More recently, Khandelwal et al., showed that patients with rare ectodermal 
dysplasia syndromes who also displayed immunodeficiency, possessed a de novo, 
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heterozygous, mutation in the gene encoding IKKα. The mutation results in IKKα 
proteins lacking kinase activity and are predicted to act in a dominant negative fashion 
to inhibit the IKK complex –with IKKβ and IKKγ- and block canonical NFκB 
signalling (Khandelwal et al., 2017). Collectively these results demonstrate an 
important role for IKKα in canonical NFκB signalling.  
Effects of SU1349 on NFκB regulated pro-inflammatory factors in prostate 
cancer cells 
Microarray data presented in this chapter show that SU1349 inhibited the NFκB 
pathway in PC3 prostate cancer cells as evident by the reduction of NFκB-regulated 
pro-inflammatory factors present in PC3 conditioned media.  The majority of the 
downregulated factors are involved in various aspects of prostate cancer cell growth 
and metastasis, this explains -at least in part- the inhibitory effects of SU1349 on PC3 
proliferation and motility described in chapter 3. For example, MCP-1 (monocyte 
chemotactic protein-1, aka. CCL2), which was the most downregulated cytokine by 
60%, was previously found to be an autocrine and paracrine factor for prostate cancer 
cell growth and invasion in vitro, also it was associated with prostate cancer bone 
metastasis in patients (Lu et al., 2006b, Lu et al., 2007, Lu et al., 2009). Similarly, IL-
1β (the second most down-regulated factor) which was found to be important in 
prostate cancer invasiveness and angiogenesis in vivo (Voronov et al., 2003). 
EMMPRIN (extracellular matrix metalloproteinase inducer), was the only factor that 
was upregulated (by 20%) by SU1349 treatment. Although, overexpression of 
EMMPRIN has been correlated with prostate cancer progression (Hao et al., 2010a), 
overexpression of a less common alternative splice form of EMMPRIN was associated 
with inhibition of hepatocellular carcinoma proliferation and invasion (Liao et al., 
2011). Interestingly, upregulation of EMMPRIN was also found to activate Wnt/β-
catenin signalling (Sidhu et al., 2010). 
In this chapter I show that PC3 conditioned media activated NFκB signalling in 
osteoclast precursors’ and in chapter 4 I show that IKKα activity and expression had a 
positive role on osteoclast formation in co-cultures of PC3 cells with bone marrow 
cells.  In agreement with these results, my microarray data show that most of SU1349 
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downregulated factors in PC3 conditioned media are involved in the positive 
regulation of osteoclast differentiation and function. For example, MCP-1 was found 
to increase the recruitment and differentiation of pre-osteoclasts (Li et al., 2007a). 
Furthermore, Lu et al., show that knockdown of MCP-1 in PC3 cells reduced PC3 
conditioned media induced osteoclast formation in vitro as well inhibiting PC3 tumour 
growth in bone after inter-tibial injection in mice (Lu et al., 2009).  
In chapter 5, I described how IKKα knockdown in PC3 promoted osteoblastic 
differentiation and bone nodule formation in vitro, on the other hand, it inhibited 
adipocyte differentiation in vitro.  In agreement with these results, a majority of the 
SU1349 downregulated factors were found to be involved in the negative regulation 
of osteoblast differentiation or activity, these include: IL-1β, IL-1α, OPN 
(Osteopontin), RBP4 (Retinol binding protein 4) and LCN2 (Lipocalin-2) (Taichman 
and Hauschka, 1992, Tanabe et al., 2004, Huang et al., 2004, Ghanem et al., 2017, 
Rucci et al., 2015). This may explain – at least in part- the stimulatory effects of IKKα 
knockdown in PC3 on osteoblast differentiation and bone nodule formation described 
in chapter 5. However, most of the SU1349 downregulated pro-inflammatory factors 
- with the exception of LCN2 and uPAR (urokinase plasminogen activator receptor)- 
were found to be involved in the negative regulation of adipocyte differentiation and 
function (Zhang et al., 2008, Kanno et al., 2010), which does not explain why 
knockdown of IKKα in PC3 inhibited adipocyte differentiation. In general, studies 
show that pro-inflammatory factors such as TNFα and IL-6, inhibit osteoblast 
differentiation by suppressing Wnt signalling and inhibit adipocyte differentiation by 
activating Wnt signalling (Heiland et al., 2010, Gustafson and Smith, 2006).  In view 
of this, it is interesting to note that many of the SU1349 regulated factors described 
above have been shown to affect osteoblast or adipocyte differentiation by supressing 
or enhancing Wnt signalling in these cells, these factors include: IL-24, IL-17a and IL-
11 (Lee et al., 2012, Kragstrup et al., 2017, Wang et al., 2017, Matsumoto et al., 2012). 
Collectively, the microarray data indicate that SU1349 may also affect the levels of 
other non-inflammatory factors present in PC3 conditioned media that regulate 
osteoblast and adipocyte differentiation that are not captured by the microarray I used 
in my experiments. In future experiments, it will be interesting to do a more 
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comprehensive investigation of the effects of SU1349 on other factors present in PC3 
conditioned media, particularly, its effects on agonists and antagonists of Wnt 
signalling. 
Conclusion 
In conclusion, I show evidence which verifies that selective IKKα inhibition, using 
SU1349, is effective in supressing the NFκB pathway in osteoclasts, osteoblasts and 
prostate cancer cells in vitro. Importantly, it supressed NFκB activation -both 
canonical and non-canonical- in osteoclasts and osteoblasts precursors by prostate 
cancer derived factors in vitro, moreover, it suppressed the ability of prostate cancer 
cells to produce NFκB regulated pro-inflammatory factors that regulate osteoclasts and 
osteoblasts. These results explain -to a large extent- the findings reported in previous 
chapters. Furthermore, I show evidence that SU1349 exerts differential effects on 
Wnt/β-catenin signalling in osteoclast and osteoblast precursors’ and this might further 
contribute to the differential effects of SU1349 on osteoclast and osteoblast 
differentiation observed in previous chapters. Collectively, the ability of verified IKKα 
inhibitor, SU1349, to suppress the NFκB pathway in prostate cancer cells, osteoclasts 
and osteoblasts, and thus disrupt their behaviour and interactions in vitro, makes it a 
promising candidate for further study in vivo.  
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In previous chapters, I show that the verified IKKα inhibitor, SU1349, reduced 
prostate cancer growth and motility, suppressed osteoclastogenesis and enhanced 
osteoblast differentiation and function, in vitro. Moreover, I showed that SU1349 
disrupted prostate cancer cell regulation of osteoclasts and osteoblasts. In this chapter 
I test my hypothesis that the verified IKKα inhibitor, SU1349, reduces prostate tumour 
metastatic growth and bone osteolysis associated with prostate cancer metastasis in 
vivo. I show that SU1349 inhibition increased trabecular bone volume and this was 
associated with a reduction of osteoclast numbers and an increase in osteoblast 
numbers on the trabecular bone surface. Paradoxically, SU1349 had the opposite effect 
in the cortical bone compartment, where it reduced cortical bone volume and this was 
associated with reduced osteoblast numbers and increased osteoclast numbers on the 
endocortical bone surface. Moreover, SU1349 showed a trend of reducing metastatic 
growth in mice. Collectively, my results show a novel role for IKKα in the differential 
regulation of trabecular and cortical bone. Whilst the effects of pharmacological IKKα 
inhibition was positive in trabecular bone, the negative effects on cortical bone may 
limits its use as a bone preserving agent. 
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Prostate cancer progression to metastatic disease in patients and TRAMP mouse 
models of prostate cancer has been linked to the activation of the NFκB that is evident 
by increased nuclear p65 and IκBα phosphorylation in tissue sections (Shukla et al., 
2004, Shukla et al., 2005). Genetic inactivation of NFB in PC3 cells was shown to 
delay the occurrence of lymph node metastasis after orthotopic injection in mice 
(Huang et al., 2001) and to inhibit PC3 growth in mouse bones after intratibial 
injection (Jin et al., 2013).  
In prostate cancer, IKK was shown to drive prostate cancer progression and 
metastasis and was shown to have a more important role in the development of prostate 
cancer than the related IKK (Shukla et al., 2005, Nguyen et al., 2014b). TRAMP mice 
treated with apigenin, an IKK inhibitor with a greater specificity for IKKα over IKKβ, 
and TRAMP mice with IKKα genetic inactivation both showed inhibited primary 
tumour growth (Shukla et al., 2004, Shukla et al., 2005, Luo et al., 2007). Furthermore, 
Luo et. al., showed that IKKα  inactivation inhibited distant soft tissue metastasis, 
however, as TRAMP mice do not usually develop skeletal metastasis (Hensley and 
Kyprianou, 2012), the role of IKKα in regulating prostate cancer metastasis to bone 
remains unknown. 
Inhibition of the NFκB pathway has been shown to disrupt normal bone remodelling 
in vivo.  Mice deficient in p105/p50 and p100/p52 members of the NFκB pathway, 
were shown to have impaired osteoclast differentiation and increased bone volume 
(Iotsova et al., 1997). Similarly, RelB deletion in mice was shown to increase 
trabecular bone volume due to increased osteoblast bone formation and this was 
associated with increased osteoblast numbers on trabecular bone surface, however, 
osteoclast numbers remained unchanged (Yao et al., 2014). Constitutive genetic 
activation of IKKβ was shown to result in severe bone loss in mice due to increased 
size and number of trabecular osteoclasts (Otero et al., 2012, Otero et al., 2010).  
Whereas genetic inactivation of NFκB in osteoblasts -by IKK deletion or expression 
of super IB repressor- significantly increased bone trabecular volume in mice and 
protected against ovariectomy induced osteolysis (Chang et al., 2009). Interestingly, 
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IKKα deletion in mice did not seem to affect bone volume, whereas IKKβ deletion in 
mice resulted in increased bone volume which was associated with reduced osteoclast 
numbers (Chaisson et al., 2004).  
Previous work by our group show that inhibition of IKKβ using parthenolide 
protects against ovariectomy induced bone loss in mice and breast cancer induced 
osteolysis in rats by inhibiting osteoclast numbers and supressing osteolytic bone 
resorption in vivo (Idris et al., 2009, Idris et al., 2010). More recently, work by Marino 
and colleagues from our group has demonstrated that pharmacological inhibition of 
the NFκB pathway using parthenolide- a general inhibitor of IKKα/β- increased bone 
volume in vivo by inhibiting breast cancer induced osteolysis, this was associated with 
reduced osteoclasts numbers and increased osteoblasts numbers on the bone surface 
(Marino et al., 2018). However, the role of selective pharmacological inhibition of 
IKKα on cancer related bone remodelling remains is not well understood. 
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In this chapter, I use a model of human PC3 cells intra-cardiacally injected into 
Immuno-deficient BALB/c mice, to investigate the effects of the verified IKKα 
inhibitor, SU1349, on prostate tumour metastatic growth in the skeleton and prostate 
cancer associated osteolysis in vivo.  The effects of SU1349 on prostate tumour 
metastatic growth is analysed using live bioluminescence imaging, while the effects 
on bone osteolysis is measured using microCT and histomorphometry. 
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7.4.1 Mice treated with the selective IKKα inhibitor SU1349 showed a 
trend of reduced metastatic prostate tumour growth 
Genetic inactivation of IKKα kinase activity was previously shown to reduce prostate 
tumour growth and soft tissue metastasis in the TRAMP mouse model of prostate 
cancer (Luo et al., 2007). In previous chapters, I show that the verified IKKα inhibitor, 
SU1349, reduced prostate cancer growth and motility in vitro. Here, I investigated the 
effects of SU1349 on tumour growth in a model of prostate cancer metastasis. 
Immuno-deficient BALB/c mice (8 per group) were intra-cardiacally injected with 
luciferase expressing human PC3 cells and treated with SU1349 (20mg/kg/3-times-
weekly) or vehicle control. Dosage and treatment regimen was based on previous data 
from Prof Simon MacKay (University of Strathclyde, UK; personnel communication). 
As shown in figure 7.1, my results showed a trend of reduced metastatic growth with 
SU1349 treatment, as assessed by IVIS-bioluminescence imaging, on day 17 ( SU1349 
treated group (n=5) vs. control group (n=6)), and on day 23 (SU1349 treated group 
n=2 vs. Control treated group n=5). 
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Figure 7.1: The IKKα inhibitor SU1349 showed a trend in reducing prostate tumour metastatic growth in vivo. Immuno-deficient BALB/c mice 
(8 mice per group) were intra-cardiacally injected with luciferase expressing human PC3 cells and treated with SU1349 (20mg/kg/3times-weekly) or 
vehicle control.  The graph shows the effects of SU1349 or vehicle control treatment on prostate tumour metastatic growth as assessed by 
bioluminescence imaging of total tumour photon intensity measured on day 17 and 23 in BALB/c mice; Note: at day 23 there were 5 mice in the 
control group vs 2 mice in treated group. (This data was generated by our collaborators Marco Ponzetti and Prof Nadia Rucci in L’Aquila, Italy).  
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7.4.2 Mice treated with the selective IKKα inhibitor SU1349 exhibited 
increased trabecular bone volume 
Recent work by Marino and colleagues from our group shows that pharmacological 
inhibition of the NFκB pathway using parthenolide- a general inhibitor of IKKα/β- 
increased bone volume in vivo by inhibiting breast cancer induced osteolysis (Marino 
et al., 2018). However, the effects of selective IKKα inhibition on prostate cancer 
metastasis to bone and prostate cancer associated osteolysis remains unknown.  In 
previous chapters I show that the verified IKKα inhibitor, SU1349, reduced PC3 cell 
growth and motility, supressed PC3 ability to induce osteoclastogenesis as well as 
supressing osteoclastogenesis directly in vitro. Here, I investigated the effects of the 
verified IKKα inhibitor, SU1349, on trabecular bone remodelling using microCT on 
the tibia of BALB/c mice intra-cardiacally injected with PC3 cells. I show that SU1349 
treatment increased trabecular bone volume and protected trabecular bone from 
prostate cancer induced osteolysis. As shown in figure 7.2 (A-G): Trabecular bone 
volume (BV/TV) was increased by 175% (p<0.0001); Trabecular thickness was 
increased by 32% (p<0.0001); Trabecular separation was reduced by 88% (p<0.0001); 
Trabecular number was increased by 200% (p<0.0001); Trabecular porosity was 
reduced by 6% (p<0.0001); Trabecular pattern factor (an indicator of trabecular 
connectivity) was increased by 1840% (p<0.0001).  
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Figure 7.2: The IKKα inhibitor SU1349 increased trabecular bone volume in mice. Immuno-deficient BALB/c mice were intra-cardiacally 
injected with PC3 cells and treated with SU1349 (20mg/kg/3times-weekly) or vehicle control; at the end of the experiment, the mice tibia were 
subjected to microCT analysis. A: Trabecular bone volume fraction (BV/TV). B: Trabecular thickness. C: Trabecular separation. D: Trabecular 
number. E: Trabecular porosity. F: Trabecular pattern factor. G: Representative microCT images. Values in the graphs are mean ± S.E.M. (control 
n=13; SU1349 n=16).  
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7.4.3 Mice treated with the selective IKKα inhibitor SU1349 exhibited 
reduced cortical bone volume 
PC3 cells are known to mainly induce osteolytic lesions in mice (Fradet et al., 2013). 
In osteolytic disease, bone loss is typically exhibited in trabecular bone when 
compared to cortical bone, as it is more metabolically active and has a higher rate of 
bone turnover (Chen et al., 2010). I had already observed that SU1349 treatment in 
mice protected against prostate cancer induced osteolysis and increased trabecular 
bone volume. Here, I investigated the effects of SU1349 on cortical bone remodelling 
using microCT in the tibia of BALB/c mice intra-cardiacally injected with PC3 cells. 
As shown in figure 7.3 (A-C), cortical bone volume (BV/TV) was reduced by 36% 
(p<0.0001) and cortical porosity was increased by 9% (p<0.0001).  
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Figure 7.3: The IKKα inhibitor SU1349 reduced cortical bone volume in mice. Immuno-deficient BALB/c mice were intra-cardiacally injected 
with PC3 cells and treated with SU1349 (20mg/kg/3times-weekly) or vehicle control; at the end of the experiment, the mice tibia were subjected to 
microCT analysis. A: Cortical bone volume fraction (BV/TV). B: Cortical porosity. C: Representative microCT images. Values in the graphs are mean 
± S.E.M. (control n=13; SU1349 n=16).
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7.4.4 The selective IKKα inhibitor SU1349 exerts differential effects on 
osteoclasts and osteoblasts numbers in vivo  
In previous chapters I show that the verified IKKα inhibitor, SU1349, supressed 
osteoclast differentiation and enhanced osteoblast differentiation in vitro. In this 
chapter I show, in mice intra-cardiacally injected with PC3 cells, SU1349 increased 
trabecular and reduced cortical bone volume. In order to examine this further, detailed 
histomorphometric analysis was carried out of mouse tibial bone sections- proximal to 
the metaphysis- to investigate the effects of SU1349 on osteoclast and osteoblast 
numbers in bone. As shown in figure 7.4 (A-D), per trabecular bone surface analysed, 
SU1349 increased osteoblast numbers by 177% (p<0.05) as well as osteoblasts surface 
fraction was increased by 232% (p=0.0631), whereas osteoclast numbers were 
decreased by 56% (p<0.01) and osteoclast surface fraction was decreased by 48% 
(p<0.01). On the other hand, analysis of endocortical bone surface, as shown in figure 
7.4 (E-H), revealed that SU1349 decreased osteoblast number by 78% (p<0.05) and 
osteoblast surface fraction by 77% (p<0.05), whereas SU1349 increased osteoclast 
numbers by 448% (p<0.05) and increased osteoclast surface fraction by 628% 
(p<0.05).  
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Figure 7.4: In vivo the IKKα inhibitor SU1349 reduced osteoclasts and increased osteoblast in trabecular bone, whereas in cortical bone 
SU1349 reduced osteoblasts and increased osteoclasts. Immuno-deficient BALB/c mice were intra-cardiacally injected with PC3 cells and treated 
with SU1349 (20mg/kg/3times-weekly) or vehicle control; at the end of the experiment sections of mouse tibial bone were TRAPc and haematoxylin 
stained before undergoing histomorphometric analysis using Osteomeasure. A: Trabecular osteoblast numbers/bone surface. B: Trabecular osteoblast 
surface/bone surface. C: Trabecular osteoclast numbers/bone surface. D: Trabecular osteoclast surface/bone surface. E: Cortical osteoblast 
numbers/endocortical bone surface. F: Cortical osteoblast surface/endocortical bone surface. G: Cortical osteoclast numbers/endocortical bone surface. 
H: Cortical osteoclast surface/endocortical bone surface. Values in the graphs are mean ± s.d. representing at least n=3 in each experimental group.   
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7.4.5 The selective IKKα inhibitor SU1349 had no significant effects on 
cachexia in mice 
In this chapter I showed that the verified IKKα inhibitor, SU1349, showed a trend of 
reducing prostate tumour metastatic growth in mice, also it increased trabecular bone 
volume and reduced cortical bone volume in these mice. Here, I show the effects of 
SU1349 on cachexia in these mice as assessed by daily body weight monitoring. As 
shown in figure 7.5, cachexia analysis revealed no significant difference between 
SU1349 treated and untreated groups (p=0.44), however, unlike the control group all 
the mice in the SU1349 treated group had to be euthanized by day 35 before the 
planned end date for the experiment of day 40. Nonetheless, cachexia analysis clearly 
shows a rapid reduction in mice weights by 80% within three weeks of start of the 
experiment in both SU1349 treated and control groups. 
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Figure 7.5: Cachexia in mice was not significantly affected by the IKKα inhibitor SU1349. Immuno-deficient BALB/c mice (8 mice per group) 
were intra-cardiacally injected with luciferase expressing human PC3 cells and treated with SU1349 (20mg/kg/3times-weekly) or vehicle control. The 
graph shows the effects of SU1349 or vehicle control treatment on cachexia in BALB/c mice as assessed by daily monitoring of body weight; cachexia 
is expressed as a ratio of mice weight measured during the experiment normalised against weight of mice at the start of the experiments. p-values for 
experimental endpoints are shown in the graphs. (This data was generated by our collaborators Marco Ponzetti and Prof Nadia Rucci in L’Aquila, 
Italy).   
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In the key study by Luo et al., genetic inactivation of IKKα kinase activity was 
demonstrated to inhibit prostate cancer metastasis in the TRAMP mouse model of 
prostate cancer (Luo et al., 2007). However, since TRAMP mice do not usually 
develop skeletal metastasis (Hensley and Kyprianou, 2012), the value of IKKα 
inhibition in reducing prostate cancer metastasis to bone and reducing osteolysis 
associated with prostate cancer has remained unknown. In this chapter, I show that in 
a mouse model of prostate cancer bone metastasis, treatment with the novel IKKα 
inhibitor SU1349, had a novel bi-directional effect in protecting against prostate 
cancer associated bone loss.  
Effects of SU1349 on prostate cancer induced osteolysis 
MicroCT analysis of mice revealed that SU1349 treatment increased overall trabecular 
bone volume as shown by the increased trabecular bone volume fraction, increased 
trabecular thickness and increased trabecular numbers. SU1349 also reduced 
trabecular separation and trabecular porosity thereby indicating a reduction of 
osteolysis that is likely induced by prostate cancer. Moreover, SU1349 treatment 
increased trabecular pattern factor, which is a calculated index that indicates the 
interconnectedness of trabecular bone and thus their mechanical strength. Previous 
work shows that genetic inactivation of IKKα in mouse hematopoietic cells impaired 
osteoclastogenesis in vitro and reduced the number of multinucleated osteoclasts in 
mouse bones (Chaisson et al., 2004). Also apigenin, an inhibitor of IKKα, was shown 
to inhibit osteoclastogenesis in vitro and to protect against ovariectomy induced 
osteolysis of mouse trabecular bone (Goto et al., 2015). These results are in agreements 
with my own findings in chapter 4 that SU1349 has anti-osteolytic effects in vitro. 
Therefore, collectively this indicates that the increase in trabecular bone volume is 
likely due to SU1349 protection from prostate cancer associated osteolysis. 
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Subsequent, histomorphometric analysis of tibial bone sections supported an anti-
osteolytic effect for SU1349 as shown by the reduced osteoclast numbers on trabecular 
bone surface, however, it also revealed an increase in osteoblast numbers. Increased 
osteoblast numbers indicate that SU1349 treatment increased bone volume not only 
by protecting bone from osteolysis but also by enhancing bone formation. This is 
supported by my previously reported results that SU1349 stimulated osteoblast 
differentiation in vitro (chapter 5) and promoted pro-osteoblastic signalling (chapter 
6) as shown by the reduced NFκB signalling and increased Wnt signalling in 
osteoblasts.  
Paradoxically, microCT analysis of cortical bone revealed that SU1349 treatment 
reduced cortical bone volume as shown by the reduction in bone volume fraction and 
the increased porosity. Subsequent histomorphometric analysis of the endocortical 
bone surface supported microCT data, revealing that SU1349 reduced osteoblasts 
numbers and this was associated with increased osteoclasts numbers. This indicates 
that the reduction of cortical bone volume is due to reduced bone formation as a result 
of reduced osteoblasts numbers, whereas the increase in cortical bone porosity is due 
to the associated increase in cortical osteoclasts numbers.  It is important to note that 
osteoclasts were less commonly observed than osteoblasts on the endocortical bone 
surface. This suggests that the reduction in cortical bone volume is mainly a result of 
reduced osteoblast numbers and therefore reduced bone formation and not due to 
increased osteoclast activity. It is unlikely that the reduction in cortical osteoblast 
numbers is due to the reduction of osteoblast numbers seen with higher concentrations 
of SU1349 in vitro (chapter 5), on the contrary, I would expect any reductions in 
osteoblast numbers to be more pronounced in the trabecular compartment as it is more 
metabolically dynamic than cortical bone (Chen et al., 2010). Additionally, the 
increase in cortical osteoclasts was not associated with increased osteoclast size. 
Altogether, histomorphometry data presented in this chapter revealed a positive 
correlation between bone cell numbers (both osteoclasts and osteoblasts) and the 
fraction of bone surface occupied by bone cells. This indicates that observed 
differences between SU1349 treated and control groups are due to changes in cell 
numbers and not due to differences in cell size. However, histomorphometry analysis 
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of bone sections was particularly limited by poor TRAPc staining of osteoclasts. This 
is a result of the bones being left in formalin for a period of time that exceeded the 
recommended limit of up to 3-6 months. The formaldehyde present in formalin when 
left for extended periods of time can oxidize to form formic acid which can erode the 
integrity of bone tissue and this in turn will severely compromise staining methods 
that rely on the preservation of native protein integrity such as antibody based staining 
methods or staining methods that rely on enzyme activity such as TRAPc staining 
(Thavarajah et al., 2012). Nonetheless, the combination of TRAPc and haematoxylin 
staining and cell morphology did allow for the identification of osteoclasts.  
A number of previous studies provide evidence for the differential regulation of 
osteoblasts in trabecular and cortical bone by various mechanisms that notably involve 
the NFκB pathway. For example, RelB knockout mice exhibit increased trabecular 
bone volume due to increased bone formation and osteoblast differentiation, however, 
cortical bone volume was unaffected (Yao et al., 2014); RelB function is known to be 
tightly regulated by IKKα activation. In another study, a peptide inhibitor of RANK-
RANKL signalling in mice was shown to increase cortical bone formation but not 
trabecular bone and this was associated with increased osteoblast differentiation and 
stimulation of Smad/BMP-2 signalling (Furuya et al., 2013); IKKα is also known to 
control Smad transcriptional activity (Brandl et al., 2010). The above studies clearly 
indicate that NFκB pathway can differentially regulate cortical and trabecular bone. 
Interestingly, differential regulation of trabecular and cortical bone can also occur 
through dysregulation of Wnt signalling. For example, a study reported that GSK3β 
inhibition increased trabecular but not cortical bone in mice with chronic kidney 
disease and these mice display increased bone fragility (Tatsumoto et al., 2016); In 
chapter 6, I show that GSK3β- a negative regulator of Wnt signalling – was inhibited 
by SU1349 treatment in osteoblast precursors. 
Intriguingly, in the literature, a number of other studies in mice report bone phenotypes 
that are more similar to the phenotype I observe that, either directly or indirectly, 
involve both Wnt and NFκB signalling. For example, a study showed that mice 
deficient in sFRP4, which is a soluble Wnt antagonist, displayed increased trabecular 
bone volume and reduced cortical bone volume, and this was associated with 
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differential regulation of Wnt and BMP signalling in the trabecular and cortical bone 
compartments (Kiper et al., 2016, Brommage et al., 2009). In a later study, microarray 
data revealed that NFκB activation upregulates sFRP4 gene expression (Song et al., 
2017). Another study reports that mice deficient in Wnt16 exhibited reduced cortical 
bone volume with increased cortical porosity whereas trabecular bone remained 
unaffected (Zheng et al., 2012, Moverare-Skrtic et al., 2015). Wnt16 is highly 
expressed in cortical but not trabecular bone (Moverare-Skrtic et al., 2014). Also, 
Wnt16 was shown to be mainly derived from osteoblast lineage cells and it acts to 
inhibit osteoclastogenesis by directly activating Wnt signalling in osteoclast 
precursors and by increasing OPG productions by osteoblasts (Moverare-Skrtic et al., 
2014). However, Wnt16 did not seem to affect osteoblast differentiation, therefore, the 
possibility of SU1349 reducing Wnt16 levels might explain the increased cortical 
porosity and the increase in cortical osteoclasts seen with SU1349 treatment in my 
experiments but does not explain the decrease in cortical osteoblast numbers. 
Interestingly, prostate cancer derived Wnt16 was shown to be upregulated by NFκB 
and promote prostate tumour survival and progression in mice in a paracrine manner 
by activating canonical Wnt signalling (Sun et al., 2012). Finally, ERα deficient male 
mice were shown to exhibit lower cortical bone volume, whereas their trabecular bone 
was unaffected (Almeida et al., 2013). IKKα is known to enhance the activity of ERα 
by its direct association and phosphorylation (Park et al., 2005). Additionally, genetic 
inactivation of ERα in osteoblast precursors, was shown suppress Wnt signalling and 
thereby inhibit their proliferation and differentiation in vitro, also it inhibited cortical 
bone formation at the periosteal surface in mice (Martin-Millan et al., 2010, Almeida 
et al., 2013). Due to poor staining and contrast in my bone sections it was not possible 
for me to analyse bone histomophometry at the periosteal surface. Altogether, it is 
interesting to note that sFRP4, Wnt16 and ERα all seem to act on Wnt signalling at 
some level.  Previously, I show that SU1349 affected the levels of prostate cancer 
derived factors that act as agonist and antagonists of Wnt signalling, and that SU1349 
has differential effects on Wnt signalling that is cell type specific. In view of this, 
future experiments should investigate whether SU1349 alter the levels of protein such 
sFRP4, Wnt16 and ERα that could explain its effects on the cortical bone 
compartment.  
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Effects of SU1349 on prostate tumour metastatic growth 
In this chapter, I also looked at the effects SU1349 on prostate tumour metastatic 
growth in a mouse model of prostate cancer bone metastasis. In both SU1349 treated 
and untreated mice groups prostate cancer metastasis appeared in various parts of the 
body including the head, torso and long bones of mice. However, SU1349 treatment 
appeared to show a non-significant trend in reducing prostate cancer metastatic 
growth. This is in broad agreement with previous studies. Luo et. al., report that 
genetic inactivation of IKKα kinase activity inhibited primary tumour growth and 
distant soft tissue metastasis (Luo et al., 2007). Similarly, apigenin, a plant derived 
IKKα inhibitor, significantly reduced primary tumour growth and abolished metastasis 
(Shukla et al., 2015). This also in agreement with previous in vitro data, which shows 
that SU1349 inhibited prostate cancer cell growth and motility (chapter 3) and 
supressed prostate cancer production of pro-inflammatory factors important for 
prostate tumour growth and metastasis (chapter 6). Moreover, results presented in this 
chapter reveals that SU1349 treatment in mice did not significantly affect cachexia in 
mice. Cachexia progressed rapidly, and to a similar extent, in both SU1349 treated and 
control group primarily due to prostate tumour growth.  Moreover, mice in both groups 
exhibited significant diarrhoea (personnel communication; Marco Ponzetti, L’Aquila, 
Italy). In our experiments mannitol was used as a vehicle to dissolve SU1349 and in 
control treatments. Mannitol is a water soluble sugar alcohol that is considered 
generally safe and is used in pharmacological and food preparations (Jaipal et al., 
2015), however, several studies report that mannitol can induce diarrhoea and body 
weight loss in rats and mice (Til et al., 1996, Olsson and Hahn, 1996). Therefore, the 
reduced survival in both group might be partially explained by the adverse effects of 
mannitol. Nonetheless, there was evidence for SU1349 having more adverse effects 
on mice survival (personnel communication; Marco Ponzetti, L’Aquila, Italy). All 
mice in the SU1349 treated group were euthanized before the planned end date of the 
experiment unlike in the control group.  IKK has long been understood not to play 
an essential role in the activation of the canonical NFκB pathway in comparison to the 
related IKK (Hacker and Karin, 2006, Lee and Hung, 2008), however, this has been 
challenged by recent studies (Adli et al., 2010, Khandelwal et al., 2017). Despite the 
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fact that the Ki values for SU1349 show it to be considerably more selective for IKKα 
over IKKβ, nonetheless, I clearly showed (in chapter 6) that SU1349 is effective in 
significantly supressing canonical NFκB activation. Previous studies argue that due to 
the importance of the canonical NFκB pathway in critical cellular process such as 
immunity, drugs that affect canonical NFκB pathway can produce deleterious systemic 
effects in vivo (Verstrepen and Beyaert, 2014, Baud and Karin, 2009).  Furthermore, 
because we were limited to the use of immunocompromised mice to model prostate 
cancer bone metastasis in vivo, this might have further amplified the deleterious effects 
of SU1349 on the immune system and thus on host survival.  
Conclusion 
In conclusion, although SU1349 seemed to show a trend of reducing prostate cancer 
metastasis in mice, however, this effect was not significant. In bone, SU1349 did 
protect trabecular bone from prostate cancer induced osteolysis, however, it was at the 
expense of increased cortical bone loss which may limit is utility as a bone preserving 
agent. Future work should investigate different dosing regimen for SU1349 in 
immune-competent mouse models. This could elucidate whether the adverse effects 
of SU1349 are due its actions on immunity or due to some other mechanism. In 
prostate cancer research there is a shortage of cell and animal models that closely 
recapitulate prostate cancer progression in humans, specifically, there is a lack of 
spontaneous prostate cancer mouse models that develop bone metastasis, also there is 
a lack of well characterised syngeneic mouse prostate cancer cell lines that are suitable 
for orthtopic injection in immune-competent mouse models that subsequently develop 
bone metastasis (Cunningham and You, 2015, Ittmann et al., 2013). The RM-1 mouse 
cell line has been described to have a high rate of bone metastasis when injected intra-
cardically into  C57BL/6 mice (Power et al., 2009). More recently, researcher have 
developed a TRAMP-derived orthotopic prostate syngeneic (TOPS) model, although 
it was not reported to metastasize to bone, it is a model that seems to closely mirror 
prostate cancer disease progression in humans to date (Lardizabal et al., 2018). 
Lardizabal et al., also derived luciferase expressing prostate cancer cells, TRAMP-C2, 
that are suitable for syngeneic injection into immune-competent C57/BL6 mice 
(therefore suitable for direct injection into bone) (Lardizabal et al., 2018).  
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Furthermore, future experiments should also investigate the use of SU1349 in 
combination with other chemotherapeutic agents in vivo. Docetaxel is commonly used 
in the treatment of prostate cancer patients with advanced metastatic disease (Puente 
et al., 2017); in preliminary in vitro experiments, I found that use of SU1349 in 
combination with chemotherapeutic agents including docetaxel had significant 
synergistic effects on reducing prostate cancer cell viability (see figure S7.2). 
Moreover, data from these experiments predict significant dose reduction values for 
SU1349 and docetaxel respectively when used in combination which indicate that 
lower doses of these drugs can be administered in vivo and thereby potentially 
minimizing their respective toxic effects. On the contrary, it is also possible that 
SU1349 and docetaxel might have an additive toxic effect in vivo. Regardless, based 
on my preliminary data, future experiments should investigate the utility of 
combinational treatments of SU1349 with conventional chemotherapy in vivo. 
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Prostate cancer is the second leading cause of cancer in men worldwide and it is 
amongst the leading causes of cancer related deaths (Haas et al., 2008, Center et al., 
2012).  A hallmark of advanced prostate cancer in patients is bone metastasis which 
significantly reduces survival rate and it is a major cause of morbidity (Jemal et al. 
2008). Prostate cancer cells that metastasise to bone disrupt bone homeostasis and can 
lead to both aberrant increases in osteolytic bone resorption and osteoblastic bone 
formation (Logothetis and Lin, 2005). The development of bone metastasis leads to a 
variety of complications in patients that reduces their quality of life, this includes: bone 
pain, fractures, reduced mobility, anaemia and susceptibility to infections (Logothetis 
and Lin, 2005, Coleman, 2001). Drugs that influence bone remodelling have been the 
standard in the treatment of prostate cancer patients with bone metastases; however, 
these treatments are palliative and only address some of the complications associated 
with bone metastasis –primarily addressing increased bone resorption- but are 
unsuccessful in preventing disease progression and significantly improving survival 
(Clement-Demange and Clezardin, 2015, Todenhofer et al., 2015). 
The nuclear factor kappa B (NFκB) pathway is known to play an important role in 
regulating bone homeostasis and cancer progression (Novack, 2011, Xia et al., 2014). 
Aberrant activation of the NFκB pathway is recognised to be important in promoting 
the ‘the vicious cycle’, that involves cancer cells, osteoclasts and osteoblasts, which 
drives bone metastasis (Roca and McCauley, 2015). The related IκB kinases alpha 
(IKKα) and beta (IKKβ) play key roles in the regulation of canonical and non-
canonical NFκB activation and signalling. IKKβ and IKKα work cooperatively in the 
activation of the canonical NFκB pathway, however, early studies have shown IKKβ 
to be more crucial for the activation of this pathway than IKKα (Yamamoto et al., 
2000). Whereas the non-canonical NFκB pathway is dependent on IKKα (Clement et 
al., 2008). In prostate cancer, IKKα has been shown to be more important in the 
development of prostate cancer than IKKβ (Shukla et al., 2005, Nguyen et al., 2014b). 
Increased activation of IKKα was correlated with prostate cancer progression in 
humans and genetic inactivation of IKKα kinase activity was demonstrated to inhibit 
prostate cancer progression and metastasis in mouse models of prostate cancer (Luo et 
al., 2007). However, the mouse model used by Luo et al., do not typically develop 
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bone metastasis and therefore the specific role of IKKα in prostate cancer bone 
metastasis has since remained unexplored. This would suggest that pharmacological 
inhibition of IKKα kinase activity represents an attractive therapeutic option for the 
treatment of prostate cancer progression and metastasis. Currently there is a lack of 
commercially available drugs that selectively inhibit the kinase activity of IKKα but 
not the related IKKβ. In this thesis I investigate for the first the time effects of selective 
pharmacological inhibition of IKKα kinase activity, using the verified IKKα inhibitor 
SU1349, on the behaviour and interaction of prostate cancer cells and bone cells in 
vitro, and its efficacy in supressing prostate cancer bone metastasis and prostate cancer 
associated bone disease in vivo.   
Effects of IKKα inhibition on osteoclastogenesis 
Activation of the NFκB pathway is essential for osteoclast differentiation and survival 
(Soysa and Alles, 2009). In this thesis, I show that IKKα inhibition suppressed 
osteoclast formation in vitro and reduced osteoclasts numbers and osteolysis in vivo. 
Chaisson et al., were first to demonstrate that knockout of IKKα in mouse 
hematopoietic precursors impairs osteoclast differentiation in vitro (Chaisson et al., 
2004). Similarly, previous work done by our group showed the non-selective IKKα/β 
inhibitor, parthenolide, inhibits osteoclastogenesis in vitro and in vivo (Idris et al., 
2010, Marino et al., 2018). I show that the IKKα inhibitor SU1349, suppressed 
RANKL induced osteoclastogenesis in a dose dependent manner (chapter 4) and this 
was due to inhibition of RANKL-induced NFκB activation in osteoclast precursors 
(chapter 6). Moreover, I show that cancer-specific IKKα activity regulates the ability 
of prostate cancer cells to influence osteoclastogenesis in vitro. In PC3-mouse bone 
marrow cell co-cultures, IKKα overexpression in PC3 significantly enhanced 
osteoclastogenesis whereas IKKα knockdown in PC3 or PC3 cells in the presence of 
SU1349 significantly supressed osteoclastogenesis. Previously, constitutive activation 
of the NFκB pathway in prostate cancer cells was shown to promote osteclastogensis 
in mouse bone marrow cultures (Jin et al., 2013). In chapter 6, I show PC3 cell derived 
factors activated both canonical both canonical and non-canonical NFκB signalling in 
osteoclast precursors. PC3 conditioned media has been reported to upregulate the 
expression of NFκB regulated genes in osteoclasts (Akech et al., 2010). Next, I show 
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that SU1349 was effective in supressing prostate cancer induced NFκB activation of 
both canonical and non-canonical signalling in osteoclast precursors. Although the 
suppression of canonical NFκB signalling by SU1349 seems to go against the 
prevailing understanding from early studies that IKKα is not important for canonical 
NFκB signalling, it is in agreement with more recent studies that show IKKα is 
important for canonical NFκB activation and that this maybe cell-type specific (Adli 
et al., 2010, Khandelwal et al., 2017). Furthermore, I show that SU1349 also supressed 
Wnt signalling in osteoclast precursors. NFκB signalling is known to influence the 
Wnt/-catenin pathway and activation of Wnt signalling inhibits osteoclast 
differentiation (Albers et al., 2013). Therefore, the effects of SU1349 on osteoclast 
differentiation can be explained, primarily, by the evident inhibition of NFκB 
signalling, but may also be partly due to SU1349 inhibition of Wnt signalling. In 
chapter 7, I show SU1349 treatment in mice, increased trabecular bone volume and 
showed a reduction in indices of trabecular osteolysis, suggesting an inhibition of 
prostate cancer induced osteolysis. This effect of SU1349 on trabecular bone is 
supported by subsequent histomorphometry analysis which show that SU1349 
treatment was associated with reduced osteoclast numbers on the trabecular bone 
surface. Previous work done in our group showed that parthenolide, an inhibitor of 
IKKα/β, supressed breast cancer induced osteolysis and as a result increased trabecular 
bone volume (Marino et al., 2018). Although the role of IKKα in bone metastasis has 
not yet been explored, there is evidence that IKKα inhibition may have a role in 
osteolysis, for example, IKKα knockout reduced the number of multinucleated 
osteoclasts in mouse bones (Chaisson et al., 2004). Also apigenin, an inhibitor of 
IKKα, was shown to protect against ovariectomy induced osteolysis of mouse 
trabecular bone (Goto et al., 2015). Furthermore, the microarray data presented in 
chapter 6, shows that SU1349 downregulated the production of soluble pro-
inflammatory factors by PC3 cells that promote osteoclast differentiation and function. 
For example, the downregulated factor MCP-1 was shown to promote prostate cancer 
induced osteoclast formation (Lu et al., 2009). SU1349 also down regulated PC3 
production of other factors that are known to promote osteoclast differentiation or 
osteolytic bone resorption directly these notably include: ENA-78, IL-1α and IL-8  
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(Sundaram et al., 2013, Tani-Ishii et al., 1999, Bendre et al., 2003). The 
downregulation of these pro-inflammatory factors might explain how IKKα inhibition 
suppressed PC3 induced osteoclast formation in vitro (chapter 4) and suppressed PC3 
induced trabecular osteolysis in vivo (chapter 4). 
Effects of IKKα inhibition on osteoblasts 
Activation of the NFκB pathway in osteoblasts is known to negatively regulate 
osteoblast differentiation and function (Chang et al., 2009, Alles et al., 2010). In this 
thesis, I show that that IKKα inhibition enhanced osteoblast differentiation in vitro and 
in vivo. In chapter 5, I show that the selective IKKα inhibitor, SU1349, significantly 
enhanced osteoblast differentiation and bone nodule formation function in vitro. This 
is in agreement with previous work by our group and others that show pharmacological 
inhibition of IKKα/β promotes osteoblast differentiation and bone nodule formation in 
vitro (Marino et al., 2018, Zhang et al., 2017b). Moreover, I show for the first time 
that conditioned media from PC3 cells with IKKα knockdown enhanced the 
differentiation and bone nodule formation of osteogenic cultures. This suggests that 
IKKα knockdown in PC3 either supresses the production of factors that inhibit 
osteoblastic differentiation and function or it stimulate the production of factors that 
promote osteoblastic differentiation and function. In support of this, the microarray 
data presented in chapter 6, revealed that SU1349 downregulated the production of 
soluble factors by PC3 cells that are known to negatively regulate osteoblast 
differentiation and function, these include: IL-1β, IL-1α, Osteopontin, Lipocalin-2, 
TSP1 and GDF15 (Taichman and Hauschka, 1992, Tanabe et al., 2004, Huang et al., 
2004, Rucci et al., 2015, Furlan et al., 2007, Westhrin et al., 2015). In contrast, I show 
that both SU1349 and conditioned media from PC3 cells with IKKα knockdown 
suppressed adipocyte differentiation in vitro. This is in broad agreement with the 
understanding that osteoblast and adipocytes share the same lineage and their 
differentiation from osteoprogenitor cells in the bone marrow microenvironment is 
generally mutually exclusive (Muruganandan and Sinal, 2014). Also, my findings are 
in agreement with a previous study which reports that IKKβ inhibition supressed 
adipocyte differentiation (Helsley et al., 2016). Taken altogether, this would suggest 
that IKKα inhibition in osteoprogenitor cells and prostate cancer specific effects of 
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IKKα inhibition on osteoprogenitors, act by the same mechanism to commit the 
differentiation programme of early MSC precursors found within bone 
microenvironment towards an osteoblast lineage at the expense of adipocytes. Future 
experiments should investigate the effect of IKKα inhibition on osteoprogenitor cell 
differentiation in vitro and in vivo.   
In chapter 6, I demonstrate that PC3 conditioned media activated both canonical and 
non-canonical NFκB signalling in osteoblast precursors. In the literature there is 
somewhat indirect evidence for this, where PC3 conditioned media is reported to 
upregulate the expression of NFκB regulated genes in osteoblast precursors (Schulze 
et al., 2012), however, to my knowledge there has not been detailed examination of 
prostate cancer effects on NFκB signalling in osteoblasts. Here, I show that SU1349 
was effective in supressing prostate cancer induced NFκB activation of both canonical 
and non-canonical signalling in osteoblasts. Significantly, I show that SU1349 also led 
to an activation of Wnt signalling in osteoblasts. Activation of Wnt signalling is 
essential for osteoblast lineage commitment, differentiation and function (Gaur et al., 
2005). My findings are in agreement, with previous work that shows that NFκB 
inhibition enhances osteoblastic differentiation and function through enhanced Wnt 
signalling (Chang et al., 2013, Marino et al., 2018). Therefore, the enhancement of 
osteoblast differentiation and bone nodule formation by SU1349 presented in chapter 
5, can be explained both by its inhibition of NFκB pathway and stimulation of Wnt 
signalling. In agreement with this, I show that increase in trabecular bone volume in 
mice treated with SU1349 was associated with increased osteoblast numbers on the 
trabecular bone surface. 
Paradoxical effects of IKKα inhibition on cortical bone 
In contrast to the effects of SU1349 in trabecular bone, SU1349, unexpectedly 
appeared to exacerbate cortical bone loss. In chapter 7, microCT analysis revealed that 
SU1349 reduced cortical bone volume and increased cortical bone porosity. This was 
supported by hitomorphometry which revealed reduced osteoblast numbers and 
increased osteoclast numbers on the endocortical bone surface. This indicates that 
effects of SU1349 on cortical bone is not simply due to reduced bone formation as a 
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result of reduced osteoblast numbers, but it may also be due to increased osteolysis.  
The differential effects of SU1349 on trabecular and cortical bone as well as 
osteoclasts and osteoblasts within these two compartments, is not unique. A number 
of studies show evidence for the differential regulation of cortical and trabecular bone 
and more specifically that osteoblasts in these two compartments are differentially 
regulated. There have been a number of studies that report that disruption of the NFκB 
pathway can have differential effects on trabecular and cortical bone (Yao et al., 2014, 
Furuya et al., 2013, Brandl et al., 2010). However, these studies do not report a 
phenotype that closely matches what I observe with SU1349. Other reports involving 
the differential regulation of Wnt signalling by factors such as sFRP4, Wnt16 and ERα 
which incidentally are also regulated by the NFκB pathway report a phenotype that is 
very similar to what I observe in trabecular and cortical bone (Kiper et al., 2016, 
Brommage et al., 2009, Zheng et al., 2012, Moverare-Skrtic et al., 2015, Almeida et 
al., 2013). Future studies should investigate if a mechanistic link exists between IKKα 
inhibition by SU1349 and the regulation of factors such as sFRP4, Wnt16 and ERα in 
bone cells that could explain the differential effects of SU1349 on trabecular and 
cortical bone. Overall SU1349 indicates a novel role for IKKα in the differential 
regulation of trabecular and cortical bone, however, its negative effects on cortical 
bone may limit its use as bone preserving agent. 
Effects of IKKα inhibition on prostate cancer cell behaviour 
Aberrant activation of IKKα has been found to drive prostate cancer progression and 
metastasis in mouse models of prostate cancer (Luo et al., 2007). However, Luo et. al. 
did not examine the role of IKKα in bone metastasis associated with prostate cancer. 
In this thesis, I provide evidence that the novel IKKα inhibitor, SU1349, suppressed 
prostate cancer cell growth and motility in vitro and showed a trend of reducing 
prostate tumour metastatic growth in vivo. In chapter 3, I show that SU1349 potently 
inhibited the growth of various prostate cancer cell lines of various metastatic abilities. 
Previously, apigenin which is a plant derived inhibitor of IKKα/β, was reported to 
reduce the proliferation of prostate cancer cells and enhance their apoptosis (Shukla 
and Gupta, 2004, Shukla et al., 2015). In order to further validate the effects of SU1349 
on prostate cancer cells I successfully generated stable overexpression and 
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knockdowns of IKKα in the highly aggressive human prostate cancer cell line PC3. I 
show that just as SU1349 reduced PC3 viability, knockdown of IKKα in PC3 reduced 
its viability whereas IKKα overexpression enhanced PC3 viability. This is in 
agreement with previous studies that showed that knockdown of IKKα in PC3 induced 
cell cycle arrest and reduced their proliferation  (Shukla et al., 2015). Next, I tested the 
effects of SU1349 on PC3 motility and invasion in vitro. I show that PC3 directed 
migration, random migration and invasion were supressed by SU1349 and IKKα 
knockdowns whereas it was enhanced by IKKα overexpression. This agrees with 
previous reports that IKKα inhibition in PC3 by siRNA or apigenin supressed PC3 
directed migration and invasion in vitro (Shukla and Gupta, 2004, Shukla et al., 2015, 
Mahato et al., 2011).  In chapter 7, I show that SU1349 treatment in mice showed a 
non-significant trend of reducing prostate cancer metastatic growth without 
significantly affecting cachexia. This is supported by microarray data presented in 
chapter 6, which shows that SU1349 suppressed prostate cancer production of soluble 
pro-inflammatory factors that are important in regulating prostate cancer cell growth, 
survival, metastasis and invasion. For example, MCP-1 which was significantly 
downregulated by SU1349 in PC3 conditioned media, was found to be an autocrine 
and paracrine factor for prostate cancer cell growth and invasion in vitro (Lu et al., 
2006b, Lu et al., 2007). In a later study Lu et al., found MCP-1 to be significantly 
elevated in the serum of patients with prostate cancer bone metastasis as opposed to 
patients with primary prostate cancer (Lu et al., 2009). 
Finally, there was some evidence that SU1349 also had adverse effects in mice, for 
example, more mice were euthanized in the SU1349 treated group compared to control 
group. Luo et al., genetically inactivated IKKα kinase activity in TRAMP mouse 
models of prostate cancer that have a fully functioning immune system, and they 
showed IKKα inactivation not only significantly reduced primary tumour growth and 
metastasis, but it also considerably enhanced their survival compared to controls with 
catalytically active IKKα (Luo et al., 2007). This suggests that any adverse effects 
associated with SU1349 treatment is unlikely to be as a result of SU1349 selective 
inhibition of IKKα kinase activity alone, rather it might be due to a combination of the 
following reasons: toxicity of SU1349 due to some yet unknown off targets effects, 
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the effects of SU1349 on supressing host immunity in combination with using an 
immune-compromised mouse model, finally, the use of mannitol as a vehicle which 
seemed to induce diaorrehea in mice. 
Many of the drugs developed to inhibit the NFκB pathway were shown to have adverse 
effects in vivo due to their effects on host immunity which is primarily regulated by 
the canonical NFκB pathway (Baud and Karin, 2009, Verstrepen and Beyaert, 2014). 
Although the Ki values for SU1349 show its selectivity for IKKα over IKKβ, I clearly 
show in chapter 6, that SU1349 significantly supressed canonical NFκB activation. 
Perhaps some of the adverse effects of SU1349 may be due to its effects in inhibiting 
canonical NFκB signalling in host cells. Therefore, future studies should investigate 
the toxicity of SU1349 in immune-competent mice so as to understand if the observed 
adverse effects of SU1349 are due to negative effects on host immunity. Although 
there has been a lack of well characterised murine prostate cancer cell lines that are 
suitable for syngeneic use in immune-competent mice and are bone metastatic, the 
mouse RM-1 cell line has been described to be highly bone metastatic when injected 
intra-cardically into C57/BL6 mice (Power et al., 2009) and thus it may represent a 
suitable model to investigate the effects of SU1349 on bone metastasis and host 
immunity. 
So far, the evidence for the efficacy of using the inhibitor of IKKα inhibitor, SU1349, 
in inhibiting prostate cancer metastasis and particularly bone metastasis appears 
mixed. On the one hand SU1349 appeared to show a trend of reducing metastatic 
growth, however, this did not reach significance possibly due to the reduced survival 
of mice in the SU1349 treated group. As mentioned previously the apparent adverse 
effects of SU1349 may have been confounded by our use of immune-comprised mice 
and this will need to be fully explored in future experiments in immune-competent 
mice. On the other hand, SU1349 did appear to mitigate prostate cancer induced 
osteolytic damage in the trabecular bone compartment whilst increasing bone loss in 
the cortical bone compartment. The negative effects of SU1349 on cortical bone may 
limit its use as bone preserving agent in vivo. Nevertheless, preliminary in vitro data I 
acquired also show that the use of SU1349 in combination with a conventional 
chemotherapeutic agent such as docetaxel (docetaxel is commonly used in the 
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treatment of advanced prostate cancer) had significant synergistic effects and predict 
significant dose reduction indices for each drug respectively. This indicates that in 
vivo, the dosage for each drug could be reduced in combinational treatments to achieve 
similar results to when individual drug treatments are used at higher doses and thereby 
this may limit some of the toxic effects of using higher doses of SU1349 or docetaxel 
alone. Future experiments should explore the use of SU1349 in combination with 
docetaxel on prostate cancer bone metastasis in mouse models. 
Conclusion 
In conclusion, I in this thesis characterised the role of IKKα kinase activity using a 
novel and highly selective small molecular inhibitor of IKKα kinase activity, SU1349, 
in prostate cancer cells and bone cell in vitro and in a model of prostate cancer bone 
metastasis in vivo. I show that SU1349 inhibited prostate cancer cell growth and 
metastatic behaviour, supressed its ability to promote osteoclast formation and 
enhanced its ability to promote osteoblast differentiation in vitro. I show that SU1349 
inhibition of the NFκB pathway supresses osteoclast differentiation and promotes 
osteoblast differentiation in vitro, and that these effects were associated with 
differential effects on Wnt/β-catenin signalling. In vivo SU1349 protected against 
prostate cancer induced osteolysis in trabecular bone yet it increased cortical bone loss, 
this points to a novel role for IKKα in the differential regulation of trabecular and 
cortical bone; however, the negative effects of SU1349 may limit its use as a bone 
preserving agent. Finally, SU1349 had adverse effects on mice survival that may have 
been exacerbated by our use of immune-compromised mice, this makes any 
conclusions about the effects of SU1349 on metastasis and particularly bone metastasis 
inconclusive. Future studies should utilise immune-competent mice to investigate the 
effects of SU1349 alone and in combination with conventional therapeutic agents to 
elucidate any toxic effects of using SU1349 alone and better understand the efficacy 
























Appendix 1: Supplementary figures 
Figure S3.1.1: LNCaP cell viability for IKKα inhibitors used in IC50 calculations (table 
3.1). Shows Alamar blue cell viability results for LNCaP cells after treatment with IKKα 
inhibitors after 48hrs in complete media, as a percentage of the vehicle control (0.3% DMSO). 
Values in the graphs are mean ± s.d. and are obtained from 3 independent experiments. 








L N C a P :   S U 1 2 5 7  (4 8 h rs )


























L N C a P :  S U 1 2 6 1  (4 8 h rs )


























L N C a P :  S U 1 3 4 9  (4 8 h rs )


























L N C a P :  S U 1 3 6 1  (4 8 h rs )


























L N C a P :  S U 1 4 1 1  (4 8 h rs )


























L N C a P :  S U 1 2 6 6  (4 8 h rs )



























L N C a P :  S U 1 0 8 7  (4 8 h rs )























Figure S3.1.2: C4-2 cell viability for IKKα inhibitors used in IC50 calculations (table 
3.1). Shows Alamar blue cell viability results for C4-2 cells after treatment with IKKα 
inhibitors after 48hrs in complete media, as a percentage of the vehicle control (0.3% DMSO). 
Values in the graphs are mean ± s.d. and are obtained from 3 independent experiments. 
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Figure S3.1.3: C4-2B4 cell viability for IKKα inhibitors used in IC50 calculations (table 
3.1). Shows Alamar blue cell viability results for C4-2B4 cells after treatment with IKKα 
inhibitors after 48hrs in complete media, as a percentage of the vehicle control (0.3% DMSO). 






Figure S3.1.4: PC3 cell viability for IKKα inhibitors used in IC50 calculations (table 3.1). 
Shows Alamar blue cell viability results for PC3 cells after treatment with IKKα inhibitors 
after 48hrs in complete media, as a percentage of the vehicle control (0.3% DMSO). Values 






Figure S3.1.5: PC3-BT cell viability for IKKα inhibitors used in IC50 calculations (table 
3.1). Shows Alamar blue cell viability results for PC3-BT cells after treatment with IKKα 
inhibitors after 48hrs in complete media, as a percentage of the vehicle control (0.3% DMSO). 






Figure S3.2: SU1349 suppressed the directed migration of PC3 cells pre-treated with 
mitomycin-C (10µg/L) in vitro. The PC3 cells pre-treated with 10µg/L mitomycin-C before 
additional treatment with 1µM SU1349 and compared to vehicle treated (0.1% DMSO) 
control. The graph shows the 2D migration of PC3 cells after 12 hours was suppressed to an 
almost identical extent to previous experiments in the absence of mitomycin-C treatment: by 
27% (p<0.001) compared to 26% (p<0.01) previously. No significant effects were seen on the 
viability of PC3 cells at the end of the migration experiment as assessed using the Alamar blue 
assay. Values in the graphs are mean ± s.d. and are obtained from 3 independent experiments 







Figure S3.3: Concentration of SU1349 selected for invasion assay had no significant 
effects on PC3 viability in vitro. The graph shows the viability of PC3 cells seeded at 3000 













Figure S4.1: PC3 conditioned supressed osteoclast formation in vitro. A: Shows the 
number of M-CSF (10 ng/ml) and RANKL (100 ng/ml) generated osteoclasts in mouse bone 
marrow cultures treated with 10% (v/v) PC3 conditioned media (PC3CM) or standard control 
media every 48hrs. Cultures were maintained for up to 7 days. Osteoclasts number was 
assessed by counting multinucleated TRAcP positive cells. Values in the graphs are mean ± 
s.d. and are obtained from 3 independent experiments (** = P≤0.01).  B: representative 














Figure S5.1: PC3 conditioned media stimulated osteoblastic differentiation, bone nodule formation activity and viability in vitro. Saos2 and 
MC3T3 cells were treated with PC3 conditioned media (20% v/v) for up to 3 weeks.  At the end of the experiments culture well were assessed for: 
osteoblastic differentiation by measuring alkaline phosphatase activity; osteoblastic bone nodule formation by quantifying Alizarin red staining 
intensity; and cell culture viability using the Alamar Blue assay. A-D: Shows results for experiments in Saos2 after 10 days. E-H: Shows results for 









Figure S5.2: PC3 conditioned media stimulated 3T3L1 adipocyte differentiation in vitro. 3T3L1 cells were differentiated as described in section 
2.4.5 in the presence and absence of PC3 conditioned media (20% v/v) for 15 days. At the end of the experiments the differentiation of 3T3L1 cultures 
was assessed by quantifying eluted oil red staining measured by spectrophotometry and the viability was measured using the Alamar Blue assay. A-
C: Shows the differentiation and viability of 3T3L1 cells after treatment with 1µM SU1349 or vehicle control; representative images are shown (5x 






Figure S6.1: Pharmacological IKKα inhibition reduced total IKKα and β-catenin in PC3 cells. PC3 cells were treated with 1µM SU1349 or 
vehicle control in serum free media for 24rs. Total cellular lysates (50µg/lane) were subjected to western blot analysis normalised against GAPDH 
loading control; A: western blot analysis of total IKKα in response to SU1349.  B: western blot analysis of total β-catenin in response to SU1349. C: 





Table S6.2 Raw data for human XL cytokine microarray used in section 6.4.6. PC3 cells 
were treated with 1μM SU1349 or vehicle control (0.1% DMSO) for 24hrs (in serum free 
media) before probing PC3 conditioned media using Proteome ProfilerTM Human XL 
Cytokine Array Kit (R&D systems) followed by chemiluemiscence detection and analysis. 
 
Probed factor  
(spotted antibody duplicates) 
Control(DMSO)  
(mean pixel density) 
SU1349 (1uM) 
(mean pixel density) 
Significance (t-test: 2 tail, type 2) 
*significant results highlighted in 
yellow 
Reference Spots 1,147,856.00 1,105,520.00 0.0491 
  1,154,744.00 1,121,496.00   
Adiponectin 36,928.00 34,508.00 0.6221 
  30,184.00 26,608.00   
aggrecan 34,764.00 26,620.00 0.6060 
  43,596.00 41,336.00   
Angiogenin 619,304.00 570,124.00 *0.0017 
  615,568.00 569,004.00   
Angiopoietin-1 22,628.00 27,716.00 0.9489 
  27,128.00 21,484.00   
Angiopoietin-2 34,916.00 36,652.00 0.5401 
  40,368.00 34,276.00   
BAFF 29,244.00 26,752.00 0.5889 
  36,856.00 33,048.00   
BDNF 43,540.00 40,068.00 0.0920 
  42,592.00 37,408.00   
C5/C5a 33,184.00 29,552.00 *0.0362 
  34,572.00 28,164.00   
CD14 38,708.00 29,032.00 0.0640 
  34,616.00 26,844.00   
CD30 47,648.00 53,992.00 0.1289 
  48,664.00 61,616.00   
Reference Spots 937,244.00 1,040,116.00 0.0507 
  976,728.00 1,042,792.00   
CD40 ligand 32,784.00 36,260.00 0.6027 
  38,984.00 30,200.00   
Chitinase 3-like 1 27,140.00 23,680.00 0.4720 
  32,784.00 29,264.00   
Adipsin 108,824.00 89,860.00 *0.0183 
  114,856.00 89,820.00   
C-Reactive Protein 35,892.00 29,984.00 0.2059 
  31,964.00 22,892.00   
Cripto-1 24,576.00 22,352.00 0.1533 
  27,700.00 22,816.00   
Cystatin C 58,816.00 50,504.00 0.3185 
  70,092.00 59,448.00   




  377,180.00 384,172.00   
DPPIV 101,640.00 98,760.00 0.8613 
  104,052.00 105,512.00   
EGF 59,176.00 46,124.00 0.3080 
  47,180.00 43,620.00   
Emmprin 204,972.00 238,264.00 *0.0017 
  205,116.00 241,132.00   
ENA-78 24,252.00 19,340.00 *0.0178 
  24,396.00 20,520.00   
Endoglin 36,224.00 25,972.00 0.1619 
  31,064.00 28,668.00   
Fas Ligand 30,528.00 26,216.00 0.6487 
  27,112.00 29,064.00   
FGF basic 37,452.00 33,672.00 0.0812 
  36,216.00 31,356.00   
FGF-7 24,440.00 21,524.00 0.1121 
  28,220.00 20,224.00   
FGF-19 62,652.00 63,392.00 0.6346 
  65,824.00 68,352.00   
Flt-3 Ligand 33,248.00 32,124.00 0.1490 
  33,232.00 30,396.00   
G-CSF 32,716.00 30,968.00 0.8407 
  43,000.00 41,404.00   
GDF-15 671,184.00 590,864.00 *0.0038 
  676,072.00 599,296.00   
GM-CSF 42,976.00 45,536.00 0.7960 
  46,204.00 42,296.00   
GROα 23,728.00 22,652.00 0.9842 
  27,256.00 28,484.00   
Growth Hormone 27,204.00 23,280.00 0.0674 
  30,168.00 23,260.00   
HGF 27,784.00 22,216.00 0.0575 
  25,692.00 22,700.00   
ICAM-1 39,656.00 39,196.00 0.2793 
  43,376.00 32,248.00   
IFN-γ 35,192.00 31,188.00 0.0612 
  34,448.00 28,796.00   
IGFBP-2 28,140.00 26,908.00 0.8251 
  24,588.00 24,780.00   
IGFBP-3 28,620.00 23,924.00 0.2780 
  30,188.00 28,184.00   
IL-1α 35,992.00 26,616.00 *0.0524 




IL-1β 32,536.00 25,304.00 *0.0391 
  36,340.00 24,504.00   
IL-1ra 39,096.00 26,348.00 0.3894 
  35,896.00 36,764.00   
IL-2 33,060.00 26,488.00 *0.0256 
  35,640.00 26,380.00   
IL-3 30,916.00 21,760.00 0.0676 
  26,860.00 20,324.00   
IL-4 24,624.00 22,784.00 0.5944 
  24,420.00 24,916.00   
IL-5 21,420.00 22,556.00 0.6599 
  22,760.00 20,268.00   
IL-6 33,252.00 25,152.00 0.0635 
  32,800.00 28,424.00   
IL-8 67,812.00 53,200.00 *0.0284 
  73,156.00 49,268.00   
IL-10 36,508.00 27,292.00 0.1501 
  30,660.00 26,376.00   
IL-11 35,704.00 29,376.00 *0.0377 
  37,740.00 31,008.00   
IL-12 p70 32,936.00 26,840.00 0.0820 
  30,008.00 26,424.00   
IL-13 27,624.00 23,596.00 0.2577 
  24,252.00 22,880.00   
IL-15 31,576.00 23,648.00 0.0796 
  28,104.00 20,556.00   
IL-16 29,948.00 24,620.00 0.1071 
  28,312.00 26,548.00   
IL-17A 57,552.00 43,772.00 *0.0465 
  62,648.00 47,688.00   
IL-18 Bpa 29,676.00 24,992.00 0.0865 
  34,296.00 22,968.00   
IL-19 19,652.00 19,904.00 0.5742 
  25,900.00 21,376.00   
IL-22 34,136.00 31,972.00 0.3340 
  32,100.00 31,664.00   
IL-23 32,296.00 27,696.00 0.1238 
  31,184.00 22,752.00   
IL-24 35,988.00 26,960.00 *0.0423 
  38,008.00 29,972.00   
IL-27 33,344.00 34,076.00 0.3573 
  37,392.00 27,660.00   




  28,176.00 27,788.00   
IL-32 36,036.00 32,864.00 0.2779 
  33,020.00 29,296.00   
IL-33 31,320.00 27,832.00 *0.0432 
  30,908.00 26,096.00   
IL-34 30,060.00 23,076.00 0.0735 
  27,264.00 23,996.00   
IP-10 32,168.00 24,164.00 0.0609 
  29,876.00 26,152.00   
I-TAC 32,492.00 22,828.00 0.3277 
  34,420.00 32,020.00   
Kallikrein 3 37,048.00 36,032.00 0.3123 
  36,424.00 32,080.00   
Leptin 21,592.00 18,520.00 0.5399 
  24,996.00 23,592.00   
LIF 24,428.00 22,480.00 0.9019 
  22,456.00 24,832.00   
Lipocalin-2 52,716.00 41,508.00 *0.0071 
  52,436.00 43,220.00   
MCP-1 29,236.00 20,704.00 *0.0038 
  28,940.00 21,636.00   
MCP-3 28,736.00 33,880.00 0.8442 
  26,176.00 23,432.00   
M-CSF 28,740.00 28,940.00 0.3411 
  31,444.00 27,372.00   
MIF 232,832.00 224,624.00 0.2486 
  225,604.00 217,764.00   
MIG 32,988.00 32,052.00 0.2618 
  38,984.00 30,216.00   
MIP-1α/MIP-1β 25,928.00 23,692.00 0.0612 
  27,500.00 22,832.00   
MIP-3α 30,420.00 26,472.00 0.4394 
  26,628.00 26,920.00   
MIP-3β 31,712.00 25,548.00 *0.0293 
  29,984.00 25,980.00   
MMP-9 27,236.00 24,324.00 0.1513 
  31,728.00 24,444.00   
Myeloperoxidase 19,528.00 18,128.00 0.7202 
  23,664.00 22,564.00   
Osteopontin 37,196.00 28,464.00 *0.0269 
  34,704.00 27,528.00   
PDGF-AA 29,532.00 19,864.00 0.2086 




PDGF-AB/BB 19,184.00 19,796.00 0.9877 
  23,940.00 23,432.00   
Pentraxin 3 37,364.00 36,372.00 0.2349 
  42,516.00 33,924.00   
PF4 28,116.00 24,604.00 0.0588 
  30,180.00 25,212.00   
RAGE 30,900.00 25,372.00 0.0576 
  29,460.00 26,828.00   
RANTES 22,548.00 24,224.00 0.9801 
  25,952.00 24,372.00   
RBP-4 162,392.00 113,296.00 *0.0039 
  158,412.00 108,560.00   
Relaxin-2 33,392.00 24,744.00 0.1179 
  30,768.00 28,112.00   
Resistin 40,224.00 35,024.00 0.4305 
  36,088.00 36,856.00   
SDF-1α 39,832.00 31,956.00 0.1552 
  44,932.00 36,920.00   
Serpin E1 51,128.00 49,288.00 0.2145 
  55,900.00 49,172.00   
SHBG 32,012.00 30,696.00 0.2738 
  31,048.00 27,788.00   
ST2 25,812.00 25,584.00 0.6558 
  23,780.00 25,092.00   
TARC 27,948.00 21,488.00 0.4382 
  22,484.00 23,388.00   
TFF3 46,184.00 38,816.00 0.1728 
  44,096.00 42,552.00   
TfR 28,540.00 24,128.00 0.2199 
  31,992.00 27,676.00   
TGF-α 32,664.00 28,036.00 *0.0117 
  32,212.00 27,068.00   
TSP-1 48,396.00 42,660.00 *0.0051 
  47,996.00 43,296.00   
TNF-α 28,612.00 26,184.00 0.1024 
  28,404.00 23,724.00   
uPAR 43,100.00 34,496.00 *0.0471 
  40,036.00 34,900.00   
VEGF 34,988.00 26,872.00 0.1901 
  34,528.00 32,200.00   
Reference Spots 1,034,860.00 1,081,072.00 0.9552 
  1,048,356.00 1,006,924.00   




  31,028.00 27,752.00   
negative reference spot 20,972.00 17,440.00 0.4781 







Figure S7.1 Example of stained bone sections analysed for histomorphometry. Immuno-deficient BALB/c mice were intra-cardiacally injected 
with PC3 cells and treated with SU1349 (20mg/kg/3times-weekly) or vehicle control; at the end of the experiment sections of mouse tibial bone were 
TRAPc and haematoxylin stained before undergoing histomorphometric analysis using Osteomeasure.  A: Shows a photomicrograph of trabecular 
bone section near the growth plate; red arrows highlight osteoclasts. B: Shows a photomicrograph of cortical bone section; highlighted in yellow border 
is an area of the endocortical bone surface with mature osteoblasts; highlighted in red border is an area of prostate tumour growth outside of the 





Figure S7.2 Combined IKKα inhibition and Docetaxel treatments showed synergistic effects on PC3 survival and favourable dose reduction 
potential for each drug. PC3 cells were pre-treated with Docetaxel (0.1, 0.3, 1, 3, 10, 30 μM) for 24hrs before treatment with SU1349 for an additional 
48hrs. A: Shows the combination index (CI) and Fraction affected (Fa) for Docetaxel concentrations in combination with 0.45μM SU1349 (D+SU L) 
or with 1.5μM SU134 (D+SU H). The lower the CI value below the horizontal line (i.e. CI <1) the more synergistic the effect is at that combination; 
CI values on the line (CI ~1) represent additive effects; CI values above the horizontal line (CI>1) represents antagonistic combinations.  Synergistic 
effects at higher Fa are more clinically relevant than synergism at lower Fa (e.g. Fa <0.3 vs Fa>0.9). B and C: Shows the dose reduction index (DRI), 
calculated for Docetaxel (D) and SU1349 (SU) at each experimental (Fa) combination point based on the computed dose for each drug to achieve the 
same Fa if used alone (i.e. not in combination), for Docetaxel + 0.45μM SU1349 and Docetaxel + 1.5μM SU1349 experiments respectively. The DRI 
represents degree fold in dose reduction; the higher the DRI values above the horizontal line (i.e. > 0) the more favourable the dose reduction. For 
example, at 0.1 μM Docetaxel and 0.45 μM SU1349, the Fa was 0.38, and the calculated DRIs for Docetaxel (blue circle) and SU1349 (red square) at 
that combination are both above the horizontal line. Fa values were calculated (using the combosyn software) based on Alamar blue results obtained 













































Appendix 3: Materials, Reagents, Apparatus and Software 
3.1 Materials and Reagents used in this study: 
Materials and reagents Supplier 
1.5ml Eppendorf tubes with cap Starlab, Milton Keynes, UK 
12% Criterion™ TGX™ Precast Midi Protein Gel, 12+2 well 
Bio-Rad Laboratories, 
Hertfordshire, UK 
3T3-L1 ATCC, Manassas, VA-USA 
5-flurouracil Sigma Aldrich, Dorset, UK 
Acetic Acid Glacial Sigma Aldrich, Dorset, UK 
AlamarBlueTM reagent Invitrogen, Paisley, UK 
Alizarin Red S Sigma Aldrich, Dorset, UK 
Ampicllin 
Fisher Scientific, Leicestershire, 
UK 
BD microlance needles (19, 21 and 25G) 
Fisher Scientific, Leicestershire, 
UK 
Bicinchoninic acid (BCA) solution Sigma Aldrich, Dorset, UK 
Bovine Insulin Sigma Aldrich, Dorset, UK 
Bovine serum albumin Sigma Aldrich, Dorset, UK 
Bromophenol Blue 
BDH Laboratory Supplies, Poole, 
Dorset, UK 
C4-2 ATCC, Manassas, VA-USA 
C4-2B4 ATCC, Manassas, VA-USA 
Centrifuge tubes 15ml 
Scientific laboratory supplies 
(SLS), Nottingham UK 
Centrifuge tubes 50ml 
Fisher Scientific, Leicestershire, 
UK 
Cetyl pyridinium chloride monohydrate Sigma Aldrich, Dorset, UK 
Clarity Western ECL Substrate 
Bio-Rad Laboratories, 
Hertfordshire, UK 
Collagenase (type 1A) Sigma Aldrich, Dorset, UK 
Copper (II)-sulfate Sigma Aldrich, Dorset, UK 
Corning™ Transwell™ Multiple Well Plate with Permeable 
Polycarbonate Membrane Inserts 
Corning, Flintshire, UK 
Cover slips 
Fisher Scientific, Leicestershire, 
UK 




Dexamethasone Sigma Aldrich, Dorset, UK 
Diethanolamin Sigma Aldrich, Dorset, UK 
DL-Dithiothreitol (DTT) Sigma Aldrich, Dorset, UK 
DMSO Sigma Aldrich, Dorset, UK 
Docetaxel Sigma Aldrich, Dorset, UK 
Doxorubicin Sigma Aldrich, Dorset, UK 
DPX mounting medium Sigma Aldrich, Dorset, UK 




Electrophoresis power supply 
Bio-Rad Laboratories, 
Hertfordshire, UK 
Ethanol Absolute Sigma Aldrich, Dorset, UK 
Fetal calf serum (FCS) 
Fisher Scientific, Leicestershire, 
UK 
Filter Tips any size Starlab, Milton Keynes, UK 
Forceps watchmaker’s 
Fisher Scientific, Leicestershire, 
UK 
Glycine Acros organics, Geel, Belgium 
Hanks buffer (HBSS) Sigma Aldrich, Dorset, UK 
Human recombinant RANKL 
Gift from Dr. Patrick Mollat 
(Proskelia SASU) 
Isobutylmethylxanthine Sigma Aldrich, Dorset, UK 
Isopropanol 
Fisher Scientific, Leicestershire, 
UK 
Jackson ImmunoResearch Anti-rabbit secondary ab  
Stratech Scientific Unit, 
Newmarket Suffolk, UK 
Kaleidoscope Pre-stained standards 
Bio-Rad Laboratories, 
Hertfordshire, UK 
LNCaP ATCC, Manassas, VA-USA 
Luria-Bertani (broth & agar) Sigma Aldrich, Dorset, UK 
Magic Marker Invitrogen, Paisley, UK 
Magnesium chloride Sigma Aldrich, Dorset, UK 
MC3T3-E1 ATCC, Manassas, VA-USA 
M-CSF mouse recombinant R & D Systems, Abingdon, UK 
Methanol 
VWR International LTD, 
Leicestershire, UK 
Microtubes (0.5, 1.5, 2ml) Sarstedt Ltd, Leicester, UK 
Minimum Essential Medium (αMEM) 
Fisher Scientific, Leicestershire, 
UK 
Minimum Essential Medium (DMEM) 
Fisher Scientific, Leicestershire, 
UK 
N,N-Dimethylformamide Sigma Aldrich, Dorset, UK 
Napthol-AS-BI-phosphate Sigma Aldrich, Dorset, UK 
Neubauer Haemocytometer Hawksley, Lancing, UK 
Oil Red O Sigma Aldrich, Dorset, UK 
Paclitaxel Sigma Aldrich, Dorset, UK 
Paraformaldehyde Taab Lab, Berkshire, UK 
Pararosanilin Sigma Aldrich, Dorset, UK 
PC3 ATCC, Manassas, VA-USA 
PC3-BT Dr. Colby Eaton (Sheffield, UK) 
PC3-NW1 (luciferase labelled) Dr. Colby Eaton (Sheffield, UK) 
Penicillin/Streptomycin 
Fisher Scientific, Leicestershire, 
UK 
Pierce™ Bovine Serum Albumin Standard Pre-Diluted Set 
Fisher Scientific, Leicestershire, 
UK 
Phosphatase inhibitor cocktail  Sigma Aldrich, Dorset, UK 
Phosphate buffered saline 





Pipette tips (all sizes) Starlab, Milton Keynes, UK 
Puromycin 
Fisher Scientific, Leicestershire, 
UK 
Protease inhibitor cocktail  Sigma Aldrich, Dorset, UK 
Proteome ProfilerTM Human XL Cytokine Array Kit R&D Systems, Abingdon, UK 
Prostate cancer tissue microarray (PR242b) Biomax, MD, USA 
4-Nitrophenyl phosphate disodium salt hexahydrate powder 
Scientific laboratory supplies 
(SLS), Nottingham UK 
Recombinant Human Semaphorin 3A Fc Chimera Protein, CF R & D Systems, Abingdon, UK 
Saos-2 ATCC, Manassas, VA-USA 
Scalpel, disposable 
VWR International LTD, 
Leicestershire, UK 
Scissors (fine points and spring bow handles) S Murray & Co Ltd, Surrey, UK 
Silver nitrate Sigma Aldrich, Dorset, UK 
Sodium acetate trihydrate  
VWR International LTD, 
Leicestershire, UK 
Sodium barbiturate Sigma Aldrich, Dorset, UK 
Sodium chloride Sigma Aldrich, Dorset, UK 




VWR International LTD, 
Leicestershire, UK 
Sodium phosphate Sigma Aldrich, Dorset, UK 
Sodium tartrate dibasic dihydrate Sigma Aldrich, Dorset, UK 
Starguard® laboratory gloves Starlab, Milton Keynes, UK 
Sterile filter (0.2 and 0.45μm) Pall lifesciences, Portsmouth, UK 
Stripettes (5, 10, 25 and 50ml)  
Fisher Scientific, Leicestershire, 
UK 
Superfrost Plus™ Adhesion Microscope Slides 
Fisher Scientific, Leicestershire, 
UK 
Syringes (all sizes) 
Fisher Scientific, Leicestershire, 
UK 
Tissue culture 25, 75, 175cm2 flasks 
Fisher Scientific, Leicestershire, 
UK 
Tissue culture microplates (6, 12, 24, 48 and 96-well plates) Corning, Flintshire, UK 
Transblot Turbo midi Size PVDF membrane 
Bio-Rad Laboratories, 
Hertfordshire, UK 






Tris-EDTA buffer Sigma Aldrich, Dorset, UK 
Tris-Glycine buffer 10x 
Bio-Rad Laboratories, 
Hertfordshire, UK 
Triton X-100TM Sigma Aldrich, Dorset, UK 
Trizma® hydrochloride Sigma Aldrich, Dorset, UK 
Trizma® base Sigma Aldrich, Dorset, UK 
Trypsin/EDTA Sigma Aldrich, Dorset, UK 
Tween-20 Acros organics, Geel, Belgium 




L-Ascorbic acid Sigma Aldrich, Dorset, UK 




Xylene Sigma Aldrich, Dorset, UK 






3.2 Antibodies in this thesis: 
 
Antibody Supplier 
Rabbit anti-p65 Cell Signalling technologies, USA 
Rabbit anti-Actin Sigma-Aldrich, UK 
Rabbit anti-β-catenin Cell Signalling technologies, USA 
Rabbit anti-GAPDH Sigma-Aldrich, UK 
Rabbit anti-phospho-GSK3β Cell Signalling technologies, USA 
Rabbit anti-Lamin A/C Cell Signalling technologies, USA 
Rabbit anti-IκBα Cell Signalling technologies, USA 
Rabbit anti-phospho-IκBα Cell Signalling technologies, USA 
Rabbit anti-IKKα Cell Signalling technologies, USA 





3.3 Apparatus used in this thesis: 
 
Apparatus Supplier 
AA Hoefer® protein transfer apparatus Fisher Scientific, Leicestershire, UK 
Bench-top Eppendorf centrifuge Fisher Scientific, Leicestershire, UK 
Grant OLS 200 water bath Thistle Scientific, Glasgow, UK 
Horizontal electrophoresis tanks Fisher Scientific, Leicestershire, UK 
Hotplate/stirrer Thistle Scientific, Glasgow, UK 
Ika Vortex Thistle Scientific, Glasgow, UK 
Leica AF6000 Leica Microsystems, Milton Keynes, UK 
Nichiryo America Inc. Pipettes (2, 10, 100, 200 and 
1000μl) 
Thistle Scientific, Glasgow, UK 
Origo PSU-400/200 power supply for electrophoresis Anachem, Bedfordshire, UK 
PowerPac basicTM Bio-Rad Laboratories, Hertfordshire, UK 
QImaging Retiga 4000R CCD camera Media Cybernetics UK, Berkshire, UK 
SkyScan 1172 X-ray Microtomography system SKYSCAN, Kontich, Belgium 
SkyScan 1176 in-vivo micro-CT SKYSCAN, Kontich, Belgium 
SpectraMax® M5 microplate reader Fisher Scientific, Leicestershire, UK 
Syngene GeneGenius Gel Bio-Imaging system Fisher Scientific, Leicestershire, UK 
SynSyngene GeneGnome Bio-Imaging system for 
chemiluminescence 
Fisher Scientific, Leicestershire, UK 















3.4 Software used in this thesis: 
 
Software Supplier 
CompuSyn ComboSyn, NJ, USA 
GraphPad Prism (version 7) GraphPad Software Inc., CA-US 
ImageJ U. S. National Institutes of Health Bethesda, 
MA-US 
Image Lab Biorad, Watford, UK 
Osteomeasure Osteometrics, DA, USA 
Skyscan 1172 MicroCT software SKYSCAN, Kontich, Belgium 
Skyscan CTAn analysis software SKYSCAN, Kontich, Belgium 
Skyscan CTVol software SKYSCAN, Kontich, Belgium 
Skyscan NRecon reconstruction system SKYSCAN, Kontich, Belgium 
SpectraMax® M5 plate reader software Fisher Scientific, Leicestershire, UK 
Syngene GeneSnap software Fisher Scientific, Leicestershire, UK 
Syngene GeneTool software Fisher Scientific, Leicestershire, UK 
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